Report Sections

See All Reports

  • drug1193: Enoxaparin
  • Placebo (467) Hydroxychloroquine (102) Standard of Care (42) Azithromycin (37) Tocilizumab (37) Remdesivir (34) Placebo oral tablet (33) Questionnaire (32) Convalescent Plasma (28) Standard of care (28) No intervention (24) Favipiravir (23) Ivermectin (23) Convalescent plasma (22) Placebos (17) Enoxaparin (16) Methylprednisolone (15) Survey (15) Vitamin C (15) Colchicine (14) Nitazoxanide (14) placebo (14) Dexamethasone (12) Hydroxychloroquine Sulfate (12) Questionnaire Administration (12) Anakinra (11) Blood sample (11) Vitamin D (11) Camostat Mesilate (10) Control (10) Ruxolitinib (10) Saline (10) Usual Care (10) blood sample (10) no intervention (10) Losartan (9) Questionnaires (9) Standard care (9) questionnaire (9) Baricitinib (8) Blood sampling (8) Lopinavir/ritonavir (8) Zinc (8) survey (8) Gam-COVID-Vac (7) Lung ultrasound (7) Nasopharyngeal swab (7) Quality-of-Life Assessment (7) Standard treatment (7) Chloroquine (6) Clazakizumab (6) DAS181 (6) LY3819253 (6) Oseltamivir (6) Prone position (6) Rivaroxaban (6) Saliva collection (6) Sarilumab (6) Vitamin D3 (6) convalescent plasma (6) AZD1222 (5) Aspirin (5) Best Practice (5) COVID-19 (5) COVID-19 Convalescent Plasma (5) COVID-19 convalescent plasma (5) Camostat (5) Cholecalciferol (5) Data collection (5) Doxycycline (5) Hydroxychloroquine (HCQ) (5) Lopinavir / Ritonavir (5) Nafamostat Mesilate (5) Online Survey (5) Online questionnaire (5) Online survey (5) Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) (5) Standard Medical Treatment (5) Standard of Care (SOC) (5) UC-MSCs (5) blood sampling (5) hydroxychloroquine (5) questionnaire assesment (5) Acalabrutinib (4) Ad26.COV2.S (4) Ascorbic Acid (4) BCG Vaccine (4) BCG vaccine (4) BNT162b2 (4) Best Supportive Care (4) Biospecimen Collection (4) CELLECTRA® 2000 (4) Colchicine Tablets (4) HCQ (4) Heparin (4) Interferon Beta-1A (4) Interview (4) Lopinavir/Ritonavir (4) Mavrilimumab (4) Melatonin (4) Nitric Oxide (4) Normal Saline (4) Normal saline (4) Observation (4) Observational (4) Opaganib (4) Oxygen (4) Placebo Administration (4) Povidone-Iodine (4) Prednisone (4) Prone positioning (4) REGN10933+REGN10987 combination therapy (4) RLS-0071 (4) SARS-CoV-2 (4) SARS-CoV-2 convalescent plasma (4) Sargramostim (4) Standard Care (4) Survey Administration (4) Telemedicine (4) Telerehabilitation (4) anti-SARS-CoV-2 convalescent plasma (4) standard care (4) 0.9% saline (3) 3D Telemedicine (3) ACE inhibitor (3) AG0302-COVID19 (3) AV-COVID-19 (3) AZD7442 (3) Abatacept (3) Allocetra-OTS (3) Anti-SARS-CoV2 Serology (3) Apremilast (3) BCG-Denmark (3) BNT162b1 (3) Blood draw (3) Blood samples (3) COVID-19 RT-PCR (3) COViage (3) Chloroquine or Hydroxychloroquine (3) Chloroquine phosphate (3) Clinical assessment (3) Clinical data (3) Clopidogrel (3) Control group (3) Cyclosporine (3) DWRX2003 (3) EIDD-2801 (3) Echocardiography (3) Famotidine (3) Hydrocortisone (3) INO-4800 (3) Ibrutinib (3) Inactivated SARS-CoV-2 Vaccine (Vero cell) (3) Interferon Beta-1B (3) Interferon beta-1a (3) Interferon beta-1b (3) LY3832479 (3) Lenzilumab (3) Leronlimab (700mg) (3) Mesenchymal Stromal Cells (3) Mesenchymal stromal cells (3) Methotrexate (3) Naltrexone (3) Niclosamide (3) Nitric Oxide Gas (3) No Intervention (3) PLACEBO (3) Phase 2 (3) Placebo (Normal saline solution) (3) Placebo oral capsule (3) Plasma (3) Povidone-Iodine Nasal Spray and Gargle (3) Probiotic (3) Prone Positioning (3) Prospective study with two measurement points investigating the impact of viral mitigation protocols on mental health (3) RT-PCR (3) Ravulizumab (3) Remestemcel-L (3) Ribavirin (3) SCTA01 (3) Saline Placebo (3) Selinexor (3) Serological test (3) SnPP Protoporphyrin plus Sunlight exposure (3) Standard of Care (SoC) (3) Standard of care (SOC) (3) Supportive Care (3) Suspension of heat killed (autoclaved) Mycobacterium w (3) TY027 (3) Telmisartan (3) Tofacitinib (3) Usual care (3) VPM1002 (3) Vitamin Super B-Complex (3) Yoga (3) blood donation SMS (3) exhaled breath sampling (3) hzVSF-v13 (3) mRNA-1273 (3) observational (3) self-administered questionnaire (3) serology (3) standard of care (3) standard therapy (3) 0.9% Saline (2) 100 mg/mL Virazole (2) 2D Telemedicine (2) 300 mg of omega3-FA (2) 50 mg/mL Virazole (2) AG0301-COVID19 (2) ARB (2) AVIGAN 200 MG Film Tablets (2) Abidol hydrochloride (2) Acebilustat (2) Aeonose (2) Aerobic Exercise Training (2) Alteplase 50 MG [Activase] (2) Ampion (2) Angiotensin 1-7 (2) Angiotensin converting enzyme inhibitor (2) Angiotensin-(1-7) (2) Apixaban 2.5 MG (2) Assessment of behavioral response to emotional stimulation (2) Assessment of work-related stress (2) Atorvastatin (2) Attention Placebo (2) Ayurveda (2) Azithromycin Tablets (2) Bacille Calmette-Guérin (BCG) (2) Baricitinib Oral Tablet (2) Bemiparin (2) Bevacizumab Injection (2) Bicalutamide 150 Mg Oral Tablet (2) Biological data (2) Biological sample collection (2) Blood collection on admission and longitudinally (2) Blood collection on their first consultation and 10 to 14 days later (2) Blood test (2) Blood tests (2) Breath Biopsy face masks with removable filters and fitted PVA strip (2) Brequinar (2) Bucillamine (2) COVID Convalescent Plasma (2) COVID-19 Serology (2) COVID-19 Therapeutic Biologics - Spike-GM-CSF Protein Lactated Ringer's Injection (2) COVID-19 exposure (2) COVID-19 pandemic (2) COVID-19 patients (2) COVID-19 survey (2) CT-P59 (2) CT-Scan (2) CVnCoV Vaccine (2) CYT107 (2) Camostat Mesylate (2) Canakinumab (2) Cannabidiol (2) Cardiac and electrodermal recordings (2) Carrimycin (2) ChAdOx1 nCoV-19 (2) Chloroquine Sulfate (2) Chloroquine or hydroxychloroquine (2) Ciclesonide (2) Clinical Examination (2) Convalescent COVID 19 Plasma (2) Convalescent Plasma (CP) (2) Convalescent Plasma (anti-SARS-CoV-2 plasma) (2) Convalescent Plasma Transfusion (2) Conventional treatment (2) Corticosteroid (2) Crizanlizumab (2) Daclatasvir (2) Data Collection (2) Data record (2) Deferoxamine (2) Defibrotide (2) Dexamethasone injection (2) Diagnostic Laboratory Biomarker Analysis (2) Diagnostic test (2) Disulfiram (2) Dornase Alfa Inhalation Solution [Pulmozyme] (2) Double-Trunk Mask (2) Duvelisib (2) EC-18 (2) ECG (2) EDP1815 (2) EXO 1 inhalation (2) EXO 2 inhalation (2) Early-Dexamethasone (2) Ebselen (2) Eculizumab (2) Electronic Health Record Review (2) Electronic questionnaire (2) Enoxaparin 40 Mg/0.4 mL Injectable Solution (2) Exercise (2) Exercise & Nutrition (2) Exercise training (2) Exposure (2) Expressive writing (2) Famotidine 20 MG (2) Favipiravir Placebo (2) Fisetin (2) Flow cytometric analysis (2) Fluoxetine (2) Fluvoxamine (2) Follow up (2) Fostamatinib (2) Guduchi Ghan Vati (2) HB-adMSCs (2) HFNC (2) High dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule (2) High intensity interval training (2) Human Amniotic Fluid (2) Human biological samples (2) Human immunoglobulin (2) Hydroxychloroquine + azithromycin (2) Hydroxychloroquine - Weekly Dosing (2) Hydroxychloroquine 200 Mg Oral Tablet (2) Hydroxychloroquine Sulfate 200 MG (2) Hydroxychloroquine Sulfate 200 MG [Plaquenil] (2) Hydroxychloroquine Sulfate Loading Dose (2) Hydroxychloroquine Sulfate Regular dose (2) Hydroxychloroquine Sulfate Tablets (2) Hydroxychloroquine and Azithromycin (2) Hyperbaric oxygen (2) ICU treatment (2) IMU-838 (2) IVIG (2) Icosapent ethyl (2) Infliximab (2) Interleukin-7 (2) Intramuscular injection (2) Iodine Complex (2) Ion Mobility Spectrometry (IMS) (2) Ivermectin Oral Product (2) Ivermectin Pill (2) Ivermectin and Doxycycline (2) KB109 + Self Supportive Care (SSC) (2) Ketogenic diet (2) L-ascorbic acid (2) Lanadelumab (2) Leflunomide (2) Lopinavir-Ritonavir (2) Low Dose Radiation Therapy (2) Low Dose Radiotherapy (2) Low dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule (2) Low molecular weight heparin (2) M5049 (2) MSC (2) MW33 injection (2) MW33 injection placebo (2) MagPro X100 Stimulator, B70 Fluid-Cooled Coil (2) Matching Placebo (2) Meditation (1 x 20-minute guided audio training) (2) Medium dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule (2) Meplazumab for Injection (2) Metformin (2) Methylprednisolone Sodium Succinate (2) Mindfulness (2) Mindfulness Based Intervention (2) Molnupiravir (2) N-Acetyl cysteine (2) N-acetylcysteine (2) NORS (Nitric Oxide Releasing Solution) (2) Nasal swab (2) Nasopharyngeal swabs (2) Niclosamide Oral Tablet (2) Nigella Sativa / Black Cumin (2) Nitrogen gas (2) Observational study (2) Olokizumab 64 mg (2) Online Questionnaire (2) Ophthalmologic exam (2) PLX-PAD (2) PUL-042 Inhalation Solution (2) Patient-Reported Online Questionnaire on Olfactory & Taste Disturbances (2) Peginterferon Lambda-1A (2) Pentoxifylline (2) Peripheral blood draw (2) Phase 1 (2) Physiotherapy (2) Pirfenidone (2) Placebo (NaCl 0.9%) (Group 2D) (2) Placebo Comparator (2) Placebo Vaccine (2) Placebo inhalation (2) Placebo on a 0- and 28-day schedule (2) Poly-ICLC (Hiltonol®) (2) Practice details (2) Pulmonary Rehabilitation (2) Pulmozyme (2) RECOP unit patient (2) RLF-100 (aviptadil) (2) RTB101 (2) Radiation therapy (2) Remdesivir placebo (2) Routine care for COVID-19 patients (2) Ruxolitinib Oral Tablet (2) SAB-185 (2) SARS-CoV-2 PCR (2) SARS-CoV-2 diagnostic rapid test (2) SARS-CoV-2 rS/Matrix-M1 Adjuvant (2) SARS-Cov2 testing (2) SOC (2) SOC + Placebo (2) Saline solution (2) Saliva sample collection (2) Sample collection (2) Self Supportive Care (SSC) Alone (2) Semi-directive interview (2) Seraph 100 (2) Serology test for COVID-19 (2) Serum testing (2) Sevoflurane (2) Silmitasertib (2) Siltuximab (2) Simple cognitive task intervention (2) Simvastatin (2) Single Dose of Hydroxychloroquine (2) Sirolimus (2) SivoMixx (200 billion) (2) Spirometry (2) Standard Therapy (2) Standard of Care Treatment (2) Standard of care treatment (2) Stellate Ganglion Block (2) TD-0903 (2) Taking blood samples (capillary and venous), saliva sampling and nasopharyngeal sampling. (2) Therapeutic Plasma Exchange (2) Therapeutic anticoagulation (2) Therapeutic plasma exchange (2) Throat swab (2) Thymalfasin (2) Tocilizumab (TCZ) (2) Tocilizumab Injection (2) Tofacitinib 10 mg (2) Tranexamic acid (2) Two doses of low dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28 (2) Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28 (2) Two doses of placebo at the schedule of day 0,28 (2) UB-612 (2) Unfractionated heparin (2) VIR-7831 (2) Volatile Organic Compounds analysis (2) basic treatment (2) blood draw (2) blood samples (2) blood test (2) conjunctival swab (2) human monoclonal antibody DZIF-10c (Group 1A-2D) (2) lung ultrasound (2) nasopharyngeal swab (2) online survey (2) other (2) oxygen therapy (2) pregnant women with laboratory-confirmed 2019-n-CoV (2) rAd26-S (2) retrospective analysis (2) unfractionated Heparin (2) venous ultrasound (2) vv-ECMO + cytokine adsorption (Cytosorb adsorber) (2) vv-ECMO only (no cytokine adsorption) (2) "Calm" is a mindfulness meditation mobile app (1) "Sham"-block with Placebo (Isotone NaCl) (1) "Vernonia amygdalina" (1) (Standard of Care) SoC (1) - Synthetic anti-malarial drugs (1) 0.075% Cetylpyridinium Chloride (1) 0.12% Chlorhexidine Gluconate (1) 0.12% Chlorhexidine Gluconate Mouth Rinse (1) 0.12% Chlorhexidine oral/nasal rinse (1) 0.5% Povidone Iodine (1) 0.5% Povidone/Iodine oral/nasal rinse (1) 0.9% (w/v) saline (1) 0.9% Normal Saline (1) 0.9% Sodium-chloride (1) 0.9% sodium chloride (normal saline) (1) 0.9%NaCl (1) 0.9%sodium chloride (1) 1% Hydrogen Peroxide (1) 1% w/v Povidone-iodide (1) 1. Characterize the immune response after infection with SARS-CoV-2 (1) 1.5-2% w/v Hydrogen Peroxide (1) 10% Povidone-iodine nasal decolonization swab plus 0.12% CHG oral rinse (1) 150 ppm Nitric Oxide delivered through LungFit Delivery System (1) 18F-αvβ6-BP (1) 1: ILT101 (1) 1: Naproxen (1) 1: Prone positioning (1) 1: Usual practice (1) 1: discontinuation of RAS blocker therapy (1) 2 post-mortem transcutaneous lung biopsies (1 anterior ; 1 posterior) using anatomical landmarks (1) 20 Mg Prednisone for 14 days (1) 2019-nCoV IgG/IgM Rapid Test Cassette (1) 2019-nCoV PCR (1) 21% Ethanol plus essential oils (1) 24 hour Holter ECG (1) 25 post ICU-patients (1) 25 post non-ICU patients (1) 25-OH cholecalciferol (1) 2: No instruction regarding positioning (1) 2: Placebo Comparator (1) 2: Standard of care (1) 2: Usual practice + SYMBICORT RAPIHALER (1) 2: continuation of RAS blocker therapy (1) 35 ml blood, 5 tubes LITHIUM HEPARINATE at each time (cured Patients) (1) 35 ml blood, 5 tubes LITHIUM HEPARINATE at each time (hospitalized Patients ) (1) 38 questions questionnaire (1) 38-questions questionnaire (1) 40-Steps-test (1) 40ml blood sample (1) 4Plants/Azythromycin (1) 5-ALA-Phosphate + SFC (5-ALA + SFC) (1) 6 minute walk test (1) 80 ppm Nitric Oxide delivered through LungFit Delivery System (1) A $10 Survey Incentive (1) A $20 Survey Incentive (1) A short video intervention (1) A vignette intervention (1) AAZ Covid-19 rapid test (1) ABBV-47D11 (1) ABPM (1) ABX464 (1) ACE Inhibitors and Calcium Channel Blockers (1) ACE inhibitor, angiotensin receptor blocker (1) ACEI (1) ACEI/ARB (1) ACEIs (1) ACP Decisions Video Program (1) ACT-20-CM (1) ACT-20-MSC (1) ADAM Sensor (1) ADM03820 (1) AI model (1) AK119 (1) AKS-452 (1) ALLOGENEIC AND EXPANDED ADIPOSE TISSUE-DERIVED MESENCHYMAL STEM CELLS (1) AMA Acknowledgement Drug Pricing (1) AMY-101 (1) AN69-Oxiris (1) AN69-Standard (1) ANNE One (1) APL-9 (1) APPS (1) ARBIDOL 100 MG KAPSUL (1) ARBOX (1) ARBs and/or ACE inhibitors (1) ARCT-021 Dose 1 (1) ARCT-021 Dose 2 (1) ARCT-021 Dose 3 (1) ARCT-021 Dose 4 (1) ARCT-021 Dose Regimen 1 (1) ARCT-021 Dose Regimen 2 (1) ARCT-021 single dose priming (1) ARCT-021 two higher dose priming (1) ARCT-021 two lower dose priming (1) ARDSNet (1) ARFC mask (1) ART Therapy (1) AS03-adjuvanted SCB-2019 vaccine (1) ASC09/ritonavir group (1) ASC09F+Oseltamivir (1) AT-001 (1) AT-100 (1) AT-527 (1) ATAFENOVIR 200 MG KAPSUL (1) ATI-450 (1) ATYR1923 1 mg/kg (1) ATYR1923 3 mg/kg (1) AVICOD 200 MG Film Tablet (1) AVIGAN (1) AVIGAN 200 mg FT (1) AVIGAN 200 mg Film Tablets (1) AVM0703 (1) AWARD advice (1) AWARD plus COVID-specific advice (1) AZD1656 (1) AZVUDINE (1) AZVUDINE placebo (1) Abdominal ultrasound (1) Abidol Hydrochloride combined with Interferon atomization (1) Abivertinib (1) Acacia Senegal (1) Acalabrutinib Treatment A (1) Acalabrutinib Treatment B (1) Acalabrutinib Treatment C (1) Acalabrutinib Treatment D (1) Accuchek Inform II platform (1) Accuracy of CAD4TB and Afinion CRP assay for pulmonary TB (1) Acetyl L-Carnitine (1) Acetylsalicylic acid (1) Acknowledgement Racial Injustice AMA (1) Active COVID-19 disease (1) Active Comparator (1) Active Comparator: Self-care group (1) Active PBMT/sMF (1) Active control:Healthy Living (1) Activity (1) Activity list (1) Ad5-nCoV (1) AdCLD-CoV19 (1) AdCOVID (1) Additional and minimal collection of products of the human body carried out during a sample for standard of care (1) Additional biological samples (1) Adenosine (1) Adenovirus Type-5 Vectored COVID-19 Vaccine (1) AdimrSC-2f (1) Adipose tissue (1) Administration of Equine immunoglobulin anti SARS-CoV-2 (1) Admission to ICU for COVID-19 (1) Adsorbed COVID-19 (inactivated) Vaccine (1) Aerobic Exercises (1) Aerobic training (1) Aerolized Hydroxychloroquine Sulfate (1) Aerosol Box (1) Aerosol-reducing Mask (1) Aerosolized 13 cis retinoic acid (1) Aerosolized 13 cis retinoic acid plus Inhalation Inhaled testosterone (1) Aerosolized 13 cis retinoic acid plus Inhalation administration by nebulization captopril 25mg (1) Aerosolized All trans retinoic acid (1) Aerosolized All-Trans Retinoic acid plus oral Tamoxifen (1) Aerosolized Isotretinoin plus Tamoxifen (1) African American Sender Acknowledgement (1) African American Sender in Informational Videos. (1) After COVID-19 Pandemic (1) AirFLO2 (1) AirGo Respiratory Monitor (1) Airwave Oscillometry (1) Airway pressure release ventilation (1) Alexa Amazon (1) Alisporivir (1) AlloStim (1) Allogeneic NK transfer (1) Allogeneic and expanded adipose tissue-derived mesenchymal stromal cells (1) Allogenic pooled olfactory mucosa-derived mesenchymal stem cells (1) Almitrine (1) Alpha-interferon alpha, abidol, ribavirin, Buzhong Yiqi plus and minus formula, Huhuang Detoxicity Paste, Baimu Qingre Jiedu Paste, fumigation/inhalation of vitamin C (1) Alpha-interferon, abidol, ribavirin, Buzhong Yiqi plus and minus formula, Huhuang Detoxicity Paste, Baimu Qingre Jiedu Paste and 5% glucose (1) Alpha-interferon, abidol, ribavirin, Buzhong Yiqi plus and minus formula, Huhuang Detoxicity Paste, Baimu Qingre Jiedu Paste and high-dose vitamin C treatment (1) Alteplase (1) Alvelestat (1) Ambrisentan (1) Amiodarone (1) Amlodipine (1) Amoxicillin-clavulanate (1) An auto-questionnaire comprising three psychometric scales (1) Anakinra +/- Ruxolitinib (stages 2b/3) (1) Anakinra 100Mg/0.67Ml Inj Syringe (1) Anakinra 149 MG/ML Prefilled Syringe [Kineret] (1) Anakinra Prefilled Syringe (1) Anakinra alone (stages 2b/3) (1) Anakinra and Ruxolitinib (Advanced stage 3) (1) Anakinra and Ruxolitinib (overcome stage 3) (1) Anakinra plus oSOC (1) Analogs, Prostaglandin E1 (1) Analysis of cytokine response, innate and adaptive immune response, complement activation, and serum neurofilaments as a marker of neurological damage. (1) Anatolian Propolis (1) Anesthesia management (1) Anger message (1) Angiography scanner (1) Angiotensin II (1) Angiotensin II Receptor Blockers (1) Angiotensin Receptor Blockers (1) Angiotensin receptor blocker (1) Angiotensin-Converting Enzyme Inhibitors (ACE-I) and Angiotensin II Receptor Blockers (ARB) (1) Anluohuaxian (1) Anti SARS-CoV 2 Convalescent Plasma in critical COVID-19 patients (1) Anti SARS-CoV 2 Convalescent Plasma in severe COVID-19 patients (1) Anti- SARS-CoV-2 Plasma (1) Anti-COVID-19 human immunoglobulin (1) Anti-SARS-CoV-2 Human Convalescent Plasma (1) Anti-SARS-CoV-2 IgT seropositivity (1) Anti-SARS-CoV-2 convalescent plasma (1) Anti-SARS-CoV-2 equine immunoglobulin fragments (INOSARS) (1) Anti-SARS-CoV-2 immunoglobulin (1) Anti-SARS-CoV2 serological controls and serum neutralization (1) Anti-Sars-CoV-2 Convalescent Plasma (1) Anti-coronavirus antibodies (immunoglobulins) obtained with DFPP form convalescent patients (1) Anti-coronavirus antibodies (immunoglobulins)obtained with DFPP from convalescent patients (1) Antibiotic (1) Antibiotics (1) Antibody Test (1) Antibody test (SARS-CoV2) (1) Antibody testing (1) Antibody titration (1) Antibody-Rich Plasma from COVID-19 recovered patients (1) Anticoagulant Therapy (1) Anticoagulation Agents (Edoxaban and/or high dose LMWH) (1) Antihypertensive Agents (1) Antioxidation Therapy (1) Antithrombin III (1) Antithrombotic Therapy (anticoagulant and/or antiplatelet) before admission for Covid19 (1) Antiviral Agents (1) Antroquinonol (1) Anxiety Reduction Training (1) Apilimod Dimesylate Capsule (1) Apixaban (1) Apixaban 5MG (1) Apo-Hydroxychloroquine (1) Appendectomy (1) Apple Watch Series 5 (1) Apremilast placebo (1) Aprepitant injectable emulsion (1) Aprotinin (1) Arbidol (1) Arbidol Hydrochloride Granules (1) Argatroban (1) Artemesia annua (1) ArtemiC (1) Artemisia Annua Leaf (1) Artemisinin / Artesunate (1) Arterial Blood Gas test (ABG) (1) Arterial blood gas (1) Artesunate (1) Artesunate-amodiaquine (1) Ascorbic Acid and Zinc Gluconate (1) Ashmolean Website (1) Aspirin 100mg (1) Aspirin 75mg (1) Aspirin 81 mg (1) Assembled mask (1) Assessing antibody responses, neutralizing capacity and memory B-cell function (1) Assessing impact of COVID19 (1) Assessment of Dietary Changes in Adults in the Quarantine (1) Assessment of cardiovascular diseases and cardiovascular risk factors (1) Assessment of coagulopathy, Platelets activation and Platelets-Neutrophils interplay (1) Assessment of lung mechanics and heart-lung interactions (1) Assessment of postnatal depression using the the Edinburgh questionnaire between 4 and 6 weeks after delivery (1) Assessment of ventilator-associated pneumonia criteria (1) Assigned Strategies: Active Choice (1) Assigned Strategies: Enhanced Active Choice (1) Assigned Strategies: Opt-in (1) Association of diltiazem and niclosamide (1) AstroStem-V (1) Asunercept (1) Asynchronies detection (1) Atazanavir (1) Atazanavir and Dexamethasone (1) Atorvastatin 20 Mg Oral Tablet (1) Atorvastatin 20mg (1) Atorvastatin 40mg (1) Atovaquone/Azithromycin (1) Attention control (1) Audio-Visual Triage System (AVT) (1) Auditory Evoked Potentials (AEP) (1) Auricular neuromodulation (1) Auricular percutaneous neurostimulation (1) Auscul-X (1) Auto-questionnaires (patients co infected HIV Sras-CoV-2) (1) Autologous Adipose MSC's (1) Autologous Non-Hematopoietic Peripheral Blood Stem Cells (NHPBSC) (1) Automated oxygen administration - FreeO2 (1) Autophagy inhibitor (GNS651) (1) Auxora (1) Avdoralimab (1) Aviptadil 67μg (1) Aviptadil by intravenous infusion + standard of care (1) Awake Prone Positioning (1) Awake Proning (1) Awake prone positioning (1) Awake proning (1) Ayurvedic Kadha (1) Azinc (1) Azithromycin (Azithro) (1) Azithromycin / Ivermectin / Ribaroxaban / Paracetamol (1) Azithromycin / Ribaroxaban / Paracetamol (1) Azithromycin 250 MG (1) Azithromycin 250 MG Oral Capsule (1) Azithromycin 500 milligram (mg) oral Tablet (1) Azithromycin 500Mg Oral Tablet (1) Azithromycin Capsule (1) Azithromycin and hydroxychloroquine (1) Azithromycin with amoxicillin/clavulanate (1) Açaí palm berry extract - natural product (1) BACMUNE (MV130) (1) BAT (1) BAT + Calcifediol (1) BAT2020 (1) BBV152 (1) BBV152A - Phase I (1) BBV152A - Phase II (1) BBV152B - Phase I (1) BBV152B - Phase II (1) BBV152C - Phase I (1) BCG (1) BCG GROUP (1) BCG vaccine (Freeze-dried) (1) BCG-10 vaccine (1) BDB-001 Injection (1) BGB DXP593 (1) BGB-DXP593 (1) BI 764198 (1) BIO 300 Oral Suspension (1) BIO101 (1) BIOMARKERS IN THE LONG TERM IMPACT OF CORONAVIRUS INFECTION IN THE CARDIORRESPIRATORY SYSTEM (1) BIOVITALS (1) BLD-2660 (1) BM-Allo.MSC (1) BM-MSCs (1) BMS-986253 (1) BNT162a1 (1) BNT162b3 (1) BNT162c2 (1) BRII-196 (1) BRII-196 and BRII-198 (1) BRII-196/BRII-198 (1) BRII-198 (1) BTL-TML-COVID (1) BVA-100 (1) Background questionnaire (1) Bactek-R (1) Bacterial species isolated (1) Bamlanivimab (1) Bardoxolone methyl (1) Bariatric procedures (1) Baricitinib (janus kinase inhibitor) (1) Baricitinib 4 MG Oral Tablet (1) Baricitinib or Anakinra (1) Base therapy (1) Baseline and during hospitalization blood samples (1) Baseline blood sample (1) Baseline message (1) Basic Body Awareness Therapy (1) Beck Depression Inventory (BDI) (1) Bedside lung ultrasound (1) Behavioral Activation SSI (1) Behavioral: OCAT (1) Behavioral: OCAT-sham (1) Behaviour Change Technique Intervention to Improve Quality of Life (1) Bemiparin sodium (1) Bempegaldesleukin (1) Berberine (1) Bereavement Virtual Support Group (1) Best Available Therapy (1) Best Message + Augmented Message or Implementation Strategy (1) Best Message Alone (1) Best Standard of Care (1) Best Standard of Care + CARDIO (1) Best available care (1) Best available treatment (1) Best standard of care (1) Best supportive care" which includes antivirals /antibiotics/ hydroxychloroquine; oxygen therapy (1) Bevacizumab (1) Bicalutamide 150 mg (1) BioMedomics COVID-19 IgM-IgG Rapid Test (1) Bioarginina® (1) Biobehavioral Tele-rehabilitation Sessions (1) Biocollection (1) Biological (1) Biological Sample Collection (1) Biological collection (patients co infected HIV Sras-CoV-2) (1) Biological collection with nasopharyngeal samples, saliva, blood, stool and urine (1) Biological sample and clinical data collection (1) Biological samples specific to research (1) Biological sampling (1) Biological test (1) Biological/Vaccine: Angiotensin peptide (1-7) derived plasma (1) Biological/Vaccine: Recombinant new coronavirus vaccine (CHO cell) low-dose group (1) Biological/Vaccine: Recombinant new coronavirus vaccine (CHO cells) high-dose group (1) Biological/Vaccine: Recombinant new coronavirus vaccine (CHO cells) placebo group (1) Biological: COVID-19 convalescent plasma (1) Biological: mRNA-1273: 100 mcg (1) Biological: mRNA-1273: 50 mcg (1) Biological: oral polio vaccine (1) Biomarker (TropT, Myoglobin, CK, CK-MB, LDH, D-dimer, CRP, PCT) (1) Biomarkers expression (1) Biosensor (1) Biosensors (1) Biospecimen collection (1) Bivalirudin Injection (1) Blink and Masseter Inhibitory Reflex (1) Blood D-dimer assay (1) Blood Sample (1) Blood analysis (1) Blood and derivatives. (1) Blood collection (1) Blood collection at Day 8, Day 16, Day 24, Month 6 and Month 12 after first symptoms from SARS-CoV-2 infection (1) Blood donation from convalescent donor (1) Blood for anti-drug antibody (ADA) (1) Blood for pharmacokinetic samples (1) Blood for research purposes (1) Blood group determination (1) Blood plasma (1) Blood sample and data record (1) Blood sample collection (1) Blood sample for serological test (1) Blood sample for serology to measure past infection with SARS-CoV-2 (1) Blood sample for whole genome sequencing (1) Blood samples (collection of 5 mL of blood in a dry tube) (1) Blood samples collection (1) Blood sampling (venesection) (1) Blood test for IgG antibodies against SARS-CoV-2 (1) Blood tests sputum, nasal lavage and brushing (1) Bloodwork (1) Bolus placebo (1) Bolus vitamin D3 (1) Bone Marrow Harvest (1) Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles Infusion Treatment (1) Bone conduction headphones (1) Botulinum Neurotoxin (1) Bovine Lactoferrin (1) Bovine Lipid Extract Surfactant (1) Bovine Plasma-Derived Immunoglobulin Concentrate (1) Brain MRI (1) Brain MRI scan (1) Brainstem Responses Assessment Sedation Score (BRASS) (1) Brazilian Green Propolis Extract (EPP-AF) (1) Breath Biopsy (1) Breath Biopsy Analysis (1) Breath Test & Cheek Swab (1) Breath biopsy sampling using the ReCIVA Breath Sampler (1) Breath sample (1) Breath test (1) Breathing exercise, intensive spirometry use, supported cough, progressive mobilisation and ambulation (1) Brexanolone (1) Bridge therapy (1) Brief Behavioral Activation with Mental Imagery (1) Brief Interpersonal Telepsychotherapy (1) Brief Psychiatric Rating Scale (1) Brief Skills for Safer Living (1) Brief cognitive behavioral therapy (1) Brief educational video (1) Brief informational infographic (1) Bromhexine 8 MG (1) Bromhexine Hydrochloride (1) Bromhexine Hydrochloride Tablets (1) Bromhexine Oral Tablet and/or hydroxychloroquine tablet (1) Bromhexine and Spironolactone (1) Broncho-Vaxom® (1) Bronchoalveolar Lavage (BAL) (1) Budesonide (1) Budesonide Nasal (1) Budesonide dry powder inhaler (1) Burnout (1) Butterfly (1) Butterfly iQ (1) C-reactive protein (1) C21 (1) C2Rx (1) C3+ Holter Monitor (1) CAD4COVID+WBC and COVID-19 RDT for SARS-CoV-2 infection (1) CAG length <22 (1) CAG length >=22 (1) CAP-1002 (1) CAP-1002 Allogeneic Cardiosphere-Derived Cells (1) CAStem (1) CBD (1) CBD Isolate (1) CCP (1) CD24Fc (1) CERC-002 (1) CHAMindWell (1) CHEST CT SCAN (1) CHLORPROMAZINE (CPZ) (1) CHX0.12+CPC0.05 oral rinse (PerioAidActive Control) (1) CIG Axial (1) CIG Tilted (1) CK0802 (1) CLBS119 (1) CLIA of IgG and IgM against SARS-Cov-2 (1) CM4620-IE (Injectable Emulsion) (1) CNM-ZnAg (1) CNS magnetic resonance imaging (MRI) imaging (1) COM-COVID anonimous survey (1) COMPASS (1) CONTROL GROUP (1) CONVALESCENT PLASMA (1) COPAN swabbing and blood sample collection (1) COR-101 (1) CORVax (1) COSH Self-help smoking cessation booklet (1) COVI-AMG (1) COVI-GUARD (1) COVI-VAC (1) COVICU (1) COVID 19 Convalescent Plasma (1) COVID 19 Diagnostic Test (1) COVID 19 Self-Questionnaire (1) COVID 19 diagnostic test by PCR (1) COVID 19 impact (1) COVID 19 serology (1) COVID WHELD (1) COVID Watch (1) COVID positive via testing (1) COVID visitation restrictions (1) COVID-19 Androgen Sensitivity Test (CoVAST) (1) COVID-19 Antibody testing (1) COVID-19 Antigen/Antibody Rapid Testing, mobile device image capture and telemedicine support (1) COVID-19 Breastfeeding Support (1) COVID-19 Convalescent Plasma (CCP) (1) COVID-19 Convalscent Plasma (1) COVID-19 Diagnostic and Assessment Tests (1) COVID-19 FACILITY (1) COVID-19 IgG / IgM rapid test (whole blood, serum, plasma) (1) COVID-19 IgG/IgM Rapid Test Cassette test (Healgen Scientific, Houston, Texas, USA) (1) COVID-19 PCR (1) COVID-19 PCR Swab (1) COVID-19 PCR and Serology (1) COVID-19 PCR and serology testing (1) COVID-19 Pandemic (1) COVID-19 Pneumonia (1) COVID-19 Specific T Cell derived exosomes (CSTC-Exo) (1) COVID-19 Swab (1) COVID-19 and Intensive Care (1) COVID-19 antibodies testing (1) COVID-19 antibody point of care test kit (1) COVID-19 antigen and antibody tests, and influenza rapid test (1) COVID-19 barrier box (1) COVID-19 convalescent hyperimmune plasma (1) COVID-19 convalescent plasma (CCP) plus standard of care (SOC) (1) COVID-19 convalescent plasma treatment (1) COVID-19 diagnostic PCR (1) COVID-19 diagnostic test (1) COVID-19 e-package: Psychological wellbeing for healthcare workers (1) COVID-19 experience surveys (1) COVID-19 infection (1) COVID-19 infection status (1) COVID-19 positive via testing (1) COVID-19 related health warning leaflet (1) COVID-19 standard care (1) COVID-19 swap test PCR (1) COVID-19 test (1) COVID-19 test, polymerase chain reaction for SARS-CoV-2 (1) COVID-19 testing (1) COVID-19 treatment (1) COVID-19 treatments (1) COVID-19 vaccines (1) COVID-19+ observational (1) COVID-HIGIV (1) COVID-VIRO® test (1) COVID-surgRES questionaire (1) COVID19 (1) COVID19 convalescent plasma infusion (1) COVID19 immunization testing (1) COVID19 vaccine (1) COVIDSeq Test (1) COVSurf Drug Delivery System (1) CPAP (1) CPAP treatment (1) CPI-006 (1) CRI management (1) CSL324 (1) CSL760 (1) CT of the chest (1) CT score (1) CT-P59/Placebo (1) CT-V (1) CT-imaging (1) CT-scan (1) CT-scan with minimal invasive autopsy (1) CTUS examination (1) CUROSURF® (poractant alfa) (1) CVnCoV (1) CVnCoV 12 μg (1) CVnCoV 12μg (1) CVnCoV 6 μg (1) CYNK-001 (1) CYP-001 (1) Calcium Channel Blockers (1) Calm Meditation App (1) Cambridge Validated Viral Detection Method (1) CanSwab (1) Canakinumab 150 MG/ML [Ilaris] (1) Canakinumab Injection 300mg (1) Canakinumab Injection 600mg (1) Candesartan (1) Canine odor detection of Volatile Organic Compounds (1) Cannabidiol, pharmaceutically produced with < 5 ppm THC (1) Cannabis, Medical (1) Capillary Collection & Testing (1) Capillary and salivary sampling (1) Capnography (1) Caption AI (1) Cardiac CT (1) Cardiac MRI (1) Cardiac Magnetic resonance imaging (1) Cardiac surgery (1) Cardiopulmonary exercise test (1) Cardiopulmonary resuscitation (1) Cardiorespiratory Exercise (1) Cardiovascular Magnetic Resonance (CMR) Imaging (1) Caring Contacts (1) Carotid Artery Reactivity Testing (1) Carrageenan nasal and throat spray (1) Cartography of air contamination, environment contamination and biological fluid by Sars-Cov2 during visceral surgery in COVID19 patients. (1) Case fatality rate (1) Cash transfer (1) Ceftaroline (1) Ceftriaxone (1) Cell therapy protocol 1 (1) Cell therapy protocol 2 (1) Cellular response (1) Cenicriviroc (1) Cenicriviroc (CVC) (1) Centricyte 1000 (1) Centrum Adult (under 50) multivitamin (1) Cerebral compliance and hemodynamics monitoring (1) Cerebrospinal fluid sampling, meningeal and brain parenchyma biopsies (1) Cereset Research (1) Certified cloth face mask plus preventive information (1) ChAdOx1 nCoV-19 (Abs 260) (1) ChAdOx1 nCoV-19 (Abs 260) + 2.2x10^10vp (qPCR) boost (1) ChAdOx1 nCoV-19 (qPCR) (1) ChAdOx1 nCoV-19 0.5mL boost (1) ChAdOx1 nCoV-19 0.5mL prime plus boost (1) ChAdOx1 nCoV-19 full boost (1) ChAdOx1 nCoV-19 half boost (1) ChAdOx1 nCoV-19 single dose + paracetamol (1) ChAdOx1 nCoV-19 two dose + paracetamol (1) Change in knowledge, motivation, skills, resources (1) Change in preference to surgery under COVID-19 pandemic. (1) Chat-based instant messaging support (1) Chat-based support (1) Chemotherapy (1) Chest CT scan + baseline spirometry (1) Chest MRI (1) Chest computed tomography (CT) (1) Chest physiotherapy post-covid19 (1) Chest physiotherapy using a non-invasive oscillating device (1) Chinese Herbal Medicine (1) Chinese medicine treatment (1) Chiropractic care (1) Chiropractic care (more than one visit) (1) Chiropractic care (one visit) (1) Chloroquine Diphosphate (1) Chloroquine Phosphate Tablets (1) Chloroquine diphosphate (1) Chlorpromazine (1) Choice of Assignment: Active Choice (1) Choice of Assignment: Enhanced Active Choice (1) Choice of Assignment: Opt-in (1) Choices and judgements (1) ChulaCov19 mRNA vaccine (1) Ciclesonide Inhalation Aerosol (1) Ciclesonide Metered Dose Inhaler [Alvesco] (1) Clarithromycin (1) Clarithromycin 500mg (1) Clazakizumab 12.5 mg (1) Clazakizumab 25 mg (1) Clevudine (1) Clinical Observation (1) Clinical Trial Matching (1) Clinical diagnosis of COVID-19 by a health care professional (1) Clinical examination (1) Clinical interview (1) Clinical, functional and radiological lung involvement evolution (1) Clinical, laboratory and imaging characteristics of pneumonia (1) Cliniporator (1) CloSYS mouthwash (1) Clofazimine (1) Clopidogrel 75mg (1) Closed face shield with Surgical face mask use (1) Closed-loop control of oxygen supplementation by O2matic (1) Cloth Face Mask (1) Clungene rapid test cassette (1) Co-mestring (co-coping) (1) Cod liver oil (1) Cognitive Behavioral Brief-Telepsychotherapy (1) Cognitive Behavioural Group Therapy for Perinatal Anxiety (1) Cognitive and behavioral intervention. (1) Cognitive behavior therapy (CBT), specifically using the Facing Your Fears (FYF) curriculum (1) Cognitive testing (1) Cognitive training (1) Cohort (1) Colchicine 0.5 MG (1) Colchicine 1 MG Oral Tablet (1) Colchicine Pill (1) Colchicine plus symptomatic treatment (paracetamol) (1) Coldamaris pro, nasal spray (1) Colgate Peroxyl mouthwash (1) Colgate Total mouthwash (1) Colgate periogard mouthwash (1) Collagen-Polyvinylpyrrolidone (1) Collection of Biological Samples (1) Collection of blood samples in order to create a biocollection (1) Collection of blood, salivary and nasopharyngeal samples. (1) Collection of breath sample (1) Collection of odour samples (1) Collection of samples (1) Collection of tears and saliva. (1) Colonoscopy (1) Colorectal resections (1) Combination (1) Combination of oral polio vaccine and NA-831 (1) Combined ART/hydroxychloroquine (1) Combined use of a respiratory broad panel multiplex PCR and procalcitonin (1) Communication (1) Communication type (1) Community interest message (1) Community popular opinion leader (POL) based intervention (1) Community-based, mobile van testing (1) Community-driven messages to promote COVID-19 testing (1) Comparable Placebo (1) Comparable Placebo of Oral Polio Vaccine and Placebo of drug (1) Comparable Placebo of drug (1) Comparative Observational Cohort Study (1) Comparator (1) Compassion focused intervention (1) Complement dosage (1) Complete blood picture, bone marrow aspiration cytology (1) Complete thrombophilic profile testing by multiplex PCR (1) Completion of post telemedicine encounter survey (1) Completion of pre-pandemic survey (1) Completion of survey after peak of pandemic (1) Complex diagnostic panel (1) Comprehensive treatment (1) Computed Tomography (CT) (1) Computer task questionnaires (1) Conestat alfa (1) Confinement and Communication During the COVID-19 Pandemic (1) Conjunctival swab and nasopharyngeal swab (1) Connected devices measurements (1) Connor-Davidson Resilience Scale 10 items (CD-RISC 10) (1) Contain COVID Anxiety SSI (1) Continuation of ACEi/ARB (1) Continuation of ARB/ACEI (1) Continuous Positive Airway Pressure (1) Continuous Positive Airway Pressure (CPAP) therapy using OxyJet (1) Continuous exercise training (1) Continuous positive airway pressure (CPAP) treatment (1) Continuous renal replacement therapy (1) Continuous vital sign monitoring - Isansys Patient Status Engine (1) Contrast-enhanced CMR (1) Control (albumin 5%) (1) Control Blend (1) Control Group (1) Control Group (pharmacotherapy and/or psychotherapy, n=10) (1) Control Period (1) Control Test (1) Control arm (1) Control message (1) Control patients (1) Control swab (1) ConvP (1) Convalescent Immune Plasma (1) Convalescent Plasma 1 Unit (1) Convalescent Plasma 2 Units (1) Convalescent Plasma Infusion (1) Convalescent Plasma as Therapy for Covid-19 patients (1) Convalescent Plasma from COVID-19 donors (1) Convalescent Plasma of patients with COVID-19 (1) Convalescent SARS COVID-19 plasma (1) Convalescent Serum (1) Convalescent anti-SARS-CoV-2 MBT Plasma (1) Convalescent anti-SARS-CoV-2 MBT plasma (1) Convalescent anti-SARS-CoV-2 plasma (1) Convalescent plasma (CP) (1) Convalescent plasma transfusion (1) Convalesscent Plasma (1) Conventional N95 respirator (1) Conventional Oxygen Therapy (1) Conventional medicines (Oxygen therapy, alfa interferon via aerosol inhalation, and lopinavir/ritonavir) (1) Conventional medicines (Oxygen therapy, alfa interferon via aerosol inhalation, and lopinavir/ritonavir) and Traditional Chinese Medicines (TCMs) granules (1) Conventional oxygen therapy (1) Conventional physical therapy (1) Conventional therapy first (1) Coping strategies video (1) Cordio App (1) Core Warming (1) Corn oil (placebo) (1) Coromec Registry with ECL-19 (1) CoronaCideTM COVID-19 IgM/IgG Rapid Test and Premier Biotech COVID-19 IgM/IgG Rapid Test (1) CoronaVac (1) Coronavirus Anxiety Scale , COVID-19 Phobia Scale (1) Coronavirus Disease 2019 (1) Corticosteroid injection (1) Corticosteroid with or without colchicine (1) Corticosteroids and Derivatives (1) Cospherunate/Azythromycine (1) Cospherunate/Phytomedicine/Azythromycien (1) Cost-Benefit Frame (1) CovX (1) Covax-19™ (1) Covid ICU containment measures (1) Covid-19 + patients (1) Covid-19 Antibody testing (IgG and IgM) (1) Covid-19 PCR , IGM (1) Covid-19 Rapid Test Kit (RAPG-COV-019) (1) Covid-19 Standard of Care (1) Covid-19 presto test (1) Covid-19 swab PCR test (1) Covid19 (1) Covid19 RT-PCR (1) Covidfree@home (1) Covigenix VAX-001 (1) Covigenix VAX-001 placebo (1) Crest Pro-Health Multi-Protection mouthwash (1) Crisis intervention therapy (1) Crisis management coaching (1) Cross Sectional study using scientifically validated psychometric Scales (1) Cross-sectional observational study (1) Cross-sectional study examining the impact of information sources to obtain information about COVID-19 on depression and anxiety symptoms (1) Cross-sectional study investigating the association of NPIs with mental health (1) Cross-sectional survey (1) Curently used therapy for COVID-19 non-critical patients (1) Current care per UCLA treating physicians (1) Current clinical practices of participating physicians (1) Customized questionnaire (1) Cyclosporin A (1) CytoSorb (1) CytoSorb 300 mL device (1) CytoSorb-Therapy (1) Cytokine Adsorption (1) Cytokines dosage (1) Cytokines measurement (1) D-beta-hydroxybutyrate-(R)-1,3 butanediol monoester (1) D-dimer,CBC.ESR,CRP, (1) DAS181 COVID-19 (1) DAS181 OL (1) DASS-21 instrument (depression and anxiety) (1) DB-001 (1) DECT (1) DFV890 (1) DIG Axial (1) DIG Tilted (1) DUR-928 (1) DWJ1248 (1) Daclatasvir 60 mg (1) Daily Coping Toolkit (1) Daily Monitoring (1) Daily Vitamin D3 (1) Daily placebo (1) Dalcetrapib (1) Danoprevir+Ritonavir (1) Dapagliflozin (1) Dapagliflozin 10 MG (1) Darunavir and Cobicistat (1) Darunavir/Cobicistat (1) Data Collection: Clinical Care Assessments (1) Data collection and clinical testing of subjects (1) Data collection and rhinopharyngeal swab (1) Data collection from blood draw (1) Data collection from lumbar puncture (1) Data collection from medical files (1) Data collection up to 1 year (1) Data extraction from medical files (1) Data monitoring for 48h within the first 12 hours of admission for COVID-19 (1) Data registry (1) Data research, database analysis (1) Ddrops® products, 50,000 IU, Oral (1) Decidual Stromal Cells (DSC) (1) Decitabine (1) Deep Breathing training (1) Deep Venous Disease Diagnostic (1) Defibrotide 25 mg/kg 24 hours continuous infusion for 15 days (1) Defibrotide Injection (1) Degarelix (1) DeltaRex-G (1) Dental pulp mesenchymal stem cells (1) Depression, Anxiety and Stress Scale (1) Descartes 30 (1) Description of groups caracteristics (1) Desferal 500 MG Injection (1) Desidustat (1) Detection of anti-COVID-19 antibody level (1) Determination of physical activity, quality of life, stress levels of isolated people at home with the danger of coronavirus. (1) Device used to record voice for screening (1) Dexamethasone (high dose) (1) Dexamethasone 2 MG/ML (1) Dexamethasone and Hydroxychloroquine (1) Dexcom G6 (1) Dexmedetomidine Injectable Product (1) DiaBetter Together (1) DiaNose (1) Diabetes type 2 (1) Diagnosis of SARS-Cov2 by RT-PCR and : IgG, Ig M serologies in the amniotoc fluid, the blood cord and the placenta (1) Diagnostic Test: serology test for COVID-19 (1) Diagnostic examination for venous thromboembolism (1) Diagnostic test Covid-19 (1) Diagnostic test for SARS-Cov2 for patients and health staff (1) Diagnostic test for detection of SARS-CoV-2 (1) Dialectical Behavioral Therapy (DBT) Skills (1) Dialyzable Leukocyte Extract (1) Diet tracking and survey (1) Dietary Supplement containing resistant starch (1) Dietary counselling on Food Groups according to IYC Feeding practices, WHO (1) Dietary supplementation in patients with covid disease admitted to hospital (1) Differences in triage (1) Differential Leucocyte Count (CLDC) device and algorithm (1) Difficulties lived by disabled children's parents in the period of COVID-19 pandemic (1) Diffusing capacity of carbon monoxide (1) DigiVis visual acuity app (1) Digital Health Online Platform (1) Digital cardiac Counseling (1) Digital oximeter monitoring (1) Digital problem solving tool (1) Diphenhydramine (1) Dipyridamole (1) Dipyridamole 100 Milligram(mg) (1) Dipyridamole ER 200mg/ Aspirin 25mg orally/enterally AND Standard of care (1) Direct Antigen Tests for COVID-19 (1) Direct laryngoscopy (1) Discontinuation of ACEi/ARB (1) Discontinuation of ARB/ACEI (1) Discussion Board for Social Support +Basic Feedback (1) Discussion Board for Social Support+Personalized Feedback (1) Disease-modifying antirheumatic drugs (DMARDs) (1) Distilled water (1) Dociparastat sodium (1) Doctella telehealth monitoring (1) Doctor Spot (1) Doctorgram Patient Kit (1) Doppler Echo (1) Dornase Alfa (1) Dornase Alfa Inhalation Solution (1) Dose Finding Phase (MTD) (1) Dose of Tinzaparin or Dalteparin (1) Dose of tinzaparin or dalteparin (1) Double-Blind NT-I7 (1) Double-Blind Placebo (1) Doxycyclin (1) Doxycycline Hcl (1) Drug COVID19-0001-USR (1) Drug Isotretinoin (13 cis retinoic acid ) capsules+standard treatment (1) Drug: GS-5734 - 1.00 mg/kg (1) Drug: GS-5734 - 2.00 mg/kg (1) Drug: Isotretinoin plus Tamoxifen (1) Drug: Isotretinoin(Aerosolized 13 cis retinoic acid) (1) Drug: Isotretinoin(Aerosolized 13 cis retinoic acid) plus Aerosolized Itraconazole (1) Drug: NA-831 (1) Drug: NA-831 - 0.10 mg/kg (1) Drug: NA-831 - 0.20 mg/kg (1) Drug: Standard treatment Standard treatment (1) Drugs and supportive care (1) Drugs: NA-831 (0.10 mg/kg) plus GS-5734 (1.00 mg/kg) (1) Drugs: NA-831 (0.20 mg/kg) plus GS-5734 (2.00 mg/kg) (1) DuACT (1) Duplex ultrasound and Computed Tomography Angiography (1) During COVID-19 Pandemic (1) Duty Frame (1) Dysphagia Handicap Index (DHI) (1) ECCO2R (1) ECG from handheld device (1) ECG-Holter (1) ECMO Implantation (1) EEG (1) EG-HPCP-03a (1) EG-HPCP-03a Placebo (1) EIT-Group (1) ELISA (1) ELISA and Rapid test to detect antibodies against COVID-19 (1) ELISPOT (1) ELMO PROJECT AT COVID-19: PROOF OF CONCEPT AND USABILITY (1) ELMO PROJECT AT COVID-19: STUDY IN HUMANS (1) EMDR (1) ENT exam (1) EP (1) EPDS (Edinburgh Postnatal Depression Scale) (1) EPIC risk score display (1) EQ001 (1) EQ001 Placebo (1) ERUCOV-VAC (1) ESOGER (1) EUROIMMUN assay (1) EXTRA-CVD Virtual Care (1) EarSats Pulse Oximeter Probe (1) Early rehabilitation (1) EasyCov POC (1) Eating habits (1) Echo-Doppler (1) Economic benefit message (1) Economic freedom message (1) Edinburgh Postnatal Depression Scale (EDPS) (1) Edoxaban Tablets (1) Education (1) Education sessions (1) Educational meetings and visual prompts (1) Eicosapentaenoic acid gastro-resistant capsules (1) Ejaculated semen sample (1) Elective Cancer Surgery (1) Electric pad for human external pain therapy (1) Electrical Impedance Tomography (EIT) (1) Electrical Impedance tomography (1) Electrical Stimulation (1) Electrical Stimulation - Sham (1) Electro impedance tomography (1) Electrocardiogram (ECG) (1) Electrocardiogram, telemetry, echocardiogram, laboratory values (1) Electrocardiogram, transthoracic echocardiography and clinico-biological parameters in routine care (1) Electroencephalogram with EKG lead (1) Electronic Survey questionnaire (1) Electronic survey (1) Elisa-test for IgM and IgG to SARS-CoV-2 (1) Eltrombopag (1) Emapalumab (1) Embarrassment message (1) Emergency Laparotomy (1) Emergency Ventilator Splitter (1) Emergency general surgical admissions (1) Emergency surgery (1) Emotion Regulation Training via Telehealth (1) Emotional Freedom Technique (1) Emotional Support Plan (1) Emphasis of Academic Researchers Involvement (1) Emphasis of Government Involvement (1) Emtricitabine/Tenofovir Alafenamide 200 MG-25 MG Oral Tablet (1) Emtricitabine/tenofovir (1) Emtricitabine/tenofovir disoproxil (1) Endoscopic intervention (1) Endoscopic management according to standard of care (1) Endoscopic procedure (1) Endothelial damage and angiogenic biomarkers (1) Endotracheal intubation (1) Enduring Happiness and Continued Self-Enhancement (ENHANCE) for COVID-19 (1) Enhanced hygiene measures (1) Enisamium Iodide (1) Enoxaparin 1 mg/kg (1) Enoxaparin 40Mg/0.4Ml Inj Syringe 0.4Ml (1) Enoxaparin Higher Dose (1) Enoxaparin Prefilled Syringe [Lovenox] (1) Enoxaparin Prophylactic Dose (1) Enoxaparin sodium (1) Enoxaparin/Lovenox Intermediate Dose (1) Enriched Survey Feedback (1) Ensifentrine Dose 1 (1) Entrée: Behavioral skills (1) Entrée: Cognitive skills (1) Entrée: Interpersonal skills (1) Environmental exposure and clinical features (1) Enzalutamide (1) Enzalutamide Pill (1) EpiVacCorona (EpiVacCorona vaccine based on peptide antigens for the prevention of COVID-19) (1) Equipment with smartwatch throughout hospital stay on the general ward (1) Eritoran (1) Escin (1) Essential Oil Blend (1) Essential oils (1) Estradiol patch (1) Estrogen Therapy (1) Ethanol with Asprin (1) Etoposide (1) Evaluate HACOR score effectivity in this patients (1) Evaluation of changes in the diagnostic-therapeutic pathway for patients affected by pancreatic cancer (1) Evaluation of clinical, instrumental and laboratory diagnostics tests (1) Evaluation of the epidemiological characteristics of coronavirus infection (SARS-CoV-2) (1) Ex vivo expanded Wharton's Jelly Mesenchymal Stem Cells (1) Examinations for the research: (1) Examine the impact of COVID-19 during pregnancy (1) Exebacase (1) Exercise Group (1) Exercise booklet (1) Exercise brochure (1) Exercise capacity (1) Exercise physiology (1) Exercise program (1) Exercise test ECG (1) Exercise training group (1) Expanded Hemodialysis for Covid19 maintenance hemodialysis patients (1) Experience of pandemic (1) Experiences in Close Relationship Scale questionnaire (ECR-S) (1) Experimental Group (1) Experimental drug (1) Experimental: Active care group (1) Experimental: Questionnaire without precaution information (1) Experts consensus (1) Expiratory training device (1) Exposure (not intervention) - SARS-CoV-2 infection (1) Exposure to telemedicine, after the onset of the pandemic (1) Exposure to the Dutch measures due to the Covid-19 pandemic. (1) Exposure to the SARS-CoV-2 (1) Exposure to the SARS-CoV-2 and its consequences (1) Exposure: Covid-19 infection (1) Expression of receptors and activating proteases (1) Extended sampling and procedures (1) External evacuation device (EED) (1) Extra blood sample (1) Extracorporeal blood purification using the oXiris® (AN69ST) hemofilter (1) Extracorporeal left hemicolectomy anastomosis (1) Extracorporeal membrane oxygenation (1) Extraoral vacuum aspirator (EVA) (1) Extravascular Lung Water Index (1) Eye Movement Desensitisation and Reprocessing Recent traumatic Event Protocol (1) F-652 (1) FAVICOVIR 200 mg Film Tablet (1) FAVIR 200 MG FT (1) FAVIRA 200 MG Film Tablet (1) FFP (1) FFP2 (1) FMD (1) FNC dummy tablet+Standard of Care (1) FNC+Standard of Care (1) FOY-305 (1) FSD201 (1) FT516 (1) FX06 (1) Face Mask + Soap (1) Face mask (1) Face mask awareness (1) Face mask sampling (1) Facebook Ads on the importance of staying safe during the Thanksgiving holiday (1) Facial fractures reduction or osteosynthesis (1) Facial mask (1) Family Nurture Intervention (FNI) (1) FamilyChildCare (provisional name of app) (1) Farmalarm (1) Fast dissolving film (1) Favipiravir (3200 mg + 1200 mg) (1) Favipiravir (3200 mg + 1200 mg) combined with Azithromycin (1) Favipiravir (3200 mg + 1200 mg) combined with Hydroxychloroquine (1) Favipiravir (3600 mg + 1600 mg) (1) Favipiravir + Currently used therapy (1) Favipiravir + Standard of Care (1) Favipiravir Combined With Tocilizumab (1) Favipiravir and Hydroxychloroquine (1) Favipiravir plus Nitazoxanide (1) Feeling Good Digital App (1) Fenofibrate (1) Fiberoptic Bronchoscopy (FOB) (1) Fibreoptic Endoscopic Evaluation of Swallowing (FEES) (1) Fibrin generation markers assays (1) File Scanning (1) File scanning (1) FilmArray PCR on respiratory samples (1) FilmArray Pneumonia (1) Filtration Test (1) Fingerstick (1) Fingolimod 0.5 mg (1) Fit test (1) Five-days oseltamivir (1) Fixed site standard of care testing (1) Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration (PH FDC SC) (1) Fixed-duration Hydrocortisone (1) Fixed-duration higher dose Hydrocortisone (1) Flow controlled ventilation (Evone-ventilator) (1) Flow cytometry (1) Flu shot (1) Flucelvax (1) Fluorescein (1) Fluvirin (1) Fluzone High Dose (1) FoTv (1) Focused/Targeted Message (1) Folic Acid (1) Follow up calls (1) Follow-up at 14 days (1) Follow-up of patients with COVID-19 (1) Follow-up phone call (1) Follow-up visit (1) Fondapariniux (1) Fondaparinux (1) Freestyle Libre 14 day CGM system (1) Full Spectrum CBD Oil (1) Functional MRI (1) Fuzheng Huayu Tablet (1) Fuzheng Huayu tablet (1) GAD-7 (7-item Generalized Anxiety Disorder) (1) GAD-7 (General Anxiety Disorder) scale (1) GAD-7 General anxiety disorder scale (1) GAMUNEX-C (1) GC4419 (1) GC5131 (1) GENETIC (1) GLS-1027 (1) GLS-1200 (1) GLS-5310 (1) GM-CSF (1) GNS561 (1) GO2 PEEP MOUTHPIECE (1) GPs reports of potential patient safety incidents, non-COVID-19 related (1) GRAd-COV2 (1) GX-19 (1) Galidesivir (1) Gam-COVID-Vac Lyo (1) Gamification (1) Ganovo+ritonavir+/-Interferon nebulization (1) Garadacimab, Factor XIIa Antagonist Monoclonal Antibody (1) Gargle/Mouthwash (1) Gas exchange measurement (1) Gas exchanges at different PEEP (1) Gastrointestinal endoscopy (1) General Communication Message (1) General Public cohort (1) General health education (1) Generalized Anxiety Disorder-7 (GAD 7) (1) Generalized Anxiety Disorder-7 (GAD-7) (1) Gimsilumab (1) Global Longitudinal Strain (1) Glucose tablets (1) Glycaemic levels (1) Glycine (1) Graded exercise test (1) Grocery store gift cards (1) Group 1 (1) Group 1: Rivaroxaban 20mg/d followed by enoxaparin/unfractionated heparin when needed (1) Group 2: control group with enoxaparin 40mg/d (1) Group A (AG0302-COVID19) (1) Group A (Placebo) (1) Group A HCQ (1) Group A: oropharygeal spray and immunostimulant (1) Group B (AG0302-COVID19) (1) Group B (Placebo) (1) Group B Control (1) Group B: Placebo oropharyngeal spray + Active principle immunostimulant (1) Group C:Active principle oropharyngeal spray + Placebo taken PO (1) Group D:Placebo oropharyngeal spray + Placebo taken PO (1) Group1 (1) Growth Hormone (1) Growth Mindset SSI (1) Guided online support program (1) Guilt message (1) HADS (1) HADS questionnaire (1) HB-adMSC (1) HCFWO (1) HCQ & AZ (1) HCQ & AZ vs HCQ+SIR (1) HCQ+AZT (1) HFB30132A (1) HFNO (1) HIT-exercise (1) HLX70 (1) HLX71 (1) HOME-CoV rule implementation (1) HOPE intervention (1) Health Care Worker Survey (1) Health Enhancement Program (1) Health Questionnaire (1) Health supplements (1) Health warning leaflet (1) Health-related quality of life (1) Healthy Minds Program Foundations Training (1) Healthy lifestyle advise (1) Helmet CPAP (1) Helmet Continuous Positive Airway Pressure (CPAP) (1) Helmet non-invasive ventilation (1) Hemodialysis by protein-leaking dialyzer for Covid19 maintenance hemodialysis patients (1) Hemodynamics changes at different PEEP (1) Hemopurifier (1) Heparin - Prophylactic dosage (1) Heparin - Therapeutic dosage (1) Heparin Infusion (1) Heparin SC (1) Heparin sodium (1) Hepatitis A vaccine (1) Hesperidin and Diosmin mixture (1) Heterologous stimuli (1) Hidroxicloroquina (1) High Dose of KBP-COVID-19 (1) High Flow Nasal Oxygen (HFNO) (1) High Flow Nasal Oxygen (HFNO) treatment (1) High Flow Nasal Therapy (1) High Intensity Interval Training group (1) High PEEP with end inspiratory pause (1) High PEEP without end inspiratory pause (1) High dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 14-day schedule (1) High dose Interferon-beta 1a (1) High dose radiation 100 cGy (1) High flow nasal cannula (1) High flow nasal cannula HFNC (1) High volume evacuation (HVE) (1) High-Concentration Essential Oil (1) High-Titer Anti-SARS-CoV-2 (COVID 19) Convalescent Plasma (1) High-Titer COVID-19 Convalescent Plasma (HT-CCP) (1) High-dose Recombinant COVID-19 vaccine (Sf9 cells) (18-59 years) & Three dose regimen (1) High-dose Recombinant COVID-19 vaccine (Sf9 cells) (18-59 years) & Two dose regimen (1) High-dose Recombinant COVID-19 vaccine (Sf9 cells) (60-85 years) & Three dose regimen (1) High-dose Recombinant COVID-19 vaccine (Sf9 cells) (60-85 years) & Two dose regimen (1) High-dose placebo (18-59 years) & Three dose regimen (1) High-dose placebo (18-59 years) & Two dose regimen (1) High-dose placebo (60-85 years) & Three dose regimen (1) High-dose placebo (60-85 years) & Two dose regimen (1) High-flow nasal cannula treatment (1) High-titer Convalescent COVID-19 Plasma (CCP1) (1) Hiking challenge (1) Home Pulse Oximetry Monitoring (1) Home Sleep Apnea Testing or In-hospital Polysomnography (1) Home exercise (1) Home exercise program (1) Home sample collection of concerning mole with physician supervision (1) Home-based exercise (1) Home-based exercise training (1) Home-use Test and Follow-up Questionnaire (1) Honey (1) Hormones (1) Hospital admission (1) Hospital anxiety and depression scale (1) Hospital: DD-CA (1) Hospital: Usual Care (UC) (1) Hospitalized Patients for COVID-19 Infection (1) Huaier Granule (1) Human Biological samples (1) Human Coach first, then Virtual Assistant (1) Human Ezrin Peptide 1 (HEP1) (1) Human milk donors (1) Human umbilical cord derived CD362 enriched MSCs (1) Human umbilical cord mesenchymal stem cells + best supportive care (1) Humoral and cellular immunity (1) Hydrogen Oxygen Generator with Nebulizer (1) Hydrogen Peroxide (1) Hydrogen-Oxygen Generator with Nebulizer, AMS-H-03 (1) Hydroxychloroquin with Azithromycin (1) Hydroxychloroquine (placebo) (1) Hydroxychloroquine + Azithromycin (1) Hydroxychloroquine + Metabolic cofactor supplementation (1) Hydroxychloroquine + Sorbitol (1) Hydroxychloroquine + azithromycin + / - tocilizumab (1) Hydroxychloroquine + lopinavir/ritonavir (1) Hydroxychloroquine + placebo (1) Hydroxychloroquine , Sofosbuvir, daclatasvir (1) Hydroxychloroquine - Daily Dosing (1) Hydroxychloroquine - Daily dosing (1) Hydroxychloroquine Only Product in Oral Dose Form (1) Hydroxychloroquine Oral Product (1) Hydroxychloroquine Pill (1) Hydroxychloroquine Pre-Exposure Prophylaxis (1) Hydroxychloroquine SAR321068 (1) Hydroxychloroquine Sulfate (HCQ) (1) Hydroxychloroquine Sulfate + Azithromycin (1) Hydroxychloroquine Sulfate + Azythromycin (1) Hydroxychloroquine Sulfate 200 milligram (mg) Tab (1) Hydroxychloroquine Sulfate 400 mg twice a day (1) Hydroxychloroquine Sulfate 600 mg once a day (1) Hydroxychloroquine Sulfate 600 mg twice a day (1) Hydroxychloroquine Sulfate Tablets plus Lopinavir/ Ritonavir Oral Tablets (1) Hydroxychloroquine and azithromycin treatment (1) Hydroxychloroquine and azithromycin treatment arm. (1) Hydroxychloroquine as post exposure prophylaxis (1) Hydroxychloroquine combined with Azithromycin (1) Hydroxychloroquine in combination of Azithromycin (1) Hydroxychloroquine plus Nitazoxanide (1) Hydroxychloroquine plus standard preventive measures (1) Hydroxychloroquine sulfate (1) Hydroxychloroquine sulfate &Azithromycin (1) Hydroxychloroquine, Azithromycin (1) Hydroxychloroquine, Clindamycin (1) Hydroxychloroquine, Clindamycin, Primaquine - high dose. (1) Hydroxychloroquine, Clindamycin, Primaquine - low dose. (1) Hydroxychloroquine, Doxycycline (1) Hydroxychloroquine, lopinavir/ritonavir or azithromycin and placebo (standard therapy) (1) Hydroxychloroquine/Azithromycine (1) Hydroxychloroquine/Chloroquine (1) Hydroxycloroquine and Azythromycine (1) Hyperbaric Chamber (1) Hyperbaric Oxygen (1) Hyperbaric Oxygen Therapy (1) Hyperbaric Oxygen Therapy (HBOT) (1) Hyperbaric oxygen therapy (1) Hyperbaric oxygen treatment (HBOT) i.e. inhalation of pressurized oxygen delivered by a hyperbaric chamber (drug/device) (1) Hyperimmune immunoglobulin to SARS-CoV-2 (hIVIG) (1) Hyperimmune plasma (1) Hyperpolarized Xe129 (1) Hyperpolarized Xenon-129 MRI of the lungs (1) Hypertension (1) Hypothermia (1) Hypothermia Via Cooling Machine- Arctic Sun 5000 (1) IC14 (1) IC14, a monoclonal antibody against CD14 (1) ICU Recovery + Physical Therapy (1) ID NOW vs. Accula (1) IER-R (posttraumatic stress) (1) IIBR-100 high-dose (prime) (1) IIBR-100 low-dose (prime-boost) (1) IIBR-100 medium dose (prime) (1) IIBR-100, low dose (prime) (1) IIEF-5 questionnaire (1) IL-12 plasmid (1) IMM-101 (1) IN01 vaccine (1) INB03 (1) INC424 / Ruxolitinib (1) INM005 (1) INOpulse (1) IP-10 in CDS protocol (1) IPSS questionnaire (1) ISIS 721744 (1) IV Deployment Of cSVF In Sterile Normal Saline IV Solution (1) IV Dexamethasone (1) IVERMECTIN (IVER P®) arm will receive IVM 600 µg / kg once daily plus standard care. CONTROL arm will receive standard care. (1) Ibudilast (1) Ibuprofen (1) Icatibant (1) Icosapent ethyl (IPE) (1) Identification by PCR of the SARS-COV-2 virus in samples taken from the fetus (1) Identification of genetic variants (1) IgG (1) IgG SARS CoV 2 antibodies (1) IgG SARS CoV2 (1) IgG antibodies immunoassay (1) IgG test (1) IgIV (1) IgM and IgG antibodies assay (1) IgM and IgG diagnostic kits to SARS-CoV-2 (1) Iloprost (1) Imaging (1) Imaging by thoracic scanner (1) Imaging of the lungs (1) Imatinib (1) Imatinib Mesylate (1) Imatinib tablets (1) Immediate vs. delayed provision of antibody test results (1) Immune response study (1) Immunfluorescence (1) ImmunoFormulation (1) Immunofree tablets and Reginmune capsule (1) Immunoglobulin (1) Immunoglobulin of cured patients (1) Immunoglubulins (1) Immunological profiling (1) Immunosuppressive (1) Immunosuppressive Agents (1) Impact Event Score (1) Impact of COVID-19 questionnaire (1) Impact of Event Scale-Revised (1) Impact of respiratory isolation on quality of life (1) In-person instruction (1) In-person postoperative visit (1) Inactivated SARS CoV 2 vaccine (Vero cell). Wuhan (1) Inactivated SARS-CoV-2 vaccine (Vero cell) (1) Inactivated convalescent plasma (1) Increasing Willingness and Uptake of COVID-19 Testing and Vaccination (1) Individualised Ayurveda (1) Individualized-Chinese herbal medicine (1) Indomethacin (1) Infectious Disease and Cardiology Clinical Consultations (1) Inflammatory cytokines and chemokines profiles of patients with dexmedetomidine administration (1) Information (1) Informational videos and social media campaigns encouraging cancer screening. (1) Informed consent (1) Infrared Energy and Dietary Supplement (1) Infusion IV of Mesenchymal Stem cells (1) Infusion placebo (1) Inhaled Hypertonic ibuprofen (1) Inhaled ILOPROST (1) Inhaled Supplemental Oxygen (1) Inhaled budesonide (1) Inhaled nitric oxide (iNO) (1) Inhaled nitric oxide gas (1) Inhaled sedation (1) Injection and infusion of LV-SMENP-DC vaccine and antigen-specific CTLs (1) Innova Lateral Flow Device (1) Inspiratory training device (1) Instrumental Activities of Daily Living Shaping (1) Insulin (1) Insulin film (1) Insulin regimen (1) Interferon alfa (1) Interferon-Alpha2B (1) Interferon-Beta (1) Interferon-ß-1a (1) Interferon-β 1a (1) Interferon-β1a (1) Interleukin 6 (IL6) Antagonist (1) Interleukin 6 (IL6) Antagonist and corticosteroids (1) Interleukin assessment in semen (1) Interleukin-1 receptor antagonist (1) Interleukin-6 Gene-174C detection (1) Intermediate dose thromboprophylaxis (1) Intermittent prone positioning instructions (1) Internet Cognitive Behavioral Therapy plus CHAMindWell (1) Internet-based Cognitive Behavioral Therapy (1) Internet-based guided self-help based on CBT principles (1) Internet-based self-help (1) Internet-based self-help after 3 weeks (1) Internet-delivered cognitive behavior therapy (ICBT) for dysfunctional worry related to the Covid-19 pandemic (1) Interpersonal Psychotherapy (1) Intervention (1) Intervention App (1) Intervention for COVID-19 preventive protocols (1) Intervention for TECC Model (1) Intervention group CoronaCope (1) Intervention group_rehabilitation program (1) Intervention program (1) Intervention training: (1) Intervention, TBN (1) Interview by psychologists (1) Intracorporeal left hemicolectomy anastomosis (1) Intramuscular Vaccine (1) Intramuscular vaccine (1) Intranasal heparin sodium (porcine) (1) Intraosseous access (1) Intravenous Immune Globulin (1) Intravenous Immunoglobulin (1) Intravenous Infusions of Stem Cells (1) Intravenous access (1) Intravenous drug (1) Intravenous saline injection (Placebo) (1) Intravenous sedation (1) Intubation Box (1) Invasive mechanical ventilation (1) Invasive mechanical ventilation using the Unisabana-Herons Ventilator during 24 hours (1) Investigation of smell and taste disorders (1) Investigation of the prevalence of test positivity (1) Investigational Product - ViraCide (1) Iota carrageenan nasal spray and Ivermectin oral drops (used as buccal drops) (1) Iota-Carrageenan (1) Isoflurane Inhalant Product (1) Isoprinosine (1) Isoquercetin (1) Isoquercetin (IQC-950AN) (1) Isotonic saline (1) Isotonic saline 0.9% (1) Isotretinoin Only Product in Oral Dose Form (1) Isotretinoin(Aerosolized 13 cis retinoic acid) +standard treatment (1) Itolizumab IV infusion (1) Ivermectin (IVM) (1) Ivermectin + Doxycycline (1) Ivermectin + Doxycycline + Placebo (1) Ivermectin + Placebo (1) Ivermectin 3mg Tab (1) Ivermectin 5 MG/ML oral solution, Aspirin 250 mg tablets (1) Ivermectin 5 MG/ML oral solution, Dexamethasone 4-mg injection, Enoxaparin injection. Inpatient treatment with mechanical ventilation in ICU. (1) Ivermectin 5 mg/mL oral solution, Dexamethasone 4-mg injection, Aspirin 250 mg tablets (1) Ivermectin 6 MG Oral Tablet (2 tablets) (1) Ivermectin Injectable Solution (1) Ivermectin Powder (1) Ivermectin Tablets (1) Ivermectin and Doxycyline (1) Ivermectin nasal (1) Ivermectin oral (1) Ivermectin plus Nitazoxanide (1) JS016 (anti-SARS-CoV-2 monoclonal antibody) (1) Janus Kinase Inhibitor (ruxolitinib) (1) KELEA Excellerated Water (1) KIR phenotype evaluation (1) Kaletra and beta interferon (1) Kamada Anti-SARS-CoV-2 (1) Kaplan Meier analysis (1) Ketamine (1) Ketogenic diet with phytoextracts (1) Ketotifen 1 MG (1) Kevzara sc (1) Knowledge, Attitude, Practice, Awareness, Preference (1) Kukaa Salama: mHealth intervention (1) Kundalini Yoga and Anxiety Reduction Training (1) L-Citrulline (1) L-citrulline (1) LAMP (1) LAU-7b (1) LB1148 (1) LEAF-4L6715 (1) LMWH (1) LSALT peptide (1) LY3127804 (1) LYMPHOCYTE MONOCYTE RATIO (1) LYT-100 (1) Lab workup (on admission and regularly during follow up). (1) Laboratory Analyses (1) Laboratory test positive for SARS-CoV-2 virus (1) Laboratory tests (1) Lactobaciltus rhamnosus GG (1) Lactobaciltus rhamnosus GG Placebo (1) Lactoferrin (1) Lactoferrin (Apolactoferrin) (1) Lambda 180 mcg S.C (1) Lanadelumab placebo (1) Late dexamethazone (1) Late-Dexamethasone (1) Lateral Position (left and right lateral decubitus) (1) Learning running subcuticular sutures on the Gamified Educational Network (1) Lenalidomide as a 5 mg capsule PO daily, days 1, 3, and 5. (1) Let It Out (LIO)-C (1) Leukapheresis (1) Levamisole (1) Levamisole Pill + Budesonide+Formoterol inhaler (1) Levamisole and Isoprinosine (1) Levamisole and isoprinosine (1) Levilimab (1) Lianhua Qingwen (1) Liberase Enzyme (Roche) (1) Licensed seasonal influenza vaccine (1) Licorice extract (1) Lidocaine 2% (1) Life2000® Ventilator (1) LifeSignals Biosensor 1AX* (1) Lifelight® Data Collect Blood Pressure Group (1) Lifelight® Data Collect Oxygen Saturation Group (1) Lifestyle change promotion program (1) Lift (1) Limbix Spark (1) Linagliptin (1) Linagliptin 5 MG (1) Linagliptin tablet (1) Liquid Alpha1-Proteinase Inhibitor (Human) (1) Listerine Mouthwash Product (1) Liu-Wei-Di-Huang formula (1) Liver function tests (1) Liver function tests ,serum ferritin and PCR for COVID-19 . (1) Liver injury (1) Liver, lung, heart and kidney biopsy (1) Local standard of care (1) Lock-down and social distancing (1) Longeveron Mesenchymal Stem Cells (LMSCs) (1) Lopinavir (1) Lopinavir / ritonavir tablets combined with Xiyanping injection (1) Lopinavir / ritonavir, alpha-interferon nebulization,Abidor Hydrochloride (1) Lopinavir 200 MG / Ritonavir 50 MG [Kaletra] (1) Lopinavir 200Mg/Ritonavir 50Mg Tab (1) Lopinavir and ritonavir (1) Lopinavir-Ritonavir Drug Combination (1) Lopinavir/ Ritonavir (1) Lopinavir/ Ritonavir Oral Tablet (1) Lopinavir/ Ritonavir Placebo (1) Lopinavir/Ritonavir + hydoxychloroquine (1) Lopinavir/Ritonavir 200 MG-50 MG Oral Tablet (1) Lopinavir/Ritonavir 200 mg/50 mg Film Coated Tablet (1) Lopinavir/Ritonavir 200 mg/50 mg Film Tablet (1) Lopinavir/Ritonavir 400 mg/100 mg (1) Lopinavir/ritonavir treatment (1) Losartan 50 mg and Spironolactone 25 mg pillules oral use (1) Losmapimod oral tablet (1) Lovenox 40 MG in 0.4 mL Prefilled Syringe (1) Low Dose (10 mg) Control (1) Low Dose Radiation Therapy (LD-RT) (1) Low Dose of KBP-COVID-19 (1) Low Molecular Weight Heparin (1) Low PEEP - FiO2 high (1) Low PEEP - FiO2 low (1) Low dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 14-day schedule (1) Low dose Interferon-beta 1a (1) Low dose Low molecular weight heparin or Placebo (1) Low dose Radiotherapy (1) Low dose prednisolone (1) Low dose radiation 35 cGy (1) Low dose radiation therapy (1) Low dose whole lung radiotherapy for older patients with COVID-19 pneumonitis (1) Low flow ECMO driving by CVVH machine (1) Low or upper respiratory tract sample (1) Low-Concentration Essential Oil (1) Low-Intensity Psychosocial Interventions through Telemental health (1) Low-dose Chest CT (1) Low-dose Recombinant COVID-19 vaccine (Sf9 cells) (18-59 years) & Three dose regimen (1) Low-dose Recombinant COVID-19 vaccine (Sf9 cells) (18-59 years) & Two dose regimen (1) Low-dose Recombinant COVID-19 vaccine (Sf9 cells) (60-85 years) & Three dose regimen (1) Low-dose Recombinant COVID-19 vaccine (Sf9 cells) (60-85 years) & Two dose regimen (1) Low-dose placebo (18-59 years) & Three dose regimen (1) Low-dose placebo (18-59 years) & Two dose regimen (1) Low-dose placebo (60-85 years) & Three dose regimen (1) Low-dose placebo (60-85 years) & Two dose regimen (1) Low-dose radiotherapy (1) Lower-dose prophylactic anticoagulation (1) Lucinactant (1) Lung CT (1) Lung CT scan analysis in COVID-19 patients (1) Lung Function Test (1) Lung Function tests (1) Lung Low Dose Radiation (1) Lung Ultrasound (1) Lung impedance technique (1) Lung ultrasound use in patients hospitalized with COVID (1) LungFit™ (1) MAGEC Spine Rod (1) MANAGEMENT OF COVID-19 (1) MAS825 (1) MCC IMS (1) MCN (Methylene blue, vitamin C, N-acetyl cysteine) (1) MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 15mcg (1) MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 45mcg (1) MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 5mcg (1) MFS (1) MK-5475 (1) MLS Laser (1) MMR vaccine (1) MPT0B640 (1) MR or M-M-R II ® vaccine (1) MR-Pro-ADM (1) MRG-001 (1) MRI (1) MRI (heart, brain, lungs, liver) (1) MRI scans (1) MRx-4DP0004 (1) MSC Treatment (1) MSCT (1) MSCs (1) MSCs-derived exosomes (1) MSTT1041A (1) MSTT1041A-matched Placebo (1) MVA-SARS-2-S vaccinations (days 0 & 28) (1) MVC-COV1901 (1) Machine Learning/AI Algorithm (1) Machine learning model (1) Macrolide administered for 3-5 days (1) Macrolide administered for up to 14 days (1) Magnetic Resonance Imaging (1) Magnetic Resonance Spectroscopy (MRS). (1) Maintenance or reduction of immunosuppression (1) MakAir (1) Male Sexual Health Questionnaire (MSHQ) (1) Maltodextrin (1) Mannitol (1) Manremyc (1) Maraviroc (1) Maraviroc + Currently used therapy (1) Maraviroc 300 mg (1) Maraviroc+Favipiravir+CT (1) Marker Therapeutics D2000 Cartridge (D2000) for use with the Spectra Optia® Apheresis System (Optia SPD Protocol) (1) Masimo, LidCO (1) Masitinib (1) Mask with Mask Adhesive/Arm 1 (1) Mask without Mask Adhesive / Arm 2 (1) Masked Saline Placebo (1) Maslach Burnout Inventory (MBI) (1) Massive parallel sequencing of host genome (1) Matched Placebo (1) Matched Placebo Hydroxychloroquine (1) Matched placebo (1) Matching placebo (1) Maternal attachment, Edinburgh depression scoring and postpartum anxiety scale scores (1) Maternal stress (1) Maximal effort test (1) Measles-Mumps-Rubella Vaccine (1) Mechanical Trombectomy (1) Mechanical ventilation with the automated BVM compressor (1) Media Intervention (1) Medical Mask (1) Medical Music (1) Medical Ozone procedure (1) Medical Record Review (1) Medical Record Review - Inpatient Treatment (1) Medication Review (1) Meditation Therapy (1) Meditation and Anxiety Reduction Training (1) Meditation app usage (1) Medium dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 14-day schedule (1) Medium dose prednisolone (1) Mefloquine (1) Mefloquine + azithromycin + / - tocilizumab (1) MejoraCare (1) Melatonin 2mg (1) Melatonin intravenous (1) Melphalan (1) MenACWY (1) MenACWY boost (1) MenACWY prime & saline placebo boost + paracetamol (1) MenACWY single dose + paracetamol (1) MenACWY vaccine (1) MenCare+/Bandebereho fathers'/couples' group education (1) Mental Health questionnaire (1) Mental imagery (1) Merimepodib (1) Mesenchymal Stem Cell (1) Mesenchymal Stem Cells derived from Wharton Jelly of Umbilical cords (1) Mesenchymal Stromal Cells infusion (1) Mesenchymal Stromal Stem Cells - KI-MSC-PL-205 (1) Mesenchymal cells (1) Mesenchymal stem cell (1) Mesenchymal stem cell therapy (1) Mesenchymal stem cells (1) Mesenchymal stromal cell-based therapy (1) Message directing subjects to information on COVID-19 vaccine safety and efficacy (1) Messaging (1) MetaNeb® System (1) Metformin Glycinate (1) Methotrexate-LDE phase 1 (1) Methotrexate-LDE phase 2 (1) MethylPREDNISolone 80 Mg/mL Injectable Suspension (1) Methylene Blue (1) Methylene Blue 5 MG/ML (1) Methylene-Blue Photodisinfection (1) Methylprednisolone Injectable Product (1) Methylprednisolone Injection (1) Methylprednisolone, Placebo (1) Microcannula Harvest Adipose Derived tissue stromal vascular fraction (tSVF) (1) Microcrystalline Cellulose, NF (1) Micronized and ultra-micronized Palmitoylethanolamide (mPEA and umPEA, 300mg + 600mg) oral suspension (1) Microscopy of defined brain regions on autopsy specimens (1) MindRhythm Harmony (1) Mindfullness based cognitive program (1) Mindfulness + Compassion Intervention (MC) (1) Mindfulness Alone (MO) Intervention (1) Mindfulness Based Cognitive Therapy for Resilience During COVID-19 plus CHAMindWell (1) Mindfulness Rounds (1) Mindfulness based intervention (1) Mindfulness intervention (1) Mindfulness program (1) Mindfulness session(s) (1) Mindfulness training (1) Mindfulness training (MT) Connect (1) Mindfulness-Based Cognitive Therapy (1) Minimal Attention Control Intervention (1) MinnRAP Peer Support Program (1) Mixture 3,6% H2 in N2 (96.4%) (1) Mobile Mental Health App - 1 (1) Mobile Mental Health App - 10 (1) Mobile Mental Health App - 2 (1) Mobile Mental Health App - 3 (1) Mobile Mental Health App - 4 (1) Mobile Mental Health App - 5 (1) Mobile Mental Health App - 6 (1) Mobile Mental Health App - 7 (1) Mobile Mental Health App - 8 (1) Mobile Mental Health App - 9 (1) Model Building (1) Model validation (1) Moderate Intensity Aerobic Exercises (1) Modified Bai He Gu Jin Tang (1) Modified CariesCare International management (1) Modified Rankin score (1) Molgramostim nebuliser solution (1) Monalizumab (1) Monitoring Visit - Baseline (1) Monitoring Visit - Week 4 (1) Monitoring Visit - Week 8 (1) Monitoring for aggravation (1) Monitoring physiological data with the Hexoskin smart shirt (1) Montelukast 10mg (1) Montmorrillonite (1) Motivational social support from nurse (1) Motivational social support from nurse with additional support from significant other (1) Motivational telephone intervention (1) Moxibustion plus Cupping (1) Moxifloxacin or Levofloxacin (1) Mucodentol (1) MultiStem (1) Multicapillary column coupled ion mobility spectrometry (1) Multifrequency Bioimpedance Spectroscopy (1) Multiple Doses of Anti-SARS-CoV-2 convalescent plasma (1) Muscle Relaxation Therapy (1) Muscle ultrasound (1) MuscleSound Ultrasound (1) Museum virtual guided tours (1) Music Therapy (1) N terminal pro B type natriuretic peptide (NTproBNP), D-Dimer, and serum Tropinin - I (1) N-803 (1) N-95 Respirator (1) N-acetyl cysteine (1) N95 respirator (1) NA (no intervention) (1) NA-831 (1) NA-831 and Atazanavir (1) NA-831and Dexamethasone (1) NAD+ (1) NBT-NM108 (1) NETosis markers (1) NG Biotech (1) NG test (1) NGM621 (1) NHANES smell and taste tests (1) NIO® (Intraosseous access) (1) NIVOLUMAB (1) NK Cells (1) NK cells,IL15-NK cells,NKG2D CAR-NK cells,ACE2 CAR-NK cells,NKG2D-ACE2 CAR-NK cells (1) NK-1R antagonist (1) NO intervention planned due to the observational study design - only a diagnostic testing (1) NO intervention planned due to the observational study design only a diagnostic testing (1) NO-Immunosuppressive (1) NOWDx COVID-19 Test (1) NOX66 (1) NP-120 (Ifenprodil) (1) NRICM101 (1) NT-I7 (1) NaCl (1) NaCl 0.9% (1) NaCl Solution (1) Nafamostat Mesylate (1) Nanocovax (1) Nanomix eLab® COVID-19 Rapid Antigen Panel (non-interventional) (1) Narrative Writing (1) Nasal Brushing (1) Nasal Dexamethasone (1) Nasal Irrigation (1) Nasal Spray (1) Nasal Swab (1) Nasal lavage (1) NasoVAX (1) Nasopharyngeal (NP) swab (1) Nasopharyngeal Swab (1) Nasopharyngeal and throat/oropharyngeal swabs analyses by RT-PCR and ddPCR (1) Nasopharyngeal swab and main laboratory (1) Nasopharyngeal, oropharyngeal, or saliva swab (1) Natural Honey (1) Natural Killer Cells infusion (1) Nebulised heparin (1) Nebulised unfractionated heparin (UFH) (1) Nebulized Furosemide (1) Nebulized Platelet Lysate (1) Nebulized Saline (1) Nebulized Sterile Saline (1) Nebulized administration of RLF-100 or Placebo (1) Negative COVID Test Result - Hypothetical Scenario (1) Neonatal resuscitation with PPE for the prevention of SARS-Cov-2 infection (1) Neonatal resuscitation without PPE for the prevention of SARS-Cov-2 infection (1) NestaCell® (1) Neural network diagnosis algorithm (1) Neurocognitive assessment (1) Neuromuscular Blocking Agents (1) Neuromuscular Electrical Stimulation (1) Neuromuscular evaluation (1) Neutral writing control (1) Neutralizing antibodies (1) New QIAstat-Dx fully automatic multiple PCR detection platform (1) New screening strategy (1) Newsfeed function (1) Next generation Sequencing (NGS) analysis (1) Niclosamide suspension (1) Nicotinamide riboside (1) Nicotine 7 mg/ 24h Transdermal Patch - 24 Hour (1) Nicotine patch (1) Nigella sativa (1) Nil intervention (1) Nintedanib (1) Nintedanib 150 MG (1) Nintedanib 150 MG [Ofev] (1) Nitazoxanide 500 MG (1) Nitazoxanide 500Mg Oral Tablet (1) Nitazoxanide Tablets (1) Nitazoxanide and atazanavir/ritonavir (1) Nitazoxanide with ivermectin (1) Nitric Oxide 0.5 % / Nitrogen 99.5 % Gas for Inhalation (1) Nitric Oxide delivered via LungFit™ system (1) Nitric Oxide lozenges, 30 mg (1) Nitric Oxide-Continuous and Sessions (1) Nitric Oxide-Releasing Drug (1) Nitric Oxide-Sessions (1) Nitroglycerin (1) Nivolumab (1) Nivolumab Injection (1) No Messaging (1) No Personal protective equipment (PPE) (1) No Racial Inequality Highlighting (1) No active intervention (observational only) (1) No intervention (survey study for medical doctors). (1) No intervention - exposure is to COVID-19 (1) No intervention - quality of life measure (1) No intervention / Compare the difference in respiratory rate between H0 and H12 of the initiation of morphine between the control and interventional groups (1) No intervention / Evaluation of the ferritin and glycosylated ferritin by standard approved serological tests (1) No intervention on patients (1) No intervention, observational (1) No intervention, this is an observational study that uses validated questionnaires and qualitative interviews.. (1) No interventions (1) No interventions planned (1) No interverntion (1) No research related technology based social interactions (1) No special intervention (1) Non Intervention (1) Non applicable (1) Non interventional study (1) Non invasive visual acuity testing (1) Non-ACEI/ARB (1) Non-Interventional (1) Non-Mindfulness intervention (1) Non-contact ECG (1) Non-contact MCE system (1) Non-convalescent Plasma (control plasma) (1) Non-convalescent fresh frozen plasma (Standard plasma) (1) Non-enhanced CT scan of the chest (1) Non-hospitalization procedures (1) Non-interventional (1) Non-interventional study (1) Non-invasive cardiac imaging (1) Non-invasive red LLLT treatment to chest of patient. (1) Non-invasive ventilatory support (1) None - NA (1) Noninvasive ventilation treatment (1) Normal Saline 0.9% (1) Normal Saline Infusion + standard of care (1) Normal Saline intranasal (1) Normal saline 0.9% (1) Normal saline solution (NSS), Placebo - Phase 1 (1) Normal saline solution (NSS), Placebo - Phase 2 (1) Normal saline solution (NSS), Placebo, Day 189 - Phase 2 (1) Normal saline solution (NSS), Placebo, Day 21 - Phase 1 (1) Normal saline solution (NSS), Placebo, Day 21 - Phase 2 (1) Not bravery message (1) Novaferon (1) Novel laser inferometry test for CORONA virus (1) NuSepin® 0.1 mg (1) NuSepin® 0.2 mg (1) Nudge (1) Nursing care to reduce anxiety, fear and loneliness (1) Nutrition (1) Nutrition Consult and Protein Supplementation (1) Nutrition support (1) Nutritional assessment (1) Nutritional support system (NSS) (1) Nuvastatic (1) NİCaS (1) OCTAPLAS (1) OLO-1 Medical Molecular Sieve Oxygen Generator (1) OP-101 (1) Obesity (1) Observation for study group (1) Observation of behavior and COVID-19 infection will be conducted. (1) Observation of different courses of SARS-CoV-2 infection in different phases (acute vs. post-acute) and settings (1) Observation of patients with known, suspected, or at risk for COVID-19 infection (1) Observation only (1) Observational (registry) (1) Observational Study (1) Observational cohort study on the natural history of hospitalized SARS-COV-2 patients. (1) Observational measurement of biometric data. No change to health care provided. (1) Observational only (1) Observational study only (1) Obtainment of nasopharyngeal, oropharyngeal, buccal, nasal and saliva samples (1) Obvio-19 app (1) Occupational health workers (1) Octagam (1) Octagam 10% (1) Odd/Even birth year intervention groups (1) Olfaction testing (1) Olfactometry (1) Olfactory retraining (1) Omega 3/Nigella Sativa Oil (1) Omega 3/Nigella Sativa Oil/Anise seed capsule (1) Omega 3/Nigella Sativa Oil/Deglycyrrhizinated Licorice (1) Omega 3/Nigella Sativa Oil/Indian Costus (1) Omega 3/Nigella Sativa Oil/Quinine pills (1) Omega-3 Fatty Acid Supplement (1) Omegaven® (1) Omeprazole 20mg (1) Omnibiotic AAD (1) On-Line Survey (1) One COVID-19 vaccine candidate (TMV-083) administration - High dose (1) Online Intervention Grief COVID-19 (1) Online Intervention Mental Health COVID-19 (1) Online Questionnaires (1) Online Survey about Dietary and Lifestyle Habits (1) Online bibliotherapy programme (1) Online cognitive behavioral therapy (CBT) (1) Online instruction (1) Online questionnaire and interviews (1) Online support Group (1) Only Standard Treatment (1) Ophtamesone (1) Opt-in Recruitment Email (1) Opt-out Recruitment Email (1) Optical Coherence Tomography (OCT) (1) Optical coherence tomography angiography (1) Optimized Management of Covid-19 Positive Kidney Transplant Recipients: Single Center Experience from the Middle East (1) Optional blood completion (1) Optional questionnaire completion (1) Oral (1) Oral 25-Hydroxyvitamin D3 (1) Oral administration of Colchicine plus Herbal Phenolic Monoterpene Fractions (1) Oral fluid swab (1) Oral supplement enriched in antioxidants (1) Oral-B Mouth Sore mouthwash (1) Oropharyngeal Swab (1) Orthopaedic Surgical Procedures (1) Oseltamivir 75mg (1) Other (1) Others(No intervention) (1) Otilimab (1) Outpatient MRI (1) Ovotransferrin (1) Oxaloacetate Medical Food/Dietary Supplement (1) Oxidative Stress ELISA Kit (1) Oxygen Hood (1) Oxygen Therapy (1) Oxygen gas (1) Oxygen supply (1) Oxygen-ozone therapy, probiotic supplementation and Standard of care (1) Oxytocin (1) Ozanimod (1) Ozone auto-hemotherapy (1) Ozonized oil (HOO (1) P2Et (Caesalpinia spinosa extract) (1) PCL COV05 - COVID 19 Ag Rapid FIA test (Rapid Antigen Test) (1) PCR (1) PCR Value (1) PCR for COVID-19 (1) PCR, lung ultrasound (1) PD-1 blocking antibody+standard treatment (1) PEEP trial (1) PEP flute (1) PET-CT of 18F-FDG (1) PF-06650833 (1) PF-07304814 (1) PH94B (1) PHQ-9 (9-item Patient Health Questionnaire) (1) PHQ-9 (Patient Health Questionnaire) Depression Scale (1) PHQ-9 Depression Scale (1) PHR160 Spray (1) PLACEBO GROUP (1) PLN-74809 (1) POOL LAMP (1) POOL RT-PCR (1) PRAYER (1) PRO-SERO-COV (1) PROTECTIVE VENTILATION (1) PSC-04 (1) PSG (1) PSQI (1) PSS (Perceived Stress Scale) (1) PT-PCR test for SARS-CoV-2 (1) PT-Pal (1) PT-X and IMT (1) PTC299 (1) PTSD (1) PWV (1) Pacebo: Calcium citrate (1) Pacritinib (1) Pamrevlumab (1) Pandemic control measures (1) Paracetamol (1) Paraclinical examination (1) Part 1 - TL-895 (1) Part 2 - Placebo (1) Part 2 - TL-895 (1) Partially HLA-matched SARS-CoVSTs (1) Participate in a massive musical event (1) Particle measurement (1) Passed infection of SARS-CoV-2 (1) Passive Microwave Radiometry (1) Patch, Nicotine (1) Patch, Placebo (1) Pathogen-specific aAPC (1) Patient Characteristics (1) Patient Education (1) Patient Health Questionnaire (PHQ-9) (1) Patient Health Questionnaire-9 (PHQ-9) (1) Patient Status Engine (1) Patient management suffering of coronavirus infection (1) Patient sampling (1) Patient with SAR-CoV-2 infection (1) Patient-centred advice on Telephone Consultation in TB Patients: (1) Patients admitted in Intensive Care Units (1) Patients admitted to Intensive Care Unit with SARS-CoV2 (1) Patients received standard of care treatment during hospitalization (1) Patients with the treatment agains COVID19 (1) Pectin (1) Peer Mentor Delivery (1) Peer Resilience Champion (1) Peginterferon Lambda-1a (1) Peginterferon beta-1a (1) Peginterferon lambda alfa-1a subcutaneous injection (1) Pegylated Interferon-α2b (1) Pegylated interferon lambda (1) Pembrolizumab (MK-3475) (1) Pemziviptadil (PB1046) (1) Percutaneous Coronary Revascularization for STEMI (1) Performance of the test antigenic and test RT-PCR (1) Performing of lung ultrasound (1) Performing routine care (clinical and paraclinical tests) (1) Peripheral Blood (1) Peripheral blood sampling (1) Peripheral venous ultrasound (1) Personal Exercise Intervention (1) Personal Protective Testing Booth (1) Personal behaviours (1) Personal freedom message (1) Personal protective equipment (1) Personal protective equipment (PPE) (1) Personal protective equipment from biological hazard (1) Personalized ambulatory training (1) Personalized health education (1) Phage Therapy (1) Philips Lumify Ultrasound System (1) Phlebotomy (1) Phone call (1) Phone call interview (1) Phone interviews (1) Phone-call screening and management by a medical student/general practitioner tandem (1) Phsyiotherapy (1) Physical Exercises (1) Physical Therapy (1) Physical Therapy Exercise (1) Physical and Cognitive Activity (1) Physical examination (1) Physical exercise (1) Physical exercise training (1) Physiological saline solution (1) Physiological serum (1) Physiology (1) Piclidenoson (1) Pilot a rapid SARS-CoV-2 testing strategy (1) Pioglitazone (1) Pioglitazone 30 mg (1) Pioglitazone 45 mg (1) Piperacillin-tazobactam (1) Piperacillin/tazobactam (1) Placebo (0.9% normal saline) (1) Placebo (1 tablet daily during 60 days) + Personal Protective Equipment (PPE) (1) Placebo (Methylcellulose) capsule (1) Placebo (PB0) (1) Placebo (PBO) (1) Placebo (Plasma-Lyte 148) (1) Placebo (carrier control) (1) Placebo (human albumin 1%) (1) Placebo (potato starch and magnesium stearate) (1) Placebo (saline) (1) Placebo (sodium chloride bufus, solvent for the preparation of dosage forms for injection 0.9%) (1) Placebo (two doses), priming (1) Placebo - Phase I (1) Placebo - Starch Powder Soft gels (1) Placebo 0.10 mg + 1.00 mg/kg (1) Placebo 0.20 mg + 2.00 mg/kg (1) Placebo 0.9% NaCl solution (1) Placebo 250 cc 24 hours continuous infusion for 15 days (1) Placebo Atazanavir (1) Placebo Atrovastatin (1) Placebo Control (1) Placebo Daclatasvir 60 mg (1) Placebo EC-18 (1) Placebo Group (1) Placebo Hydroxychloroquine (1) Placebo Nitazoxanide (1) Placebo Oil (1) Placebo PBMT/sMF (1) Placebo Ribavirin (1) Placebo Saline (1) Placebo Sofusbuvir + Daclatasvir 60 mg (1) Placebo Starch (1) Placebo Subcutaneous Solution (1) Placebo Tablet (1) Placebo booster (1) Placebo capsules (1) Placebo comparator: DW-NI (1) Placebo comparator: DW-NS (1) Placebo control (non-behavioral infographic) (1) Placebo control + best supportive care (1) Placebo for "Deficiency of Qi and Yang" (1) Placebo for "Deficiency of Qi and Yin" (1) Placebo for ABBV-47D11 (1) Placebo for Azithromycin (1) Placebo for Camostat Mesilate (1) Placebo for Hydroxychloroquine (1) Placebo intravenous (1) Placebo mouthwash (water) (1) Placebo multiple (1) Placebo nebuliser solution (1) Placebo of FX06 (1) Placebo of Hydroxychloroquine (1) Placebo of LPV/r Tablets (1) Placebo of NICOTINE Transdermal patch (1) Placebo of excipient(s) will be administered (1) Placebo on a 0- and 14-day schedule (1) Placebo oral (1) Placebo oral capsule; From August 2020 'no additional treatment' (1) Placebo pMDI (1) Placebo patch (1) Placebo plus standard preventive measures (1) Placebo single (1) Placebo solution (1) Placebo to Match RDV (1) Placebo videos (1) Placebo- 0.10 mg/kg (1) Placebo- 0.20 mg/kg (1) Placebo- 1.00 mg/kg (1) Placebo- 2.00 mg/kg (1) Placebo-LDE phase 2 (1) Placebo/Aluminum Adjuvant of Inactivated SARS-CoV-2 vaccine (1) Placebo/Control (1) Placebo: Emtricitabine/tenofovir disoproxil Placebo (1) Placebo: Hydroxychloroquine (1) Placebo; 0.9% saline (1) Placenta-Derived MMSCs; Cryopreserved Placenta-Derived Multipotent Mesenchymal Stromal Cells (1) Plant Polyphenol (1) Plaquenil 200Mg Tablet (1) Plasma Donation (1) Plasma IgG levels (1) Plasma exchange (1) Plasma exchange and convalescent plasma (1) Plasma expansion with Ringer's Acetate (1) Plasma from COVID-19 convalescent patient (1) Plasma from a volunteer donor (1) Platelet count, platelet, mean platelet volume and platelet distribution Width in COVID-19 (1) Pleth variability index (1) Plethysmography & DLCO (1) Plitidepsin 1.5 mg/day (1) Plitidepsin 2.0 mg/day (1) Plitidepsin 2.5 mg/day (1) Pneumococcal vaccine (1) Point-of-Care Ultrasonography (POCUS) (1) Point-of-care test for SARS-CoV-2 (1) Polymorphism of the HSD3B1 (1) Polyoxidonium (1) Positive COVID Test Result - Hypothetical Scenario (1) Positive feedback (1) Post COVID-19 Functional Satus Scale (1) Post Traumatic Stress Disorder questionnaire (PTSD-8) (1) Post-intensive Care unit syndrome (1) Postpartum women under investigation for Coronavirus or diagnosed with COVID-19 (1) Postural Positioning (1) Povidine iodine nasal swabs (1) Povidone-Iodine 0.4% NI (1) Povidone-Iodine 0.5% (1) Povidone-Iodine 0.5% NI (1) Povidone-Iodine 0.5% NS (1) Povidone-Iodine 0.6% NI (1) Povidone-Iodine 0.6% NS (1) Povidone-Iodine 2% (1) Povidone-Iodine Solution 1.25% w/w [0.125% available iodine] USP (1) Povidone-iodine (1) Prasugrel (1) Prasugrel Hydrochloride 10 MG Oral Tablet (1) Prazosin (1) Prediction Market (1) Predictive factors for clinical response in patients with COVID-19. (1) Predictors adverse evolution (1) Predictors of health care provide (1) Prednisolone 5 mg (1) Prednisone tablet (1) Pregnant women under investigation for Coronavirus or diagnosed with COVID-19 (1) Premier Biotech COVID-19 IgG/IgM Rapid test Cassette (1) Presence of specific anti-SARS-CoV-2 antibodies (1) PreserVision AREDS formulation gel tabs (1) Preservative-free saline (1) Prevalence of COVID-19 (1) Preventive information (1) Previfenon® (1) Primary care (1) Primary care professionals reports of potential patient safety incidents, non-COVID-19 related (1) Primary exposure is hypoxia (no intervention) (1) PrimePro (1) PrimePro™/ PrimeMSK™ (1) Pro BNP , Vitamin D (1) Probiorinse (1) Probiotics (1) Probiotics (2 strains 10x10^9 UFC) (1) Problem-solving and relationship improvement intervention. (1) Produce prescription program (1) Progesterone 100 MG (1) Prognostic score (1) Progressive cycling exercise test to exhaustion (1) Progressive muscle relaxation (1) Project ECHO (1) Prolastin (1) Prolectin-M; a (1-6)-alpha-D-Mannopyranose class (1) Prolonged Exposure Therapy (1) Prolonged Proned Positioning (1) Prone (1) Prone Position (PP) (1) Prone Positioning (PP) (1) Prone decubitus (1) Prone position ventilation (1) Prone positioning (PP) (1) Prophylactic/Intermediate Dose Enoxaparin (1) Propofol (1) Propranolol Hydrochloride (1) Proprietary extract of Nerium oleander (1) Prosocial acts (1) Prospective Chart Review (1) Prospective oberservational registry (1) Prospective observation (1) Prospective study across two time-points examining the impact of viral mitigation protocols on mental health (1) Prospective study with two measurement points investigating the impact of viral mitigation protocols on parental burnout (1) Protocolised mechanical ventilation strategy (1) Prototype swab (1) Proxalutamide (1) Psychiatric counseling (1) Psycho-Social Questionnaire (1) Psycho-education (1) Psychoeducation (1) Psychoeducational intervention (1) Psychological and Behaviour Change Support (1) Psychological stress and adaptation at work score (PSAS) (1) Psychological treatment (1) Public Health England Gold Standard (1) Public space exposure (1) Pulmonary Function Tests (PFT) (1) Pulmonary Physiotherapy Techniques (1) Pulmonary Vascular Permeability Index (1) Pulmonary and Motor Rehabilitation (1) Pulmonary function testing (1) Pulmonary function tests (1) Pulmonary tele-rehabilitation (1) Pulmonary ultrasound (1) Pulmozyme/ Recombinant human deoxyribonuclease (rh-DNase) (1) Pulse Oximeter (1) Pulse oximetry (1) Pyridostigmine Bromide (1) Pyronaridine-Artesunate (1) Pyronaridine-artesunate (1) Q-NRG Metobolic Cart Device (1) Q16 testing (1) QUANTIFERON (1) QazCovid-in® - COVID-19 inactivated vaccine (1) QazCovid-in®-vaccine against COVID-19 (1) QuadraMune(TM) (1) Qualitative interviews (in 40 patients : 20 with COVID-19 and 20 without COVID-19) (1) Quality of Life (1) Quality of life assessment (1) Quality of life promotion (1) Quantitative IgG Test (1) Quantitative analysis of SARS-CoV-2 antibodies (1) Quantitative analysis of anti-SARS-CoV-2-antibodies (1) Quantitative and qualitative assessments of mental health (1) Quantra System (1) Quasistatic pressure-volume curve (1) Quercetin (1) Quercetin Phytosome (1) Quercetin Prophylaxis (1) Quercetin Treatment (1) Querying the INSEE database (1) Questionaire (1) Questionnaire : Preparedness for Caregiving Scale (1) Questionnaire and interview (1) Questionnaire by phone call (1) Questionnaire collection (1) Questionnaire completion (1) Questionnaire for evaluation of confinement on deviant sexual fantasies (1) Questionnaire forms (1) Questionnaire including validated tools such as Patient Health Questionnaire (PHQ-9), the 7-item Generalised Anxiety Disorder (GAD- 7), the 7-item insomnia severity index (1) Questionnaire with precaution information (1) Questionnaire, phone call (1) Questionnaire, same tools as before, with inclusion of PCL5 questionnaire too. (1) Questionnaire-based observational study (1) Questionnaires for specific phobia (1) Questionnaires on psychological quality of life (1) Questionnaires, spirometry (1) Questionnary (1) Quetiapine (1) Quidel Sofia SARS Antigen FIA (1) Quinquina-Stevia/Azythromycin (1) RAAS inhibitor [continued standard of care] (1) RAPA-501-Allo off-the-shelf Therapy of COVID-19 (1) RAPID-3 (1) RBA-2 (1) RBT-9 (90 mg) (1) RD-X19 (1) RDV (1) RECHARGE (1) REGN10933 + REGN10987 (1) REGN10933+REGN10987 (1) RESP301, a Nitric Oxide generating solution (1) REmotely Monitored, Mhealth (REMM) supported High Intensity Interval Training (HIIT) (1) RIA-device (Remote Investigation and Assessment) (1) RPH-104 80 mg (1) RT PCR SARS-CoV-2 (1) RT-PCR Covid-19 (1) RT-PCR SARS-Cov2 (1) RT-PCR and antibody testing (1) RT-qPCR test (1) RUTI® vaccine (1) Racial Inequality Highlighted (1) Racial/Ethnic Frame (1) Radiological Detection (1) Radiotherapy (1) Raman analysis of saliva, characterization of the Raman database and building of the classification model (1) Ramelteon 8mg (1) Ramipril 2.5 MG Oral Capsule (1) Random Donor Plasma (1) Randomized booster (1) Rapamycin (1) Rapid Antigen Test (1) Rapid Diagnostic Test vs PCR (1) Rapid Onsite COVID-19 Detection (1) Rapid Pathogen Detection (1) Rapid detection test (1) Rapid molecular test (1) Rarefaction (1) Rayaldee 30Mcg Extended-Release (ER) Capsule (1) Razuprotafib (1) Razuprotafib Subcutaneous Solution (1) Reading a Book (1) Recombinant Bacterial ACE2 receptors -like enzyme of B38-CAP (rbACE2) (1) Recombinant Bacterial ACE2 receptors -like enzyme of B38-CAP (rbACE2) plus Aerosolized 13 cis retinoic acid (1) Recombinant Human Interferon α2b Spray (1) Recombinant Interferon Alfa-2b (1) Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) -placebo (1) Recombinant human angiotensin-converting enzyme 2 (rhACE2) (1) Recombinant human interferon α1β (1) Recombinant human plasma gelsolin (Rhu-pGSN) (1) Recombinant new coronavirus vaccine (CHO cell) group (1) Recombinant new coronavirus vaccine (CHO cells) placebo group (1) Recombinant novel coronavirus vaccine (Adenovirus type 5 vector) (1) Recombinase aided amplification (RAA) assay (1) Reference: Favipiravir 200 mg (Avigan) (1) Referral card (1) Regadenoson (1) Registery Data Collection (1) Regular Inpatient Medical Care (1) Rehabilitation (1) Rehabilitation by Concentric exercises (1) Rehabilitation by Eccentric exercises (1) Rehabilitation exercise protocol (1) Rehabilitation-focused program (1) Reinforcement learning message delivery (1) Relation between frailty and clinical outcomes in elderly patients with COVID-19. (1) Remain COVID Free SSI (1) Remdesivir (RDV) (1) Remdesivir-HU (1) Remimazolam (1) Remote Automated Monitoring System (1) Remote Cognitive Behavioral Therapy for Insomnia (1) Remote Ischemic Conditioning (1) Remote Problem Management Plus (1) Remote consultation (1) Remote controlled exercise (1) Remote pulmonary rehabilitation (1) Removal of dead space filter (1) Renin-angiotensin system inhibitors (1) Repeat SARS-CoV-2 IgG antibodies at 45-65 days (1) Reporting of anosmia, ageusia and other clinical symptoms (1) ResCure™ (1) Resilience Program (1) Respiratory Exercise Training (1) Respiratory Mechanics (1) Respiratory Training (1) Respiratory and psychological rehabilitation (1) Respiratory infections (1) Respiratory mechanics measurement (1) Respiratory monitoring (1) Respiratory muscles ultrasound (1) Respiratory physiotherapy (1) Respiratory rehabilitation (1) Respiratory rehabilitation program (RR). (1) Respiratory symptoms, symptoms of anxiety and depression, and post-traumatic stress screening (1) Respiratory tele-rehabilitation program (TRR). (1) Resting 12 lead ECG (1) Resveratrol (1) Resveratrol Placebo (1) Retrospective case-control analysis (1) Retrospective data collection (1) Reverse transcription polymerase chain reaction (1) Reverse-transcription polymerase chain reaction (RT-PCR) (1) Review of medical patient file (1) Reward Re-Training (1) RhACE2 APN01 (1) Rhea Health Tone® (1) Ringer solution (1) Ringer's lactate (1) Rintatolimod (1) Risankizumab (1) Risk factors (1) Ritonavir (1) Ritonavir+Oseltamivir (1) Ritonavir/lopinavir (1) Rivaroxaban 10 MG (1) Rivaroxaban 2.5 MG (1) RoActemra iv (1) RoActemra sc (1) Robot Assisted Percutaneous Cardiovascular Intervention (1) Robotic therapy (1) Rosuvastatin (1) Routine care (no SARS-CoVSTs) (1) Routine standard of care (1) Rt PCR (1) Ruconest (1) Ruxolitinib 5 MG (1) Ruxolitinib administration (1) Ruxolitinib plus simvastatin (1) SAMBA II (Diagnostic for the Real World) (1) SAR443122 (1) SARILUMAB (1) SARS-CoV 2 RNA PCR Semen (1) SARS-CoV 2 RNA PCR Urine (1) SARS-CoV-2 Ab (1) SARS-CoV-2 Antibody Analysis (1) SARS-CoV-2 IgG (1) SARS-CoV-2 IgG Antibody Testing Kit (1) SARS-CoV-2 S1/S2 IgG (1) SARS-CoV-2 Specific T Cells (1) SARS-CoV-2 and/or MIS-C Exposure (1) SARS-CoV-2 antibody based IVIG therapy (1) SARS-CoV-2 antibody immunoassays (1) SARS-CoV-2 antibody test (1) SARS-CoV-2 antibody testing (1) SARS-CoV-2 convalescent plasma treatment (1) SARS-CoV-2 inactivated vaccine (1) SARS-CoV-2 non-immune Plasma (1) SARS-CoV-2 plasma (1) SARS-CoV-2 questionnaire survey (1) SARS-CoV-2 rS - Phase 1 (1) SARS-CoV-2 rS/Matrix M1-Adjuvant (1) SARS-CoV-2 rS/Matrix-M Adjuvant - Day 189 - Phase 2 (1) SARS-CoV-2 rS/Matrix-M Adjuvant - Phase 1 (1) SARS-CoV-2 rS/Matrix-M Adjuvant, Day 0 - Phase 1 (1) SARS-CoV-2 rS/Matrix-M Adjuvant, Day 0 - Phase 2 (1) SARS-CoV-2 rS/Matrix-M Adjuvant, Days 0 and 21 - Phase 2 (1) SARS-CoV-2 rapid diagnostic test (COVID-PRESTO® IgM/IgG, AAZ, Boulogne-Billancourt, France) (1) SARS-CoV-2 research in nasopharyngeal swab, sperm and serologics (1) SARS-CoV-2 serological assessment (IgG) (1) SARS-CoV-2 serology (1) SARS-CoV-2 testing on the Eppendorf Thermal Cycler PCR system using self-collected saliva as the specimen (1) SARS-CoV-2 vaccine (inactivated) (1) SARS-CoV-2 vaccine formulation 1 with adjuvant 1 (1) SARS-CoV-2 vaccine formulation 1 with adjuvant 2 (1) SARS-CoV-2 vaccine formulation 2 with adjuvant 1 (1) SARS-CoV-2 vaccine formulation 2 with adjuvant 2 (1) SARS-CoV-2 vaccine formulation 2 without adjuvant (1) SARS-CoV-2 viral composition (1) SARS-CoV-2-test (1) SARS-CoV2 Autoantibody detection (1) SARS-CoV2 Infection (1) SARS-CoV2 infection (1) SARS-CoV2 nasal swab (1) SARS-CoV2 serum antibody testing (1) SARS-Cov-2 infection (1) SARSCoV2 Convalescent Plasma (1) SBI-101 (1) SCB-2019 (1) SCB-2019 with AS03 adjuvant (1) SCB-2019 with CpG 1018 adjuvant plus Alum adjuvant (1) SCD (1) SCH Intervention (1) SCTA01 Placebo (1) SECRET questionnaire (1) SELF-BREATHE (1) SF12, EQ-5D-5L and work status standardized quantitative assessments (1) SHG (1) SHINGRIX (Zoster Vaccine REcombinant, Adjuvanted) (1) SIR1-365 (1) SLEDD with a L-MOD (1) SMS message support (1) SMS-based support (1) SNDX-6352 (1) SNG001 (1) SNO (1) SOC + IFX-1 (1) SOC + Intravenous Famotidine (1) SOC plus 15mg/kg EB05 IV (1) SOC plus Placebo IV (1) SPEQ (Specific Psychotic Experiences Questionnaire) - Paranoia and Grandiosity Subscales (1) SPIN-CHAT Program (1) SSE educational intervention (1) STC-19 score (1) STI-5656 (1) STP + COVID-19 Convalescent Plasma (CP) (1) STP + Standard Plasma (SP) (1) Saline Control (1) Saline Nasal Irrigation (1) Saline containing 1% Human serum albumin(solution without UC-MSCs) (1) Saline nasal and throat spray (1) Saline oral/nasal rinse (1) Saline with Baby Shampoo Nasal Irrigation (1) Saline-sodium citrate (SSC) buffer (1) Saliva Assay (1) Saliva and NPS test (1) Saliva based assay: crude RNA extraction (1) Saliva sample (1) Saliva specimen (1) Saliva test kit (1) Saliva-based testing (1) Sample (1) Sample Collection/Performance Evaluation (A) (1) Sample Collection/Performance Evaluation (B) (1) Sampler skills (1) Sampling (1) Sampling (EDTA blood, pharyngeal and nose swabs, bronchoalveolar lavage ,urine) (1) Sampling of SARS-CoV-2 RNA from nasopharyngeal swab specimen or saliva collected via Salivette Cortisol (1) Sampling of tissue (1) Sampling salivary (1) Sarilumab 200 MG/1.14 ML Subcutaneous Solution [KEVZARA] (1) Sarilumab 400 MG/2.28 ML Subcutaneous Solution [KEVZARA] (1) Sarilumab Prefilled Syringe (1) Sarilumab SAR153191 (1) Sars-Cov-2 serology (1) Sars-Cov2 serology (1) Satisfaction evaluation (1) Savicell's ImmunoBiopsy™ (1) Scanning Chest X-rays and performing AI algorithms on images (1) Schirmer Test I (1) Screening test for covid ( RT PCR and CT Chest) (1) Secukinumab 150 MG/ML Subcutaneous Solution [COSENTYX] (1) Self Study (1) Self measurement with pulse oximeter (1) Self-Compassion for Chronic Pain Virtual Group Treatment Program (1) Self-Help Therapy (1) Self-acupressure (1) Self-administered questionnaires (1) Self-collected, home-based testing (1) Self-focused acts (1) Self-guided exercises (1) Self-help booklet (1) Self-interest message (1) Self-management booklet (SWitCh: Stay well during COVID-19) (1) Self-prone position recommendation (1) Self-questionnary (1) Semen Qualitative Analysis (1) Semi-structured interviews-Health system (1) Semi-structured interviews-Patients (1) Semi-structured telephone questionnaire (1) Sending thorax ct video images via smartphone applications (1) Senicapoc (1) Sensbiosys (1) SensiumVitals wearable sensor (1) Sequencing (1) Seraph®-100 Microbind® Affinity Blood Filter (1) Serelogy testing, RT PCR (1) Serial seroconversion measurements in hospital employees during the COVID-19 pandemic (1) Serologic SARS-CoV-2 screening (1) Serologic assays for antibodies to SARS-CoV-2 (1) Serologic immunoassays to SARS-CoV-2 antibodies (1) Serologic testing (1) Serological Assay or IgG for SARS-CoV-2 (1) Serological analyses to be lead on a pre-existing biobank (1) Serological screening for IgG and IgM antibodies against COVID-19 (1) Serological test and phone interview (1) Serological test for COVID-19. (1) Serological testing (1) Serological tests will be applied on patients blood sampling (1) Serology (1) Serology SARS-CoV2 (1) Serology Test (1) Serology for Covid-19 (1) Serology test follow-up (1) Seroprevalence of SARS-CoV-2 infection in patients with HIV infection (1) Serum SARs COV 2 IGg screening in health care workers (1) Serum protein level analysis (1) Serum test (1) Serum tube collection (1) Serum zinc, vitamin d vitamin b12 levels . (1) Severe Acute Respiratory Syndrome CoronaVirus 2 detection (1) Sevoflurane inhalant product (1) Sham (1) Sham Device Treatment (1) Sham intervention (1) Sham irradiation (1) Shanshamani Vati Plus (1) Shared Decision Making (1) Shock-dependent hydrocortisone (1) Sildenafil (1) Sildenafil citrate tablets (1) Silymarin (1) Simha Kriya (1) Simple chest tomography (1) Simulation Intervention (1) Simulation of Repurposed Drugs for COVID-19 (1) Single fraction whole lung radiotherapy (1) Single high dose vitamin D (1) Single passive leg movement (1) Sirolimus 1 MG/ML (1) Sirukumab (1) Sit-To-Stand test (1) Sitagliptin (1) Six Minute Walk Test (6MWT) (1) Six-minute walk test (6MWT) (1) Six-month ARV dispensing (1) Skin biopsy (1) Slef questionnaires fulfilment (1) Smartphone-based voice and self-reported symptom collection (1) Social Distancing Advertisements (1) Social media & news consumption (1) Socialization (1) Sodium Bicarbonate (1) Sodium Bicarbonate 150Meq/L/D5W Inj (1) Sodium Chloride 9mg/mL (1) Sodium Nitrite (1) Sodium bicarbonate (1) Sodium chloride (1) Sofosbuvir (1) Sofosbuvir 400 MG plus Daclatasvir 200mg (1) Sofosbuvir and Ledipasvir (1) Sofosbuvir ledipsavir (1) Sofosbuvir plus Ledipasvir (1) Sofosbuvir/Daclatasvir (1) Sofosbuvir/daclatasvir (1) Software Messaging (1) Sofusbuvir + Daclastavir 60 mg (1) Soluble Urokinase Plasminogen Activator Receptor (1) Solution-Focused Support Program (1) Sonclot Coagulation and platelet function Analyzer SCP1, Sienco, USA (1) Sonoclot (1) Soterix taVNS model 0125-LTE Stimulator - Active-Active Group (1) Soterix taVNS model 0125-LTE Stimulator - Sham-Active Group (1) Spartan COVID-19 System (1) Spartan COVID-19 Test (1) Spartan COVID-19 v2 System (1) Spartan Cube Point-of Care Covid-19 test (1) Specific anti-SARS-CoV-2 antibodies (1) Specimen Collection (1) Speed of Processing Training (1) Sphenopalatine Ganglion Block with Local Anesthetic (1) Sphenopalatine Ganglion Block with Placebo (Isotone NaCl) (1) Spironolactone 100mg (1) Sputum analysis (1) St. George's Respiratory Questionnaire (SGRQ) (1) Stabilized hypochlorous acid (1) Staff Wellbeing Centres (1) Staff will wear and evaluate Bubble-PAPR (non-CE marked PAPR) (1) Stakeholder of TIP-OA Program (1) Standar medical treatmen (1) Standar of care (1) Standard (specific) therapy for COVID-19 (1) Standard 12-lead ECG, NT-proBNP, echocardiography (1) Standard COVID-19 care (1) Standard COVID-19 therapies (1) Standard Care Plus Monitoring (1) Standard Care Therapy (1) Standard Donor Plasma (1) Standard Mask (1) Standard Of Care (SOC) (1) Standard Of Care (SOC) + Placebo (1) Standard Oxygen Delivery System (1) Standard Plasma (FFP) (1) Standard Public Health measures (1) Standard Q COVID-19 Ag - test, produced by SD Biosensor INC. (1) Standard Therapy Protocol (STP) (1) Standard Treatment (1) Standard Ventilation Strategy (1) Standard administration of oxygen flow (1) Standard care delivered in the isolation hospitals. (1) Standard care therapy (1) Standard charity resources (1) Standard interface (1) Standard medical care (1) Standard of Care (Intravenous access) (1) Standard of Care (SOC) + ANG-3777 (1) Standard of Care (SOC) and Colchicine+Rosuvastatin (1) Standard of Care thromboprophylaxis (1) Standard of care (Paracetamol) (1) Standard of care (SOC) plus placebo (1) Standard of care for SARS-CoV-2 infection (1) Standard of care management (1) Standard of care therapies (1) Standard of care therapy (1) Standard of care. (1) Standard oxygen therapy (1) Standard screening strategy (1) Standard supportive care (1) Standard therapeutic protocol (1) Standard therapy (1) Standard therapy for COVID-19 according to the stablished hospital protocols. (1) Standard therapy recommended by the Ministry of Health of the Russian Federation and Dalargin inhalation (1) Standard therapy recommended by the Ministry of Health of the Russian Federation and Dalargin intramuscular injection (1) Standard therapy recommended by the Ministry of Health of the Russian Federation and Dalargin intramuscular injection combined with Dalargin inhalation (1) Standard therapy recommended by the Ministry of Health of the Russian Federation. (1) Standard treatment according to the Clinical protocols (1) Standard treatment for COVID-19 (1) Standard-of-care (1) Standard-of-care treatment (1) Standard-titer Convalescent COVID-19 plasma (CCP2) (1) Standardised questionnaires (1) Standardized crisis management and coping protocol plan toward Coronavirus disease 2019 (COVID-19) (1) Standards of Care (1) State-trait anxiety inventory scale (1) Statins (Cardiovascular Agents) (1) Stem Cell Educator-Treated Mononuclear Cells Apheresis (1) Stem Cell Product (1) Sterile Normal Saline for Intravenous Use (1) Sterile Water for Injection (1) Sterile normal saline (0.9%) (1) Stimulation test with arginine infusion in order to verify the possible existence of damage to the beta cell function induced by COVID-19 infection (1) Stool collection (1) Stool collection or fecal swab (1) Stools (1) Storage of operating waste (1) Stress and emotion management (1) Study A (1) Study Arm (1) Study B (1) Study C (1) Study D (1) Study Group (1) Study of immune-mediated mechanisms in patients tested positive for SARS-CoV-2 (1) Subacute rehabilitation (1) Sublingual Methylene blue (1) Sudarshan Kriya Yoga (SKY) (1) Sulfonatoporphyrin(TPPS) plus Sunlight exposure. (1) Sulfur hexafluoride lipid-type A microspheres (1) Sulodexide (1) Supine Positioning (1) Supine position (1) Support treatment (1) Supportive Therapy (1) Supportive Therapy SSI (1) Supportive Trauma Exposure Preparation Program (1) Supportive tratment (1) Surfactant (1) Surfactant assessment (1) Surge Index (1) Surge capacity (1) Surgery (1) Surgery: Dynamic Hip Screw, hemiarthroplasty, hip replacement, intramedullary nail (1) Surgical Mask (1) Surgical face mask use only (1) Surgical facial mask (1) Surgical procedures performed under general anesthesia (1) Survey Group (1) Survey administration (1) Survey and Questionnaire (1) Survey to assess Post traumatic stress and anxiety at inclusion and 6 months later (1) Surveys (1) Susceptibility to infection (1) Suspension or Maintenance of Angiotensin Receptor Blockers and Angiotensin-converting Enzyme Inhibitors (1) Swab (1) Swallowing evaluation with the EAT-10 and the volume-viscosity swallowing test (V-VST) (1) Symptom Survey (1) Symptom and Exposure Surveys (1) Symptomatic drugs (1) Symptomatic treatment (paracetamol or best symptomatic treatment based on doctor recommendations) (1) Symptomatology, Treatment. daily Activities and Anxiety for Cardiovascular patients Survey (STRATA) (1) Symptoms entered into the CovidX application (1) Symptoms questionnare (1) Synthetic neutralising antibodies (1) Systemic indirect endovenous ozone therapy (1) T memory cells and NK cells (1) T-Detect™ SARS-CoV-2 Assay (1) T-cell receptor (TCR) repertoire (1) T3 solution for injection (1) T89 (1) T89 capsule (1) TAK-671 (1) TAK-671 Placebo (1) TAK-919 (1) TAK-981 (1) TAPE-Software (1) TAVR or SAVR (1) TCC-COVID mHealth solution (1) TCM prescriptions (1) TD139 (1) TDR (1) TEM-tPA (1) TJ003234 (1) TLRs activation measurement (1) TM5614 (1) TNKase (1) TOF protocol (1) TRV027 (1) TXA127 (1) Tacrolimus (1) Tafenoquine Oral Tablet (1) Taking biological samples (1) Tap water (1) Taste and olfactory function evaluation (1) Tear Collection (1) Tears swab (1) Technology based social interactions (1) Tele-Pulmonary rehabilitation (1) Tele-Yoga Therapy (1) Tele-delivered psychological intervention (1) Tele-interventions related to diabetes management and mental well-being (1) Tele-medicine platform (1) Tele-yoga therapy (1) Teleconsultation either by phone or by computer consultation (1) Telehealth (1) Telehealth coaching sessions (1) Telehealth monitoring (1) Telehealth phone calls (1) Telemedicine to remote outpatient visit in bariatric patient (1) Telemedicine visit (1) Telephone follow-up (1) Telephone interview (1) Telephone survey (1) Telephonic interview during the Italian lockdown. (1) Telephonic medical visit (1) Telepsychoeducation (1) Telepsychoeducation with personalized videos (1) Telepsychoeducation without personalized videos (1) Telerehabilitation-Based (1) Telesimulation (1) Telmisartan 40Mg Oral Tablet (1) Telmisartan 40mg (1) Telmisartan arm will receive 80 mg Telmisartan twice daily plus standard care. (1) Temporarily holding the RAAS inhibitor [intervention] (1) Ten-days oseltamivir (1) Tenecteplase (1) Tenofovir/ Emtricitabine ( 300 mg / 200 mg daily during 60 days) + Personal Protective Equipment (PPE) (1) Test Group: experimental - UVC Therapy applied (1) Test PCR (1) Test for SARS-CoV-2 (1) Test: Favipiravir 200 mg (LOQULAR) (1) TestNPass (1) Tested for SARS-CoV-2 (regardless of the result) (1) Testing Sensitivity for SARS-CoV-2 Virus in Symptomatic Individuals (1) Testing for SARS-CoV-2 (1) Testing of SARS-CoV-2 antibodies (1) Testing procedure for Binding antibodies (1) Tetrandrine (1) Text material for psychoeducation and audio for relaxation techniques (1) Thalidomide (1) The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care: (1) The PREPARE program (1) The Vie Scope laryngoscope (1) The control group will not receive hydroxychloroquine (1) The demographic, clinical, laboratory, and instrumental data (1) The psychosocial effects of COVID-19 pandemic on dental professionals (1) The standard Macintosh laryngoscope (1) The standard of care (1) The standard therapy (1) The study does not required (1) The use of the MentalPlus® digital game for assessment and rehabilitation of cognitive function after remission of the symptoms of COVID-19 (1) The usual treatment (1) Therapeutic Anticoagulation (1) Therapeutic Exercise and Education (1) Therapeutic Plasma Exchange (TPE) (1) Therapeutic Plasma exchange (1) Therapeutic plasma exchange (TPE) (1) Therapist Guided E-Therapy (1) Therapy Intervention (1) There is no intervention (1) There is no intervention in this study (1) Thermography (1) Thiazide or Thiazide-like diuretics (1) This is an online survey with no intervention. (1) Thoracic CT Scan (1) Thorax CT (1) Thoraxic computed tomography (1) Three doses of high-dose recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14, 28 (1) Three doses of high-dose recombinant SARS-CoV-2 vaccine (Sf9 Cell) at the schedule of day 0, 14, 28 (1) Three doses of middle-dose recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14, 28 (1) Three doses of placebo at the schedule of day 0, 14, 28 #High-dose group# (1) Three doses of placebo at the schedule of day 0, 14, 28 #middle-dose group# (1) Three doses of placebo at the schedule of day 0, 14, 28(high-dose group) (1) Threshold IMT device (1) Throat swab sample for measuring current infection with SARS-CoV-2 (1) Thrombin Generation Assay (TGA) (1) Thrombin generation test assay (1) Thrombomodulin Modified Thrombin Generation Assay (TGA-TM) (1) Thromboprophylaxis (1) Thymosin+standard treatment (1) Thyroidectomy (1) Ticagrelor (1) Tice® BCG (for intravesical use) BCG LIVE strain of the BCG (Merck) vaccine (1) Tigerase® and best available care (1) Tinzaparin or unfractionated heparin (1) Tirofiban Injection (1) Tissue plasminogen activator (1) Titanium blood test (1) To assess for development of IgG antibodies against SARS-CoV2 (1) Tociliuzumab (1) Tocilizumab +/- ruxolitinib (stages 2b/3) (1) Tocilizumab 180 MG/ML (1) Tocilizumab 20 MG/ML Intravenous Solution [ACTEMRA] (1) Tocilizumab 20 MG/ML Intravenous Solution [ACTEMRA]_#1 (1) Tocilizumab 20 MG/ML Intravenous Solution [ACTEMRA]_#1 (2 doses) (1) Tocilizumab Injection [Actemra] (1) Tocilizumab Prefilled Syringe (1) Tocilizumab and Ruxolitinib (Advanced stage 3) (1) Tomeka® (1) Toraymyxin PMX-20R (PMX Cartridge) (1) Toremifene (1) Tracheal intubation and cardiopulmonary resuscitation (1) Tracheostomy (1) Tracheostomy with aerosol box in COVID-19 positive patients (1) Tracheotomy (1) Tradipitant (1) Traditional Chinese Medicine Prescription (1) Traditional Proning Arm (1) Traditional antirheumatic drugs (1) Training clinicians in basic critical care and the management of severe COVID-19 cases (1) Training for Awareness, Resilience, and Action (TARA) (1) Training load (1) Training of youth, community health assistants and community health workers. (1) Training session adressing information and health literacy (1) Training video on anxiety, fear and loneliness in the COVID-19 environment. (1) Tramadol (1) Tranexamic acid tablets (1) Trans Sodium Crocetinate (1) Transcendental Meditation (1) Transcutaneous Auricular Vagus Nerve Stimulation (1) Transfer Package from CI Therapy (1) Transfusion of COVID-19 convalescent plasma (1) Transfusion of SARS-CoV-2 Convalescent Plasma. (1) Transfusion of standard Plasma. (1) Transitional Online Peer Support Group (n=20) (1) Transparent mask (1) Transplant patient (1) Transpulmonary pressure measurements (1) Transpulmonary thermodilution (1) Transthoracic echocardiogram (TTE) (1) Trauma Informed Psychotherapy (1) Trauma Informed Yoga (1) Trauma-informed yoga video recording (1) Travelan OTC (1) Treamid (1) Treatment and prophylaxis (1) Treatment as usual (1) Treatment as usual vitamin D (1) Treatment for COVID-19 (1) Treatment group (1) Treatment group: will receive a combination of Nitazoxanide, Ribavirin and Ivermectin for a duration of seven days : (1) Treatment with Dexmedetomidine (1) TriCor® 145mg tablets (1) Triazavirin (Riamilovir) (1) Trier Social Stress Test (1) Trimodulin (1) Trust in science message (1) Tuberculin test (1) Two COVID-19 vaccine candidate (TMV-083) administrations - High dose (1) Two COVID-19 vaccine candidate (TMV-083) administrations - Low dose (1) Two dose ChAdOx1 nCoV-19/Covishield 0.25mL & 0.5mL (1) Two dose ChAdOx1 nCoV-19/Covishield 0.5mL (1) Two dose MenACWY vaccine (1) Two dose MenACWY vaccine min. 4 weeks apart (1) Two doses of commercial scale inactivated SARS-CoV-2 vaccine at the schedule of day 0,14 (1) Two doses of high dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule (1) Two doses of high dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule (1) Two doses of high dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28 (1) Two doses of high-dose recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14 (1) Two doses of high-dose recombinant SARS-CoV-2 vaccine (Sf9 Cell) at the schedule of day 0, 28 (1) Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule (1) Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule (1) Two doses of middle-dose recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14 (1) Two doses of middle-dose recombinant SARS-CoV-2 vaccine (Sf9 Cell) at the schedule of day 0, 28 (1) Two doses of pilot scale inactivated SARS-CoV-2 vaccine at the schedule of day 0,14 (1) Two doses of pilot scale inactivated SARS-CoV-2 vaccine at the schedule of day 0,14 in elderly (1) Two doses of placebo at the emergency vaccination schedule (1) Two doses of placebo at the routine vaccination schedule (1) Two doses of placebo at the schedule of day 0, 14 #High-dose group# (1) Two doses of placebo at the schedule of day 0, 14 #middle-dose group# (1) Two doses of placebo at the schedule of day 0, 28(high-dose group) (1) Two doses of placebo at the schedule of day 0, 28(middle-dose group) (1) Tympanic Temperature (1) Typical surgical covered mask (1) UCMSCs (1) ULTRAPROTECTIVE VENTILATION (1) UNI911 INHALATION (1) UNIKINON (Chloroquine phosphate) 200mg tablets (1) UTTR1147A (1) UTTR1147A-matched Placebo (1) UV Light Treatment (1) Ulinastatin (1) Ultra Brief Online Mindfulness-based Intervention (1) Ultra-Low-dose radiotherapy (1) Ultrasonography (1) Ultrasound lung imaging as part of FAST+ evaluation (1) Ultrasound of the lower limbs (1) Umbilical Cord Lining Stem Cells (ULSC) (1) Umbilical Cord Mesenchymal Stem Cells (1) Umbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care. (1) Umbilical cord Wharton's jelly-derived human (1) Umbilical cord derived mesenchymal stem cells (1) Umifenovir (1) Unavailable COVID Test Result - Hypothetical Scenario (1) Unfractionated Heparin IV (1) Unfractionated heparin SC (1) Unfractionated heparin nebulized (1) Unified Protocol for COVID-19 Parenting Stress (UP-COVID) (1) Uniform random message delivery (1) Unsupervised physical activities (1) Use of Facetime with child and parents during induction (1) Use of mobile application (1) Use of social media during COVID-19 (1) Use of the pinpointIQ solution (physIQ, Inc.) (1) Use of virus (Covid-19) genome sequence report to inform infection prevention control procedures (1) Usual Care Only (1) Usual antibiotic treatment (1) Usual care positioning with no instructions (1) V-SARS (1) V/Q SPECT-CT (1) V/Q Vest (1) V590 (1) V591 (1) VC (1) VCPM (1) VESTA respirator (1) VIB7734 (1) VITROS Anti-SARS-CoV-2 IgG test (1) VLA2001 (1) VR for psychoeducation and relaxation (1) VXA-CoV2-1 (1) Vacciantion status in health care workers (1) Vaccinated with polio vaccine (IPV) (1) Vaccine Therapy (1) Vaccine coverage assessment (1) Vaginal fluid Covid-19 PCR test (1) Validation of the LAMP assays (1) Validation of the NGS method (1) Validation of the POCT Antigen tests (1) Valproate (1) Valsartan (Diovan) (1) Vascular occlusion test (1) Vascular surgery (1) Vehicle + Heparin along with best supportive care (1) Vehicle Control (1) Venepuncture (1) Venous Draw & Testing (1) Venous blood was collected for biochemistry testing (1) Venous blood was collected for biochemistry testing. (1) VentaProst (inhaled epoprostenol delivered via a dedicated delivery system) (1) Verapamil (1) Veru-111 (1) VibroLUNG (1) Video Chat + Basic Feedback (1) Video Chat +Personalized Feedback (1) Video Dance classes (1) Video about safety and effectiveness of adult seasonal flu vaccination (1) Video based aerobic exercise (1) Video based exercise (1) Video-Based (1) Video-Based intervention (1) Videofluoroscopic Swallowing Study (VFSS) (1) Videofluoroscopy (1) Vie Scope laryngoscopy (1) Vielight RX Plus (1) Views and experiences of health care professionals working in intensive care units during the COVID-19 pandemic (1) Viral Specific T-cells (VSTs) (1) Virtual Assistant first, then Human Coach (1) Virtual Care and Remote Automated Monitoring (1) Virtual Care at Home (1) Virtual Family-Based Treatment (1) Virtual Group Exercise (1) Virtual Group Intervention (1) Virtual Peer Support Platform (1) Virtual Reality (1) Virtual reality therapy first (1) Virtual-Care Cognitive Behavioural Therapy (1) Viruxal Oral and Nasal Spray (1) Vit D (1) VitalConnect Vital Sign Patch (1) VitalTalk communication skills training (1) Vitamin B12 (1) Vitamin C tablets (1) Vitamin D 1000 IU (1) Vitamin D supplementation (1) Vitamin D3 (cholecalciferol) (1) Vitamin D3 or Placebo (1) Vitamin E (1) Vitamins (1) Vitamins and Minerals (1) Viusid and Asbrip (1) VivaDiag™ COVID-19 lgM/IgG Rapid Test (1) Voice Symptom Scale (VoiSS) (1) Volunteer of TIP-OA Program (1) WEB embolization (1) WFI 5% glucose (1) WFI water nebulization (1) WHO recommendations (waiting condition) (1) WHOQOL-BREF (1) WHOQOL-BREF survey (1) WJ-MSCs (1) Walk Test (1) Water Without an Elevated Level of KELEA (1) Wearable Medical Device (Empatica E4) (1) Wearing surgical face mask sprayed with hypertonic saline (1) Web Based Questionnaire (1) Web Based Survey (1) Web application users (1) Web-based REDCap survey (1) Web-based psychosocial peer-to-peer support (1) WebEx Physical Activity Program (1) Weck-cel Swab Collection (1) Weekly Assessment (1) Weight Counseling (1) Wharton's jelly derived Mesenchymal stem cells. (1) White Sender in Acknowledgement (1) White Sender in Informational Videos (1) Whole Exome Sequencing (1) Whole Genome Analysis (1) Whole exome sequencing (1) Withings ScanWatch (1) Woebot Substance Use Disorder (1) WofB (1) Written Information (1) Written Summary of Rounds (1) XAV-19 (1) XC221 (1) XC7 100 mg single (1) XC7 200 mg multiple (1) XC7 200 mg single (1) XCEL-UMC-BETA (1) Xiang-Sha-Liu-Jun formula (1) Xiyanping injection (1) Yin Hu Qing Wen Granula(low does) (1) YinHu QingWen Decoction (1) YinHu QingWen Decoction(low dose) (1) Yinhu Qingwen Granula (1) Yoga group (1) Yu-Ping-Feng formula (1) Zanubrutinib (1) Zaritt Burden Interview (1) Zavegepant (BHV-3500) (1) Zilucoplan (1) Zilucoplan placebo (1) Zilucoplan® (1) Zinc (Placebo) (1) Zinc (zinc gluconate) (1) Zinc (zinc gluconate) & Vitamin D (cholecalciferol) (1) Zinc Citrate (1) Zinc Gluconate (1) Zinc Picolinate (1) Zinc Picolinate Placebo (1) Zinc Sulfate (1) Zinc Sulfate 220 MG (1) Zinc gluconate (1) Zithromax Oral Product (1) Zofin (1) ZofinTM (OrganicellTM Flow) (1) Zotatifin (1) [18F]FP-R01-MG-F2 (1) [68Ga]Ga-DOTA-(RGD)2 PET/CT (1) [TIMP-2]*[IGFBP-7] (1) a specifically designed self-administered questionnaire (1) a survey (1) acetylsalicylic acid (1) actigraphy (1) acute kidney injury (1) additional blood tubes (1) aerosol box (1) aerosolized DNase (1) after-each-case room disinfection (1) agenT-797 (1) airway management during sedation or general anesthesia (1) albuterol sulfate (MDI) (1) albuterol sulfate (nebulizer) (1) all treatment about COVID-2019 (1) allogeneic human dental pulp stem cells (BSH BTC & Utooth BTC) (1) allogeneic mesenchymal stem cell (1) alpha one antitrypsin inhalation (1) alpha1-proteinase inhibitor (1) alveolar recruitment (1) amoxicillin/clavulanate (1) anti-SARS-CoV-2 IgY (1) anti-SARS-CoV-2 human convalescent plasma (1) anti-SARS-CoV-2 plasma (1) antidiabetic treatment (1) appendectomy (1) assessment of the sequelae after hospitalization for Sars-COV-2 (1) attendance by ambulance crew (1) autologous adipose-derived stem cells (1) autopsy (1) avdoralimab (1) azithromycin (1) azoximer bromide (1) bacTRL-Spike (1) bamlanivimab (1) bidirectional oxygenation mouthpiece (1) biochemical analysis (1) biological assays in particular on the lipid metabolism (1) biological sample (1) biological samples collection (1) biological samples day of delivery (1) biological samples, questionnaires and interviews (1) biopsies of subcutaneous adipose tissue (1) blood collection via fingerprick (1) blood sample for seroepidemiological investigation (1) blood sampling for biobank (1) blood test for SARS-COV2 serology (1) blood tests (1) bovhyaluronidase azoxymer (1) brief mindfulness based intervention (1) bromelain (1) canakinumab (1) captopril 25mg (1) cardiac magnetic resonance (1) cardiovascular and respiratory systems monitoring (1) care as usual (1) care modalities (1) carotid-femoral pulse-wave velocity (1) cellulose-containing placebo capsules (1) cenicriviroc (1) chest radiography (1) chest x-ray (1) chlorine dioxide (1) chlorine dioxide 3000 ppm (1) chloroquine (1) cholecalciferol 200,000 IU (1) cholecalciferol 50,000 IU (1) clinical features and laboratory values (1) collection of biological samples (1) collection of mucosal lining fluid (1) collection of swabs (1) community health worker support (1) comparison of sample collection methods (1) complication (1) congenital malformation (1) conjunctival RT PCR (1) consultation (1) control (1) control group (1) convalescent plasma application to SARS-CoV-2 infected patients (1) convalescent plasma from recovered COVID 19 donor (1) conventional management of patients (1) conventional oxygen (1) corticosteroid nasal irrigation (1) covid-19 positive pregnant women (1) cries 13 questionnaire (1) current IPAC-UHN PPE (1) daily room disinfection (1) daily syndromic surveillance (1) dapansutrile capsules (1) data record (1) decisions of limitations and stop processing (1) demographic and clinical data obtained from hospital's electronic medical record. (1) diagnostic (1) diagnostic tests for COVID-19 infection (1) dialysis (1) double gloves (1) draw blood (1) duplex sonography (1) e-Psychotherapy (1) e-ink screen (1) eHealth (1) eHealth +counselling contacts (1) echocardiogram 2D (1) eculizumab (1) electrolytes (1) ensoETM device (1) evaluation of skin microvascular flow and reactivity (1) exchange blood transfusion from normal donor (1) exercise brochure (1) exercise capacity (1) exercise group (1) exercise training (1) exposure (1) faecal sample collector (1) favipiravir (1) favorable outcome (1) feces samples (COVI-BIOME ancillary study) (1) fingertip tests for POC assays (1) fostamatinib (1) fsfi survey (1) further processing of health data (1) gammaCore® (Vagus nerve stimulation) (1) gammaCore® Sapphire (non-invasive vagus nerve stimulator) (1) geko T3 (1) glenzocimab (1) global survey (1) glucose control and sensor usage (1) hAd5-S-Fusion+N-ETSD vaccine (1) heat therapy (1) high flow nasal cannula (HFNC) (1) high flow nasal cannula device (1) high-titer anti-Sars-CoV-2 plasma (1) hip arthropalsty (1) home care monitoring (1) home spirometry (1) hormones (1) hospital bedroom booking (1) hospitalisation, necessity of ICU, mortality rate, lung involvement (1) hospitalization for premature birth (1) hospitalized children with Covid19 (1) host genotype (1) host immune factors (1) human cord tissue mesenchymal stromal cells (1) hydrocortisone (1) hydroxychloroquine + azithromycin (1) hydroxychloroquine in combination with camostat mesylate (1) hydroxychloroquine placebo (1) hydroxychloroquine sulfate 200 MG (1) hyper immunoglobulins containing anti-Corona VS2 immunoglobulin (1) hyperbaric oxygen therapy (HBOT) (1) hyperimmune plasma (1) hypoxia : 14.3 and 12.7% FIO2, hypercapnia 7% CO2, inspiratory mechanical constraint (1) iAMP test (1) iNO (inhaled nitric oxide) delivered via the INOpulse Delivery System (1) identify SARS-CoV-2 infection by serology (1) imPulse™ Una e-stethoscope (1) imaging, blood tests (1) immune plasma (1) impliminting Online Distance Learning (1) in-hospital mortality rate (1) indirect calorimetry (1) inhalable hydroxychloroquine (HCQ) (1) inhaled hydroxychloroquine (1) inhaled type I interferon (1) inspiratory muscle traiing (1) insurance navigation (1) integrated clinical evaluation (1) intensive care unit admission ratio (1) interleuken 6 level measurment (1) intermediate dose Enoxaparin/ unfractionated heparin (1) intradermal injection of BCG Vaccine (1) intramuscular accine (1) intravenous immunoglobulin therapy (1) it is a survey (1) iv Tocillizumab (TCZ) (1) laboratory biomarkers (1) labs (1) lactoferrin, green tea extract (1) lanadelumab (1) laparoscopic or open appendicectomy (1) lay telephone coaching (1) less-frequency hemodialysis (1) life questionnaires (1) liposomal lactoferrin (1) lopinavir/ritonavir (1) lopinavir/ritonavir group (1) lopinavir/ritonavir tablets or Arbidol or chloroquine phosphate (1) low-molecular-weight heparin (1) lung mechanics at different PEEP (1) lung ultrasound (LUS) (1) mHealth Assessments (1) mMRC (Modified Medical Research Council) Dyspnea Scale (1) mRNA in urine test (1) management strategy of outpatient with mild to moderate SARS-CoV-2 pneumonia (1) maslach burnout inventory questionnair (1) mavrilimumab (1) measurement of circulating sFlt1 concentration (1) mechanical ventilation (1) mechanical ventilator settings and position (1) melatonin (1) mesenchymal stem cells (1) metenkefalin + tridecactide (1) metformin glycinate (1) methylprednisolone therapy (1) microcirculation recording (1) miniprobe Alveoflex (1) mobile internet survey on self-test (1) modification of the planned therapeutic management (1) modified IPAC-UHN PPE (1) molecular testing for virus RNA using RT-PCR (1) mometasone furoate nasal spray (1) monthly serologic IgM/G test (1) morning Yoga-based breathing support (1) mortality (1) mouthrinse with bêta-cyclodextrin and citrox (1) mouthrinse without bêta-cyclodextrin and citrox (1) multipeptide cocktail (1) muscle ultrasound (1) n/a - samples collected along routine care samples only (1) nCapp, a cell phone-based auto-diagnosis system (1) nangibotide (1) nasal pharyngeal (NP) swab samples (1) nasopharyngeal Covid 19 RT-PCR (1) nasopharyngeal and throat swab (1) nebulised recombinant tissue-Plasminogen Activator (rt-PA) (1) newborns from covid 19 positive mothers (1) no intervention-mechanistic study (1) no intervention. observational cohort study (1) no interventional study (1) non (1) non applicable (1) non interventional study (1) non-RAS blocking antihypertensives (1) non-contact magnetically-controlled capsule endoscopy (1) non-interventional (1) none - observational (1) none, this study is observational (1) noninvasive ventilation (1) normal saline (1) nosocomial infection/hospital acquired infection (1) not applicable (observational study) (1) not required (1) nutritional intervention (1) oSOC (1) observation (1) observation of covid 19 pneumonia (1) olfactory and gustatory tests (1) olfactory device (1) online KKH Sports Singapore Program with Usual Care (1) online mindfulness group (1) online questionnaires (1) oral co-trimoxazole (1) oral polio vaccine + information (1) oropharyngeal and intestinal microbiota (1) oropharyngeal swabs (1) oxygen treatment (1) oxyhydrogen (1) pathogen reduced SARS-CoV-2 convalescent plasma (1) patients COVID 19 (1) patients receiving nasal high flow (1) performance evaluation study of RealDetect RT-PCR Kit for COVID-19 detection (1) peripheral blood draw (1) personal protective Measures (1) phone call (1) photobiomodulation and photodynamic therapy (1) physical activity program (1) physiological effects of awake prone position in COVID 19 patients (1) placebo (hartmann plus albumine) (1) placebo capsules (1) placebo for clazakizumab (1) placebo rinse (1) plasma from convalescent patients with COVID-19 (1) plasma hyperimmune (1) plasma therapy using convalescent plasma with antibody against SARS-CoV-2 (1) poractant alfa (1) power breathe (1) prayer (1) pre-operative screening (1) pre_dinner Yoga-based breathing support (1) pre_lunch Yoga-based breathing support (1) predict admission of covid-19 patients to ICU and death with routine and quickly avalaible clinical, biological and radiological variables? (1) prone position (1) proper diet (1) prophylactic heparin (1) prophylactic lactoferrin daily (1) psycho-education video (1) psychological and sociological interviews (1) psychological assessment (1) pulmonary anomalies 4 months after documented COVID-19 pneumonia (1) pulmonary rehabilitation (1) pulmonary ultrasound (1) pulse oximeter (1) qRT-PCR and serology (1) quality of life questionnaires (1) quality of live assessment (1) quesionnair (1) questionaire to husband and wife (1) questionnair about Emerging Legal and Ehical Disputes Over Patient Confidentiality (1) questionnaire and optional interview (1) questionnaire filling (1) quetionnary (1) rNAPc2 (1) rapid salivary test (1) rapid serological test (1) realtime PCR (1) recombinant human interferon Alpha-1b (1) recovered covid 19 patients plasma (1) rectal swab (1) regular care (1) research specific blood sample (1) respiratory function rehabilitation training (1) retrospective metagenomics on clinical samples collected during hospitalization (1) revised HOME-CoV score (1) rhDNase I (1) rhTPO (1) risk factors (1) saint george respiratory questionnaire (1) saliva collection (1) saliva sample (1) samling of oropharynx and nasopharynx (1) sample of blood and saliva (1) self-administered structured questionnaire (1) self-care tools (1) semaglutide (1) semen analysis (1) serological test (1) serology test (1) serum NGAL and cystatin c (1) serum chemistry analysis (1) serum inflammatory biomarkers (1) service of questionnaire (1) severe covid-19 pneumonia with ET (1) severity of lung involvement with COVID-19. (1) smell household Items (1) sodium chloride 0.9% (1) sofosbuvir (1) specific exercise rehabilitation treatment (1) spirometry (1) spirometry, thoracic CT, CPET, 6 minute walking test, SF-36 questionnaire (1) standard concomitant therapy (1) standard medical treatment (1) standard operating procedures (1) standard procedure (1) standard prophylactic dose Enoxaparin/ unfractionated heparin (1) standard protocol (1) standard treatment (1) standard western medicine treatment (1) standardized Lung Ultrasound (LUS) examination (1) stem cells (1) stress and anxiety questionnaire (1) supportive and symptomatic treatment (1) survey work (1) surveys and questionnaires (1) suspected of COVID-19 infection (1) sweat samples (COVIDOG ancillary study) (1) teleconsultation (1) telehealth applications (1) telemedicine (1) telephone consult (1) tenofovir disoproxil and emtricitabine (1) test (1) thalidomide (1) therapeutic plasmaexchnage (1) theraputic heparin (1) this study is non- interventional (1) this study is not an intervention study (1) thoracic CT-scan (1) thoracic computed tomography scan (1) thoracic lung ultrasound (1) thromboprofylaxis protocol (1) thromboprophylaxis with low-molecular-weight heparin or fondaparinux (1) thymosin alpha 1 (1) topical steroids and cyclosporin-A (1) traditional communication tools (1) transparent sheet (1) treated with hyperimmune plasma (1) turkish physicians (1) unfractionated heparin (1) urinary NGAL, TIMP-2, IGFBP7, IL-6, viral load and metabolomic (1) users (1) vaccine (1) vaccine BCG (1) vadadustat (1) venipuncture in peripheral vein (1) ventilatory support with oxygen therapy (1) viral sequence (1) virgin coconut oil (VCO) (1) visual analogue scale (1) vitamin D (1) vitamin d (1) vv-ECMO (1) washed microbiota transplantation (1) web based survey (1) zinc (1) zinc acetate (1) zinc gluconate and ascorbic acid (1) ıt will be compared pain, sleep, fatigue, physical activity level and quality of life and questioning exercise habits before and after the covid-19 outbreak in patients with Behçet and FMF. (1) γ-Globulin (1) Оxygen therapy (1)

    Enoxaparin

    Developed by Shray Alag, The Harker School
    Sections: Correlations, Clinical Trials, and HPO

    Correlations computed by analyzing all clinical trials.

    Navigate: Clinical Trials and HPO


    Correlated Drug Terms (24)


    Name (Synonyms) Correlation
    drug1192 Enisamium Iodide Wiki 0.25
    drug2321 Online instruction Wiki 0.25
    drug4127 unfractionated heparin Wiki 0.25
    Name (Synonyms) Correlation
    drug2865 Reverse-transcription polymerase chain reaction (RT-PCR) Wiki 0.25
    drug1639 In-person instruction Wiki 0.25
    drug3846 further processing of health data Wiki 0.25
    drug2587 Platelet count, platelet, mean platelet volume and platelet distribution Width in COVID-19 Wiki 0.25
    drug1442 Heparin sodium Wiki 0.25
    drug1949 MakAir Wiki 0.25
    drug748 Chest computed tomography (CT) Wiki 0.25
    drug2667 Prophylactic/Intermediate Dose Enoxaparin Wiki 0.25
    drug3548 Unfractionated heparin nebulized Wiki 0.25
    drug3717 acetylsalicylic acid Wiki 0.25
    drug265 Apixaban Wiki 0.25
    drug609 COVID-19 PCR and serology testing Wiki 0.25
    drug2453 Personal Protective Testing Booth Wiki 0.25
    drug596 COVID-19 Antibody testing Wiki 0.25
    drug1195 Enoxaparin 40 Mg/0.4 mL Injectable Solution Wiki 0.18
    drug4126 unfractionated Heparin Wiki 0.18
    drug394 Bacille Calmette-Guérin (BCG) Wiki 0.18
    drug2879 Rivaroxaban Wiki 0.10
    drug2032 Methylprednisolone Wiki 0.06
    drug2215 No intervention Wiki 0.05
    drug2490 Placebo Wiki 0.02

    Correlated MeSH Terms (22)


    Name (Synonyms) Correlation
    D018357 Respiratory Syncytial Virus Infections NIH 0.25
    D013927 Thrombosis NIH 0.14
    D020141 Hemostatic Disorders NIH 0.13
    Name (Synonyms) Correlation
    D011655 Pulmonary Embolism NIH 0.13
    D001778 Blood Coagulation Disorders NIH 0.13
    D004617 Embolism NIH 0.13
    D003141 Communicable Diseases NIH 0.12
    D054556 Venous Thromboembolism NIH 0.08
    D007239 Infection NIH 0.08
    D020246 Venous Thrombosis NIH 0.08
    D013923 Thromboembolism NIH 0.06
    D011024 Pneumonia, Viral NIH 0.06
    D045169 Severe Acute Respiratory Syndrome NIH 0.05
    D014777 Virus Diseases NIH 0.05
    D011014 Pneumonia NIH 0.05
    D018352 Coronavirus Infections NIH 0.04
    D002318 Cardiovascular Diseases NIH 0.04
    D012141 Respiratory Tract Infections NIH 0.04
    D016638 Critical Illness NIH 0.03
    D012127 Respiratory Distress Syndrome, Newborn NIH 0.02
    D055371 Acute Lung Injury NIH 0.02
    D012128 Respiratory Distress Syndrome, Adult NIH 0.02

    Correlated HPO Terms (7)


    Name (Synonyms) Correlation
    HP:0001928 Abnormality of coagulation HPO 0.13
    HP:0002204 Pulmonary embolism HPO 0.13
    HP:0002625 Deep venous thrombosis HPO 0.08
    Name (Synonyms) Correlation
    HP:0002090 Pneumonia HPO 0.05
    HP:0001907 Thromboembolism HPO 0.05
    HP:0011947 Respiratory tract infection HPO 0.04
    HP:0001626 Abnormality of the cardiovascular system HPO 0.04

    Clinical Trials

    Navigate: Correlations   HPO

    There are 16 clinical trials


    1 Preventing COVID-19-associated Thrombosis, Coagulopathy and Mortality With Low- and High-dose Anticoagulation: a Multicentric Randomized, Open-label Clinical Trial

    The ongoing COVID-19 pandemic affects millions of humans worldwide and has led to thousands of acute medical hospitalizations. There is evidence that hospitalized cases often suffer from an important infection-related coagulopathy and from elevated risks of thrombosis. Anticoagulants may have positive effects here, to reduce the burden of thrombotic disease and the hyperactivity of coagulation, and may also hold beneficial anti-inflammatory effects against sepsis and the development of ARDS. The investigators hypothesize that high-dose anticoagulants, compared with low-dose anticoagulants, lower the risk of venous and arterial thrombosis, disseminated intravascular coagulation (DIC) and mortality. This open-label controlled trial will randomize hospitalized adults with severe COVID-19 infection to therapeutic anticoagulation vs. thromboprophylaxis during the hospital stay.

    NCT04345848
    Conditions
    1. COVID
    2. Sars-CoV2
    Interventions
    1. Drug: Enoxaparin
    MeSH:Thrombosis

    Primary Outcomes

    Description: Risk of arterial or venous thrombosis, disseminated intravascular coagulation and all-cause mortality

    Measure: Composite outcome of arterial or venous thrombosis, disseminated intravascular coagulation and all-cause mortality

    Time: 30 days

    Secondary Outcomes

    Description: Risk of ischemic stroke, myocardial infarction and/or limb ischemia

    Measure: Arterial thrombosis

    Time: 30 days

    Description: Risk of symptomatic venous thromboembolism or asymptomatic proximal leg deep vein thrombosis

    Measure: Venous thromboembolism

    Time: 30 days

    Description: Risk of DIC

    Measure: Disseminated intravascular coagulation

    Time: 30 days

    Description: Risk of all-cause mortality

    Measure: All-cause mortality

    Time: 30 days

    Description: Risk of SIC

    Measure: Sepsis-induced coagulopathy

    Time: 30 days

    Description: Risk of ARDS

    Measure: Acute respiratory distress syndrome

    Time: 30 days

    Description: Number of days with these care processes

    Measure: Durations of hospital stay, ICU stay, ventilation

    Time: 30 days

    Description: Highest score per participant

    Measure: Sequential organ failure assessment score

    Time: 30 days

    Description: Risk of clinical deterioration

    Measure: Clinical deterioration

    Time: 30 days

    Other Outcomes

    Description: Risk of ISTH-defined major bleeding

    Measure: Major bleeding

    Time: 30 days

    Description: Risk of ISTH-defined CRNMB

    Measure: Clinically relevant non-major bleeding

    Time: 30 days

    Description: Risk of documented HIT

    Measure: Heparin-induced thrombocytopenia

    Time: 30 days

    Description: Measures of PaO2/FiO2 among participants with mechanical ventilation

    Measure: PaO2/FiO2 index

    Time: 30 days
    2 Enoxaparin for Thromboprophylaxis in Hospitalized COVID-19 Patients: Comparison of 40 mg o.d. Versus 40 mg b.i.d. A Randomized Clinical Trial

    The purpose of this study is to determine whether a higher dose of low molecular weight heparin (enoxaparin 40 mg b.i.d.) is superior than the standard prophylaxis dose (enoxaparin 40 mg o.d.) in reducing thromboembolic events in COVID-19 patients.

    NCT04366960
    Conditions
    1. Covid19
    Interventions
    1. Drug: Enoxaparin

    Primary Outcomes

    Description: Deep vein thrombosis events diagnosed by serial compression ultrasonography and pulmonary embolism events diagnosed by computed tomography scan

    Measure: Incidence of venous thromboembolism detected by imaging

    Time: 30 days

    Secondary Outcomes

    Description: death, venous thromboembolism, use of mechanical ventilation, stroke, acute myocardial infarction and admission to an intensive care

    Measure: In hospital major complications

    Time: 30 days

    Description: Deep venous thrombosis events diagnosed by serial compression ultrasonography

    Measure: Number of deep venous thrombosis events

    Time: 30 days

    Description: Maximum sequential organ failure assessment (SOFA) score comparison between the two groups. The SOFA score ranges from 0 to 24. Higher SOFA score is associated with a greater risk of death or prolonged intensive care unit stay.

    Measure: Sequential organ failure assessment

    Time: 30 days

    Description: To compare C-reactive protein levels as % above the upper reference limit [URL]) among the two groups.

    Measure: C-reactive protein

    Time: 30 days

    Description: To compare Interleukin-6 levels as % above the upper reference limit [URL]) among the two groups.

    Measure: Interleukin-6

    Time: 30 days

    Description: To D-dimer compare levels as % above the upper reference limit [URL]) among the two groups.

    Measure: D-dimer

    Time: 30 days

    Description: To compare hs-troponin levels as % above the upper reference limit [URL]) among the two groups.

    Measure: hs-troponin levels

    Time: 30 days

    Description: To compare the incidence of SARS-CoV-2-related Acute Respiratory Distress Syndrome (ARDS) between the two groups.

    Measure: Acute Respiratory Distress Syndrome

    Time: 30 days

    Description: To compare length of hospital stay between the two groups.

    Measure: Hospital stay

    Time: 30 days

    Description: To compare measures of right ventricular function at trans-thoracic echocardiography or CT between admission and follow-up, whenever available

    Measure: Right ventricular function

    Time: 30 days

    Description: Pulmonary embolism events diagnosed by computed tomography scan

    Measure: Number of pulmonary embolism events

    Time: 30 days
    3 Effectiveness of Weight-adjusted Prophylactic Low Molecular Weight Heparin Doses Compared With Lower Fixed Prophylactic Doses to Prevent Venous Thromboembolism in COVID-2019. The Multicenter Randomized Controlled Open-label Trial COVI-DOSE

    Worldwide observational studies indicate a significant prothrombogenic effect associated with SARS-CoV-2 infection with a high incidence of venous thromboembolism (VTE), notably life-threatening pulmonary embolism. According to recommendations for acute medical illnesses, all COVID-19 hospitalized patients should be given VTE prophylaxis such as a low molecular weight heparin (LMWH). A standard prophylactic dose (eg. Enoxaparin 4000IU once daily) could be insufficient in obese patients and VTE has been reported in patients treated with a standard prophylactic dose. In COVID-19 patients, guidelines from several international societies confirm the existence of an hypercoagulability and the importance of thromboprophylaxis but the "optimal dose is unknown" and comparative studies are needed. In view of these elements, carrying out a trial comparing various therapeutic strategies for the prevention of VTE in hospitalized patients with COVID-19 constitutes a health emergency. Thus, we hypothesize that an increased prophylactic dose of weight-adjusted LMWH would be greater than a lower prophylactic dose of LMWH to reduce the risk of life-threatening VTE in hospitalized patients. The benefit-risk balance of this increase dose will be carefully evaluated because of bleeding complications favored by possible renal / hepatic dysfunctions, drug interactions or invasive procedures in COVID-19 patients. This multicenter randomized (1:1) open-label controlled trial will randomize hospitalized adults with COVID-19 infection to weight-adjusted prophylactic dose vs. lower prophylactic dose of LMWH.

    NCT04373707
    Conditions
    1. COVID
    2. Thrombosis
    3. Pulmonary Embolism
    4. Deep Vein Thrombosis
    Interventions
    1. Drug: Enoxaparin
    2. Drug: Enoxaparin
    MeSH:Pulmonary Embolism Thrombosis Thromboembolism Emb Embolism Venous Thromboembolism Venous Thrombosis
    HPO:Deep venous thrombosis Pulmonary embolism Thromboembolism Venous thrombosis

    Primary Outcomes

    Description: Risk of deep vein thrombosis or pulmonary embolism or venous thromboembolism-related death

    Measure: Venous thromboembolism

    Time: 28 days

    Secondary Outcomes

    Description: Risk of major bleeding defined by the ISTH

    Measure: Major bleeding

    Time: 28 days

    Description: Risk of Major Bleeding and Clinically Relevant Non-Major Bleeding Defined by the ISTH

    Measure: Major Bleeding and Clinically Relevant Non-Major Bleeding

    Time: 28 days

    Description: Risk of Venous Thromboembolism and Major Bleeding

    Measure: Net Clinical Benefit

    Time: 28 days and 2 months

    Description: Risk of venous thrombosis at other sites: e.g. superficial vein, catheters, hemodialysis access, ECMO, splanchnic, encephalic, upper limb

    Measure: Venous Thromboembolism at other sites

    Time: 28 days

    Description: Risk of arterial thrombosis at any sites

    Measure: Arterial Thrombosis

    Time: 28 days

    Description: Risk of all-cause mortality

    Measure: All-Cause Mortality

    Time: 28 days and 2 months

    Description: Identification of associations between the risk of venous thromboembolism and clinical (eg. past medical history of thrombosis, cardiovascular risk factors, treatments, severity of COVID-19) and laboratory variables (e.g. D-dimers, fibrinogen, CRP) collected in the eCRF

    Measure: Factors associated with the risk of venous thromboembolism

    Time: 28 days
    4 Effectiveness of Weight-adjusted Prophylactic Low Molecular Weight Heparin Doses Compared With Lower Fixed Prophylactic Doses to Prevent Venous Thromboembolism in COVID-2019. The Multicenter Randomized Controlled Open-label Trial COVI-DOSE

    Worldwide observational studies indicate a significant prothrombogenic effect associated with SARS-CoV-2 infection with a high incidence of venous thromboembolism (VTE), notably life-threatening pulmonary embolism. According to recommendations for acute medical illnesses, all COVID-19 hospitalized patients should be given VTE prophylaxis such as a low molecular weight heparin (LMWH). A standard prophylactic dose (eg. Enoxaparin 4000IU once daily) could be insufficient in obese patients and VTE has been reported in patients treated with a standard prophylactic dose. In COVID-19 patients, guidelines from several international societies confirm the existence of an hypercoagulability and the importance of thromboprophylaxis but the "optimal dose is unknown" and comparative studies are needed. In view of these elements, carrying out a trial comparing various therapeutic strategies for the prevention of VTE in hospitalized patients with COVID-19 constitutes a health emergency. Thus, we hypothesize that an increased prophylactic dose of weight-adjusted LMWH would be greater than a lower prophylactic dose of LMWH to reduce the risk of life-threatening VTE in hospitalized patients. The benefit-risk balance of this increase dose will be carefully evaluated because of bleeding complications favored by possible renal / hepatic dysfunctions, drug interactions or invasive procedures in COVID-19 patients. This multicenter randomized (1:1) open-label controlled trial will randomize hospitalized adults with COVID-19 infection to weight-adjusted prophylactic dose vs. lower prophylactic dose of LMWH.

    NCT04373707
    Conditions
    1. COVID
    2. Thrombosis
    3. Pulmonary Embolism
    4. Deep Vein Thrombosis
    Interventions
    1. Drug: Enoxaparin
    2. Drug: Enoxaparin
    MeSH:Pulmonary Embolism Thrombosis Thromboembolism Emb Embolism Venous Thromboembolism Venous Thrombosis
    HPO:Deep venous thrombosis Pulmonary embolism Thromboembolism Venous thrombosis

    Primary Outcomes

    Description: Risk of deep vein thrombosis or pulmonary embolism or venous thromboembolism-related death

    Measure: Venous thromboembolism

    Time: 28 days

    Secondary Outcomes

    Description: Risk of major bleeding defined by the ISTH

    Measure: Major bleeding

    Time: 28 days

    Description: Risk of Major Bleeding and Clinically Relevant Non-Major Bleeding Defined by the ISTH

    Measure: Major Bleeding and Clinically Relevant Non-Major Bleeding

    Time: 28 days

    Description: Risk of Venous Thromboembolism and Major Bleeding

    Measure: Net Clinical Benefit

    Time: 28 days and 2 months

    Description: Risk of venous thrombosis at other sites: e.g. superficial vein, catheters, hemodialysis access, ECMO, splanchnic, encephalic, upper limb

    Measure: Venous Thromboembolism at other sites

    Time: 28 days

    Description: Risk of arterial thrombosis at any sites

    Measure: Arterial Thrombosis

    Time: 28 days

    Description: Risk of all-cause mortality

    Measure: All-Cause Mortality

    Time: 28 days and 2 months

    Description: Identification of associations between the risk of venous thromboembolism and clinical (eg. past medical history of thrombosis, cardiovascular risk factors, treatments, severity of COVID-19) and laboratory variables (e.g. D-dimers, fibrinogen, CRP) collected in the eCRF

    Measure: Factors associated with the risk of venous thromboembolism

    Time: 28 days
    5 A Randomized, Open-Label Trial of Therapeutic Anticoagulation in COVID-19 Patients With an Elevated D-Dimer

    The coronavirus disease 2019 (COVID-19) global pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused considerable morbidity and mortality in over 170 countries. Increasing age and burden of cardiovascular comorbidities are associated with a worse prognosis among patients with COVID-19. In addition, serologic markers of more severe disease including coagulation abnormalities and thrombocytopenia, are not uncommon among patients hospitalized with severe COVID-19 infection and are more common in patients who died in-hospital. As the COVID-19 pandemic continues to grow, there is a pressing need to identify safe, effective, and widely available therapies that can be scaled and rapidly incorporated into clinical practice. Understanding the putative mechanism of increased mortality risk associated with abnormal coagulation function and cardiac injury is critical to guide studies of promising therapeutic interventions. Published and anecdotal reports indicate that endothelial dysfunction and thrombosis are common in critically ill patients with COVID-19, including reports of diffuse microvascular thrombosis in the lungs, heart, liver, and kidneys. Patients with cardiovascular disease (CVD) and CVD risk factors are known to have endothelial dysfunction and a heightened risk of thrombosis. A recent study of COVID-19 inpatients from Wuhan, China observed that an elevated D-dimer level greater than 1 ug/mL was associated with an 18 times higher risk of in-hospital death, underscoring the importance of increased coagulation activity as a potential modifiable risk marker that may drive end-organ injury. Given the established link between endothelial dysfunction and thrombosis in patients with cardiovascular disease, and the association between coagulopathy and adverse outcomes in patients with sepsis, the association between increased coagulation activity, end-organ injury, and mortality risk may represent a modifiable risk factor among COVID-19 patients with critical illness. Therefore, we propose to conduct a randomized, open-label trial of therapeutic anticoagulation in COVID-19 patients with an elevated D-dimer to evaluate the efficacy and safety.

    NCT04377997
    Conditions
    1. Cardiovascular Diseases
    2. COVID-19
    Interventions
    1. Drug: Enoxaparin
    MeSH:Cardiovascular Diseases
    HPO:Abnormality of the cardiovascular system

    Primary Outcomes

    Description: Aim 1 - Risk of death, cardiac arrest, symptomatic deep venous thrombosis, pulmonary embolism, arterial thromboembolism, myocardial infarction, or hemodynamic shock.

    Measure: Number of patients with the composite efficacy endpoint of death, cardiac arrest, symptomatic deep venous thrombosis, pulmonary embolism, arterial thromboembolism, myocardial infarction, or hemodynamic shock.

    Time: 12 weeks

    Description: Aim 2 - Risk of major bleeding event according to the International Society on Thrombosis and Haemostasis (ISTH) definition.

    Measure: Number of patients with a major bleeding event according to the International Society on Thrombosis and Haemostasis (ISTH) definition.

    Time: 12 weeks
    6 Systemic Anticoagulation With Full Dose Low Molecular Weight Heparin (LMWH) Vs. Prophylactic or Intermediate Dose LMWH in High Risk COVID-19 Patients (HEP-COVID Trial)

    The aim of this study is to test the hypothesis that prophylaxis of severe COVID-19 patients with treatment dose LMWH leads to better thromboembolic-free outcomes and associated complications during hospitalization than prophylaxis with institutional standard of care with prophylactic to intermediate-doses of UFH or LMWH

    NCT04401293
    Conditions
    1. Sars-CoV2
    2. COVID
    Interventions
    1. Drug: Enoxaparin
    2. Drug: Prophylactic/Intermediate Dose Enoxaparin

    Primary Outcomes

    Description: Risk of arterial thromboembolic events (including myocardial infarction, stroke, systemic embolism), venous thromboembolism (including symptomatic deep vein thrombosis (DVT) of the upper or lower extremity, asymptomatic proximal DVT of the lower extremity, non-fatal pulmonary embolism (PE)), and all-cause mortality at Day 30 ± 2 days.

    Measure: Composite outcome of arterial thromboembolic events, venous thromboembolic events and all-cause mortality at Day 30 ± 2 days.

    Time: Day 30 ± 2 days

    Secondary Outcomes

    Description: Risk of major bleeding defined using the International Society of Thrombosis and Haemostasis (ISTH) criteria

    Measure: Major bleeding

    Time: Day 30 ± 2 days

    Description: The composite of arterial thromboembolic events (including myocardial infarction, stroke, systemic embolism), venous thromboembolism (including symptomatic deep vein thrombosis (DVT) of the upper or lower extremity, asymptomatic proximal DVT of the lower extremity, non-fatal pulmonary embolism (PE)), and all-cause mortality at Hospital Day 10 + 4

    Measure: Composite outcome of arterial thromboembolic events, venous thromboembolic events and all-cause mortality at Hospital Day 10 + 4

    Time: Day 10 + 4

    Description: Sepsis-induced coagulopathy (SIC) score based on ISTH guidelines. Platelets, K/uL (thousands per microliter) [0-2] INR (International Normalized Ratio) [0-2] D-Dimer Levels, ng/mL [0-3] Fibrinogen, mg/dL [0-1] Calculated (SIC) scores greater or equal to 4 predicted higher mortality rates within 30 days and greater risk of pulmonary embolism.

    Measure: Sepsis-induced coagulopathy (SIC) score

    Time: Day 30 ± 2 days.

    Description: Progression to Acute Respiratory Distress Syndrome (ARDS) based on monitoring of patient conditions.

    Measure: Progression to Acute Respiratory Distress Syndrome (ARDS)

    Time: Day 30 ± 2 days.

    Description: Need for Intubation will be based on monitoring of patient conditions.

    Measure: Need for Intubation

    Time: Day 30 ± 2 days.

    Description: Need for Re-hospitalization will be based on monitoring of patient conditions.

    Measure: Re-hospitalization

    Time: Day 30 ± 2 days.
    7 Randomised Controlled Trial Comparing High Versus Low LMWH Dosages in Hospitalized Patients With Severe COVID-19 Pneumonia and Coagulopathy Not Requiring Invasive Mechanical Ventilation

    Randomized, controlled study conducted in hospitalized patients with severe COViD-19 pneumonia and coagulopathy not requiring invasive mechanical ventilation. Aim of this study is to assess whether high doses of Low Molecular Weight Heparin (LMWH) (ie. Enoxaparin 70 IU/kg twice daily) compared to standard prophylactic dose (ie, Enoxaparin 4000 IU once day) are: 1. More effective to prevent clinical worsening, defined as the occurrence of at least one of the following events, whichever comes first, during hospital stay: 1. Death 2. Acute Myocardial Infarction [AMI] 3. Objectively confirmed, symptomatic arterial or venous thromboembolism [TE] 4. Need for either non-invasive - Continuous Positive Airway Pressure (Cpap) or Non-Invasive Ventilation (NIV) - or invasive mechanical ventilation for patients who are in standard oxygen therapy by delivery interfaces at randomisation 5. Need for invasive mechanical ventilation for patients who are in non-invasive mechanical ventilation at randomisation 2. Similar in terms of major bleeding risk during hospital stay

    NCT04408235
    Conditions
    1. COVID
    2. Pneumonia, Viral
    3. Coagulation Disorder
    Interventions
    1. Drug: Enoxaparin
    MeSH:Pneumonia, Viral Pneumonia Hemostatic Disorders Blood Coagulation Disorders
    HPO:Abnormality of coagulation Abnormality of the coagulation cascade Pneumonia

    Primary Outcomes

    Description: Death Acute Myocardial Infarction [AMI] Objectively confirmed, symptomatic arterial or venous thromboembolism [TE] Need for either non-invasive - Continuous Positive Airway Pressure (Cpap) or Non-Invasive Ventilation (NIV) - or invasive mechanical ventilation for patients, who are in standard oxygen therapy by delivery interfaces at randomisation Need for invasive mechanical ventilation for patients, who are in non-invasive mechanical ventilation at randomisation

    Measure: Clinical worsening, defined as the occurrence of at least one of the following events, whichever comes first:

    Time: through study completion, up to 30 days

    Secondary Outcomes

    Description: Death Acute Myocardial Infarction [AMI] Objectively confirmed, symptomatic arterial or venous thromboembolism [TE] Need for either non-invasive - Continuous Positive Airway Pressure (Cpap) or Non-Invasive Ventilation (NIV) - or invasive mechanical ventilation for patients, who are in standard oxygen therapy by delivery interfaces at randomisation Need for invasive mechanical ventilation for patients, who are in non-invasive mechanical ventilation at randomisation Improvement of laboratory parameters of disease severity, including: D-dimer level Plasma fibrinogen levels Mean Platelet Volume Lymphocyte/Neutrophil ratio IL-6 plasma levels

    Measure: Any of the following events occurring within the hospital stay

    Time: through study completion, up to 30 days

    Description: Information about patients' status will be sought in those who are discharged before 30 days on Day 30 from randomisation.

    Measure: Mortality at 30 days

    Time: 30 days
    8 Intermediate Dose Enoxaparin in Hospitalized Patients With Moderate-severe COVID19: A Pilot Phase II Single-arm Study, INHIXACOVID19

    General objective of the study To assess the efficacy and safety of enoxaparin in hospitalized patients with moderate to severe COVID-19 (Coronavirus Disease 2019) infection. Study Design The study consists of two parts: - a phase II single-arm interventional prospective study including all patients treated with the study drug; - an observational prospective cohort study including all patients screened for receiving the study drug but not included in the phase II study. Patients will be enrolled from "date of study approval" for 1 month. Each patient will be followed-up for a minimum of 90 days after COVID19 diagnosis.

    NCT04427098
    Conditions
    1. COVID-19
    Interventions
    1. Drug: Enoxaparin 40 Mg/0.4 mL Injectable Solution
    2. Drug: Enoxaparin

    Primary Outcomes

    Description: Rates of hospitalized patients dead for all-cause within 30 days and 90 days from the first LMWH subcutaneous injection

    Measure: To investigate the efficacy of enoxaparin in improving the clinical outcome of hospitalized patients with moderate-severe COVID-19.

    Time: 30 days and 90 days from the first LMWH subcutaneous injection

    Description: Based on the four levels scale of severity of symptoms. Any change from one level to another will be detected for all the enrolled patients, in order to evalutate the clinical efficacy of enoxaparin on the outcome of COVID 19.

    Measure: To investigate the efficacy of enoxaparin in improving the clinical outcome of hospitalized patients with moderate-severe COVID-19.

    Time: This evaluation will be performed at 30 days and 90 days from the first LMWH subcutaneous injection

    Description: Evolution of the clinical severity during treatment, based on the number and rate of patients admitted to ICU and the length of their ICU stay

    Measure: To investigate the efficacy of enoxaparin in improving the clinical outcome of hospitalized patients with moderate-severe COVID-19.

    Time: This evaluation will be performed at 14 days (the last day of treatment adminstration), at 30 days and 90 days from the first LMWH subcutaneous injection

    Description: Difference between groups in number of days of hospitalization from admission to discharge

    Measure: To investigate the efficacy of enoxaparin in improving the clinical outcome of hospitalized patients with moderate-severe COVID-19.

    Time: This evaluation will be performed at 90 days from admission

    Secondary Outcomes

    Description: Rate of adverse events (AEs) during treatment, at the end of treatment (EOT) and at 30 days after EOT. • Severity of AEs classified according to common terminology criteria for adverse events (CTCAE). The worst degree ever suffered will be considered.

    Measure: To analyse the safety of enoxaparin in hospitalized patients with moderatesevere COVID-19.

    Time: 45 days

    Description: Occurrence of thromboembolic event at 90 days after COVID-19 diagnosis. Description of the type, distribution and severity of thromboembolic events.

    Measure: To describe the rates and the types of thromboembolic events among hospitalized patients with confirmed diagnosis of COVID-19.

    Time: 90 days
    9 Dynamics of Hemostatic Parameters in COVID-19 and Comparison of Intervention Strategies Through Adaptive Clinical Trial

    Hypercoagulability has been demonstrated in COVID-19, leading to respiratory distress and increased mortality. This is adaptive clinical trial to compare effectiveness and safety of four therapeutic strategies in hospital mortality in patients with COVID-19: standard prophylaxis, therapeutic dose anticoagulation, inhaled UFH associated with standard prophylaxis and ASA associated with standard prophylaxis.

    NCT04466670
    Conditions
    1. COVID-19
    Interventions
    1. Drug: unfractionated Heparin
    2. Drug: Unfractionated heparin nebulized
    3. Drug: acetylsalicylic acid
    4. Drug: Enoxaparin

    Primary Outcomes

    Description: Number of COVID-19 positive patients who are alive within 30 days of symptoms onset

    Measure: Hospital discharge - alive / death

    Time: 30 days

    Secondary Outcomes

    Description: Comparison of length of mechanical ventilation free days between each treatment arm

    Measure: Length of mechanical ventilation free days

    Time: 30 days

    Description: Comparison of length of renal replacement therapy free days between each treatment arm

    Measure: Length of renal replacement therapy free days

    Time: 30 days

    Description: Comparison of number of thrombosis events between each treatment arm.

    Measure: Number of documented venous thromboembolism or arterial thrombosis

    Time: 3 months
    10 Early Thromboprophylaxis in COVID-19 (ETHIC Trial): an Open Label, Randomized Phase IIIb Trial of Community-based (LMWH) Versus Standard of Care in COVID-19 Positive Patients

    Evidence has shown that COVID-19 infections can lead to an increased risk of blood clots. These blood clots can lead to individuals being admitted to hospital, or, unfortunately in severe cases, death. Enoxaparin is a blood-thinning drug which has been used by doctors and nurses in hospitals for many years to prevent the thickening of blood which may lead to a clot. It is easier for doctors to prevent new blood clots from forming than treating existing blood clots. Currently, there are no treatments for COVID-19. There is an urgent need to find a safe and effective treatment to prevent worsening of the disease that may lead to hospital admission and/or death. The ETHIC (Early Thromboprophylaxis in COVID-19) study aims to find out if giving enoxaparin in an early stage of the COVID-19 disease can prevent individuals being admitted to hospital and/or death. The study will take place in approximately 8 to 10 countries, in approximately 30 to 50 centres. Patients will be allowed to take part if they have had a confirmed COVID-19 infection, are ≥ 55 years of age and have at least two of the following additional risk factors; age ≥ 70 years, body mass index > 25 kg/m2, chronic obstructive pulmonary disease, diabetes, cardiovascular disease, or corticosteroid use. Half the patients in the study will receive the blood-thinning drug enoxaparin for three weeks, and half will receive no treatment. Individuals will be randomly allocated to one of these groups. After 21 days, the number of patients in each group who were either admitted to hospital, or died, will be compared. The number of patients in each group who developed a blood clot (venous thromboembolism) will also be compared. Further comparisons will be made at both 50 and 90 days after the beginning of the study.

    NCT04492254
    Conditions
    1. COVID-19
    Interventions
    1. Drug: Enoxaparin

    Primary Outcomes

    Description: Hospital admission including: Pneumonia Acute Respiratory distress syndrome Admission to intensive care unit (ICU) Mechanical ventilation (MV)/intubation requirement Continuous positive airway pressure (CPAP)/Non-invasive ventilation Extracorporeal membrane oxygenation (ECMO)

    Measure: Hospital Admission

    Time: 21 days

    Description: Hospital admission including: Pneumonia Acute Respiratory distress syndrome Admission to intensive care unit (ICU) Mechanical ventilation (MV)/intubation requirement Continuous positive airway pressure (CPAP)/Non-invasive ventilation Extracorporeal membrane oxygenation (ECMO)

    Measure: Hospital Admission

    Time: 50 days

    Description: Hospital admission including: Pneumonia Acute Respiratory distress syndrome Admission to intensive care unit (ICU) Mechanical ventilation (MV)/intubation requirement Continuous positive airway pressure (CPAP)/Non-invasive ventilation Extracorporeal membrane oxygenation (ECMO)

    Measure: Hospital Admission

    Time: 90 days

    Description: All-cause Cardiovascular Non-Cardiovascular Specific causes Fatal bleed

    Measure: Death

    Time: 21 days

    Description: All-cause Cardiovascular Non-Cardiovascular Specific causes Fatal bleed

    Measure: Death

    Time: 50 days

    Description: All-cause Cardiovascular Non-Cardiovascular Specific causes Fatal bleed

    Measure: Death

    Time: 90 days

    Secondary Outcomes

    Description: Frequency Location Treatment (transfusion and units of blood products transfused) Severity (classified as major, clinically relevant non-major and minor)

    Measure: Bleeding (as defined by ISTH criteria)

    Time: 21 and 50 days

    Description: Deep Vein Thrombosis (DVT) or Pulmonary Embolism (PE)

    Measure: Diagnosis of VTE

    Time: 21, 50 and 90 days
    11 Effect of the Use of Anticoagulant Therapy During Hospitalization and Discharge in Patients With COVID-19 Infection

    Viral infections provoke the systemic inflammatory response and cause an imbalance between the procoagulant and anticoagulant homeostatic mechanisms. Multiple pathogenic mechanisms are involved, including endothelial dysfunction, increased von Willebrand factor, Toll receptor activation, and tissue factor pathway activation. D-dimer levels greater than 1000 ng / mL are associated with an 18-fold increased risk of mortality. In this context, many patients may require prophylaxis or antithrombotic treatment with low molecular weight heparins. Currently, there is no validated scheme on the dose and timing of the use of antithrombotic drugs. The study aims to identify the effect of two anticoagulant strategies (prophylactic and therapeutic) on the progression to ventilatory support or death in patients with COVID-19 infection who require hospital care.

    NCT04508439
    Conditions
    1. Covid19
    2. Pneumonia
    3. Coagulation Disorder
    4. Pulmonary Embolism
    Interventions
    1. Drug: Enoxaparin
    MeSH:Pneumonia Pulmonary Embolism Embolism Hemostatic Disorders Blood Coagulation Disorders
    HPO:Abnormality of coagulation Abnormality of the coagulation cascade Pneumonia Pulmonary embolism

    Primary Outcomes

    Description: Identify the benefit of different doses of low molecular weight heparin (enoxaparin) on ventilatory support time in patients requiring hospital care for COVID-19 infection.

    Measure: low molecular weight heparin (enoxaparin) and ventilatory support time

    Time: 30 days

    Description: To compare oral anticoagulation therapy by administering Rivaroxaban 10mg PO every 24 hours on early thrombotic complications

    Measure: thrombotic complications and Rivaroxaban

    Time: 30 days

    Description: Identify the benefit of different doses of low molecular weight heparin (enoxaparin) on the length of hospital stay in patients requiring hospital care for COVID-19 infection.

    Measure: low molecular weight heparin (enoxaparin) and length of hospital stay

    Time: 30 days

    Description: Identify the benefit of different doses of low molecular weight heparin (enoxaparin) over mortality rate in patients requiring hospital care for COVID-19 infection.

    Measure: low molecular weight heparin (enoxaparin) and mortality rate

    Time: 30 days
    12 FREEDOM COVID Anticoagulation Strategy Randomized Trial

    Coronavirus Disease (COVID-19), caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has led to unprecedented morbidity and mortality in the modern era. To date, nearly 13 million people have contracted COVID-19, leading to more than 550,000 deaths worldwide. As the number of affected individuals continues to climb, effective strategies for treatment and prevention of the disease are of paramount importance. SARS-CoV-2 is understood to directly invade cells via the human angiotensin-converting enzyme 2 (ACE2) receptor, which is expressed predominantly in the lungs but also throughout the cardiovascular system. Thus, while acute respiratory distress syndrome remains a feared complication, new thromboembolic disease has emerged as a common and potentially catastrophic manifestation of COVID-19.

    NCT04512079
    Conditions
    1. COVID-19
    2. SARS-CoV-2
    Interventions
    1. Drug: Enoxaparin
    2. Drug: Apixaban

    Primary Outcomes

    Description: The time to first event rate within 30 days of randomization of the composite of all-cause mortality, intubation requiring mechanical ventilation, systemic thromboembolism (including pulmonary emboli) confirmed by imaging or requiring surgical intervention OR ischemic stroke confirmed by imaging.

    Measure: Time to first event

    Time: 30 days

    Description: Number of in-hospital rate of BARC 3 or 5 bleeding (binary). BARC Type 3: a. Overt bleeding plus hemoglobin drop of 3 to < 5 g/dL (provided hemoglobin drop is related to bleed); transfusion with overt bleeding b. Overt bleeding plus hemoglobin drop < 5 g/dL (provided hemoglobin drop is related to bleed); cardiac tamponade; bleeding requiring surgical intervention for control; bleeding requiring IV vasoactive agents c. Intracranial hemorrhage confirmed by autopsy, imaging, or lumbar puncture; intraocular bleed compromising vision. BARC Type 5: Probable fatal bleeding Definite fatal bleeding (overt or autopsy or imaging confirmation)

    Measure: Number of in-hospital rate of BARC 3 or 5

    Time: 30 days

    Secondary Outcomes

    Description: Myocardial infarction (according to the 4th universal definition, types 1,2, and 3)

    Measure: Number of participants with Myocardial infarction

    Time: 30 days after randomization

    Description: Myocardial infarction (according to the 4th universal definition, types 1,2, and 3)

    Measure: Number of participants with Myocardial infarction

    Time: 90 days after randomization

    Description: Deep vein thrombosis with confirmation on imaging

    Measure: Number of participants with Deep Vein Thrombosis

    Time: 30 days after randomization

    Description: Deep vein thrombosis with confirmation on imaging

    Measure: Number of participants with Deep Vein Thrombosis

    Time: 90 days after randomization

    Description: Intubation and mechanical ventilation

    Measure: Number of participants requiring Ventilation

    Time: 30 after randomization

    Description: Intubation and mechanical ventilation

    Measure: Number of participants requiring Ventilation

    Time: 90 days after randomization

    Description: All-cause death

    Measure: Number of All Death

    Time: 30 days after randomization

    Description: All-cause death

    Measure: Number of All Death

    Time: 90 days after randomization

    Description: Cause of Death

    Measure: Cause of Death

    Time: 30 days after randomization

    Description: Cause of Death

    Measure: Cause of Death

    Time: 90 days after randomization

    Description: Stroke confirmed by imaging or autopsy (all, ischemic and hemorrhagic)

    Measure: Number of participants with Stroke

    Time: 30 days after randomization

    Description: Stroke confirmed by imaging or autopsy (all, ischemic and hemorrhagic)

    Measure: Number of participants with Stroke

    Time: 90 days after randomization

    Description: Pulmonary emboli confirmed by imaging or autopsy

    Measure: Number of participants with Pulmonary Emboli

    Time: 30 days after randomization

    Description: Pulmonary emboli confirmed by imaging or autopsy

    Measure: Number of participants with Pulmonary Emboli

    Time: 90 days after randomization

    Description: Systemic thromboembolism confirmed by imaging or requiring surgical intervention

    Measure: Number of participants with Systemic Thromboembolism

    Time: 30 days after randomization

    Description: Systemic thromboembolism confirmed by imaging or requiring surgical intervention

    Measure: Number of participants with Systemic Thromboembolism

    Time: 90 days after randomization
    13 Steroids and Unfractionated Heparin in Critically Ill Patients With Pneumonia From COVID-19 Infection. A Multicenter, Interventional, Randomized, Three Arms Study Design

    SARS-CoV-2 infection seems to induce in most critical cases an excessive and aberrant hyper-inflammatory host immune response that is associated with a so-called "cytokine storm", moreover pro-thrombotic derangements of haemostatic system is another common finding in most severe forms of COVID19 infections, which may be explained by the activation of coagulative cascade primed by inflammatory stimuli, in line with what is observed in many other forms of sepsis. Targeting inflammatory responses exploiting steroids' anti-inflammatory activity along with thrombosis prevention may be a promising therapeutic option to improve patients' outcome. Despite the biological plausibility, no good evidence is available on the efficacy and safety of heparin on sepsis patients, and many issues have to be addressed, regarding the proper timing, dosages and administration schedules of anticoagulant drugs. The primary objective is to assess the hypothesis that an adjunctive therapy with steroids and unfractionated heparin (UFH) or with steroids and low molecular weight heparin (LMWH) are more effective in reducing any-cause mortality in critically-ill patients with pneumonia from COVID- 19 infection compared to low molecular weight heparin (LMWH) alone. Mortality will be measured at 28 days. The study is designed as a multicenter, national, interventional, randomized, investigator sponsored, three arms study. Patients, who satisfy all inclusion criteria and no exclusion criteria, will be randomly assigned in a ratio 1:1:1 to one of the three treatment groups: LMWH group, LMWH+steroids or UFH+steroid group. A possible result showing the efficacy of the composite treatment in reducing the mortality rate among critically ill patients with pneumonia from COVID-19 infection will lead to a revision of the current clinical approach to this disease.

    NCT04528888
    Conditions
    1. Covid19
    2. SARS-CoV Infection
    3. Pneumonia, Viral
    4. Coagulopathy
    Interventions
    1. Drug: Enoxaparin
    2. Drug: Methylprednisolone
    3. Drug: unfractionated heparin
    MeSH:Infection Communicable Diseases Coronavirus Infections Severe Acute Respiratory Syndrome Pneumonia, Viral Pneumonia Critical Illness
    HPO:Pneumonia

    Primary Outcomes

    Description: All-cause mortality at day 28, defined as the comparison of proportions of patients death for any cause at day 28 from randomization.

    Measure: All-cause mortality at day 28

    Time: Day 28 from randomization

    Secondary Outcomes

    Description: All-cause mortality at ICU discharge, defined as the comparison of proportions of patients death for any cause at ICU discharge.

    Measure: All-cause mortality at ICU discharge

    Time: from randomization to ICU discharge, censored at day 30

    Description: All-cause mortality at Hospital discharge, defined as the comparison of proportions of patients death for any cause at hospital discharge

    Measure: All-cause mortality at hospital discharge

    Time: from randomization to ICU discharge, censored at day 90

    Description: Occurrence of rescue administration of high-dose steroids or immune-modulatory drugs

    Measure: Need of rescue administration of high-dose steroids or immune-modulatory drugs

    Time: from randomization to ICU discharge, censored at day 28

    Description: Occurrence of new organ dysfunction during ICU stay. Organ dysfunction is defined as a Sequential Organ Failure Assessment (SOFA) score ≥3 for the corresponding organ occurring after randomization.

    Measure: New organ dysfunction during ICU stay

    Time: From randomization to ICU discharge, censored at day 28

    Description: Grade of organ dysfunction during ICU stay, grade of dysfunction is measured with Sequential Organ Failure Assessment (SOFA) score daily from randomization to day 28 or ICU discharge.

    Measure: Grade of organ dysfunction during ICU stay

    Time: From randomization to ICU discharge, censored at day 28

    Description: Total number of days between ICU discharge and day 28. If death occurs during the ICU stay before day 28 the ICU free days calculation will be 0. The ICU readmission before day 28 after randomization will be considered.

    Measure: ICU free days at day 28

    Time: From randomization to day 28

    Description: Occurrence of new infections including bacterial infections, fungal infections by Candida, Aspergillus, and viral reactivations including Adenovirus, Herpes Virus e Cytomegalovirus

    Measure: Occurrence of new infections

    Time: from randomization to day 28

    Description: Total number of days that patient is alive and free of ventilation between randomisation and day 28. Ventilation is considered as positive pressure ventilation, either invasive or non-invasive. Periods of assisted breathing lasting less than 24 hours for surgical procedures will not count against the ventilation free days calculation.

    Measure: Ventilation free days at day 28

    Time: From randomization to day 28, censored at hospital discharge

    Description: Total number of days that patient is alive and free of vasopressors between randomisation and day 28.

    Measure: Vasopressors free-days at day 28

    Time: From randomization to day 28, censored at hospital discharge

    Description: Occurrence of switch from non-invasive to invasive mechanical ventilation

    Measure: Switch from non-invasive to invasive mechanical ventilation

    Time: from randomization to ICU discharge, censored at day 28

    Description: Total number of hours from start of non-invasive to invasive ventilation to switch to invasive ventilation

    Measure: Delay from start of non-invasive ventilation to switch to invasive ventilation

    Time: from randomization to ICU discharge, censored at day 28

    Description: Adverse events occurred from randomization to day 28. Events that are part of the natural history of the primary disease process or expected complications of critical illness will not be reported as adverse events.

    Measure: Occurrence of protocol related adverse events

    Time: From randomization to day 28

    Description: Occurrence of objectively confirmed venous thromboembolism, stroke or myocardial infarction

    Measure: Occurrence of venous thromboembolism, stroke or myocardial infarction

    Time: from randomization to ICU discharge, censored at day 28

    Description: Occurrence of major bleeding defined as transfusion of 2 or more units of packed red blood cells in a day, bleeding that occurs in at least one of the following critical sites [intracranial, intraspinal, intraocular (within the corpus of the eye; thus, a conjunctival bleed is not an intraocular bleed), pericardial, intra-articular, intramuscular with compartment syndrome, or retroperitoneal], bleeding that necessitates surgical intervention and bleeding that is fatal (defined as a bleeding event that was the primary cause of death or contributed directly to death)

    Measure: Occurrence of major bleeding (safety end point)

    Time: from randomization to ICU discharge, censored at day 28

    Description: Occurrence of clinically relevant non-major bleeding defined ad acute clinically overt bleeding that does not meet the criteria for major and consists of any bleeding compromising hemodynamic; spontaneous hematoma larger than 25 cm2, or 100 cm2, intramuscular hematoma documented by ultrasonography, haematuria that was macroscopic and was spontaneous or lasted for more than 24 hours after invasive procedures; haemoptysis, hematemesis or spontaneous rectal bleeding requiring endoscopy or other medical intervention or any other bleeding requiring temporary cessation of a study drug.

    Measure: Occurrence of clinically relevant non-major bleeding (safety end point)

    Time: from randomization to ICU discharge, censored at day 28

    Other Outcomes

    Description: Mean arterial pressure will be measured in millimeters of mercury

    Measure: Mean arterial pressure

    Time: Daily from inclusion until ICU discharge, censored day 28

    Description: hearth rate will be measured in beats per minute

    Measure: hearth rate

    Time: Daily from inclusion until ICU discharge, censored day 28

    Description: respiratory rate will be measured in breaths per minute

    Measure: respiratory rate

    Time: Daily from inclusion until ICU discharge, censored day 28

    Description: diuresis will be measured daily in milliliters of urine output in the previous 24 hours

    Measure: diuresis

    Time: Daily from inclusion until ICU discharge, censored day 28

    Description: systemic body temperature will be measured in celsius degrees

    Measure: systemic body temperature

    Time: Daily from inclusion until ICU discharge, censored day 28

    Description: fluid balance will be measured in milliliters of fluids input and output in the previous 24 hours

    Measure: fluid balance

    Time: Daily from inclusion until ICU discharge, censored day 28

    Description: Haemoglobin will be measured in mg/dl

    Measure: Haemoglobin concentration

    Time: Daily from inclusion to ICU discharge (censored at day 28)

    Description: platelets count will be measured in U 10^3/mm^3

    Measure: platelets count

    Time: Daily from inclusion to ICU discharge (censored at day 28)

    Description: white blood cells count will be measured in U per 10^9/L

    Measure: white blood cells count

    Time: Daily from inclusion to ICU discharge (censored at day 28)

    Description: troponin will be measured in µg/L

    Measure: troponin

    Time: Daily from inclusion to ICU discharge (censored at day 28)

    Description: coagulative function will be measured with parameters INR, PT, aPTT

    Measure: coagulative function

    Time: Daily from inclusion to ICU discharge (censored at day 28)

    Description: D-dimer will be measured in µg/ml

    Measure: D-dimer

    Time: Daily from inclusion to ICU discharge (censored at day 28)

    Description: anti-thrombin will be measured as a percentage

    Measure: anti-thrombin

    Time: Daily from inclusion to ICU discharge (censored at day 28)

    Description: liver function will be assessed through measurement of AST, ALT in U/L

    Measure: Liver function

    Time: Daily from inclusion to ICU discharge (censored at day 28)

    Description: Bilirubin will be measured in mg/dL

    Measure: Bilirubin

    Time: Daily from inclusion to ICU discharge (censored at day 28)

    Description: Creatinine will be measured in mg/dL

    Measure: Creatinine

    Time: Daily from inclusion to ICU discharge (censored at day 28)

    Description: Blood cells count will be measured in Units per x 10^9/L of blood

    Measure: Blood cells count

    Time: daily from inclusion to ICU discharge (censored at day 28)

    Description: C-reactive protein (CRP) will be measured in mg/dl

    Measure: C-reactive protein (CRP)

    Time: daily from inclusion to ICU discharge (censored at day 28)

    Description: procalcitonin(PCT) wiull be measured in ng/ml

    Measure: procalcitonin(PCT)

    Time: daily from inclusion to ICU discharge (censored at day 28)

    Description: interleukin 6 (IL-6) will be measured in pg/ml

    Measure: interleukin 6 (IL-6)

    Time: daily from inclusion to ICU discharge (censored at day 28)

    Description: Ventilation mode will be cathegorized in spontaneous breathing, invasive or non invasive ventilation

    Measure: Ventilation mode

    Time: Daily from inclusion to ICU discharge (censored at day 28)

    Description: inspired oxygen fraction will be measured in percentage of oxygen in inspired air

    Measure: inspired oxygen fraction

    Time: Daily from inclusion to ICU discharge (censored at day 28)

    Description: Gas exchanges will be assessed by measurement of PaO2, PaCO2 in mmHg by arterial blood gas analysis

    Measure: Gas exchanges

    Time: Daily from inclusion to ICU discharge (censored at day 28)

    Description: lactates will be measured in mMol/L

    Measure: lactates

    Time: Daily from inclusion to ICU discharge (censored at day 28)

    Description: pH will be measured in pH scale

    Measure: pH

    Time: Daily from inclusion to ICU discharge (censored at day 28)

    Description: oxygen saturation in blood will be measured in arterial and venous samples in percentage values

    Measure: oxygen saturation in blood

    Time: Daily from inclusion to ICU discharge (censored at day 28)

    Description: New blood, respiratory and urinary-tract infections will be recorded

    Measure: New infections

    Time: From randomization to day 28

    Description: Viral reactivation measured by CMV DNA titres will be recorded.

    Measure: Viral reactivation

    Time: From randomization to day 28

    Description: Need of new renal replacement therapy (intermittent haemodialysis or continuous veno-venous hemofiltration) will be recorded.

    Measure: Need of new renal replacement therapy

    Time: from randomization to day 28

    Description: Adjunctive treatment such as pronation cycles, Nitric Oxide or ECMO will be recorded

    Measure: Adjunctive treatments

    Time: from randomization to ICU discharge (censored at day 28);
    14 Efficacy and Safety Study to Evaluate the Use of Nebulized Heparin in Patients With Severe Acute Respiratory Syndrome Covid-19 (SARS-CoV-2)

    To evaluate the safety and efficacy of the use of inhalational heparin in patients with pulmonary compromise / pneumonia / SARS associated with COVID-19, laboratory with marked inflammation parameters, and prothrombotic state secondary to it (Fibrinogen, Ferritin and / or elevated D-Dimer) , from admission to hospitalization. The combination of inhalation heparin combined with prophylactic doses of LMWH could reduce the progression to severe forms of the disease, and consequently the need for intensive care units and mechanical ventilation.

    NCT04530578
    Conditions
    1. Covid19
    2. Pneumonia
    Interventions
    1. Drug: Heparin sodium
    2. Drug: Enoxaparin
    MeSH:Severe Acute Respiratory Syndrome Coronavirus Infections Pneumonia
    HPO:Pneumonia

    Primary Outcomes

    Description: Blood Gas criteria :PaO2 / FiO2 <200 (or the inability to maintain an SpO2 of at least 92% with a reservoir mask). Acute ventilatory failure (pH less than 7.35 with PaCO2 greater than 45 mmHg)

    Measure: Percentage of patients requirement mechanical ventilation

    Time: 15 days

    Secondary Outcomes

    Description: Mean every 48 hours PaO2 to FiO2 ratio

    Measure: Percentage of patients with PaO2 to Fi02 ratio > 300

    Time: 7 days

    Description: To compare the lengths of hospital-stay

    Measure: Lengths of hospital-stay

    Time: Days 60

    Description: All cause mortality

    Measure: Mortality rate

    Time: 30 days
    15 A Phase 2-3, Multi-Center, Randomized Trial to Study the Potential Benefit of Factor Xa Inhibitor (Rivaroxaban) Versus Standard of Care Low Molecular Weight Heparin (Lovenox) in Hospitalized Patients With COVID-19 (XACT)

    This study is a multicenter, randomized trial to study the potential benefit of treatments with a direct FXa inhibitor (rivaroxaban) versus standard of care dose subcutaneous low molecular weight heparin (LMWH) (Lovenox) in hospitalized subjects with COVID-19.

    NCT04640181
    Conditions
    1. Covid19
    Interventions
    1. Drug: Enoxaparin
    2. Drug: Rivaroxaban

    Primary Outcomes

    Measure: Death or 30-day all cause mortality

    Time: 30 days

    Measure: Mechanical ventilation, intubation

    Time: 30 days

    Measure: Transfer to an ICU setting

    Time: 30 days

    Secondary Outcomes

    Measure: New requirement for hemodialysis (HD) or continuous renal replacement therapy (CRRT) or extracorporeal membrane oxygenation (ECMO)

    Time: 30 days

    Measure: New thrombotic events

    Time: 30 days

    Measure: Major bleeding event

    Time: 30 days

    Measure: Time to recovery (defined as no limitation or minor limitation in activity level or hospitalized but require no oxygen)

    Time: 30 days
    16 Enoxaparin at Prophylactic or Therapeutic Doses With Monitoring of Outcomes in Subjects Infected With COVID-19: a Pilot Study on 300 Cases Enrolled at ASST-FBF-Sacco

    SINGLE CENTER PHASE III INTERVENTIONAL RANDOMIZED CONTROLLED TRIAL comparing efficacy and safety of enoxaparin at prophylactic dose (standard treatment) and enoxaparin at therapeutic dose (OFF-LABEL treatment) in 300 COVID-19 infected patients with moderate-severe respiratory failure (PaO2/FiO2<250) and/or increased D-dimer levels enrolled in different Units (Infectious disease, Internal Medicine, Emergency Medicine, Pneumology) of Azienda Socio Sanitaria Territoriale Fatebenefratelli Sacco (ASST-FBF-SACCO).

    NCT04646655
    Conditions
    1. Covid19
    2. Thrombosis
    Interventions
    1. Drug: Enoxaparin
    MeSH:Thrombosis

    Primary Outcomes

    Description: Mortality registered during the time frame

    Measure: Mortality rate

    Time: 30 days from enrollment

    Description: Progression of respiratory failure defined as duration of continuous positive pressure ventilation (CPAP)

    Measure: Progression of respiratory failure

    Time: 30 days from enrollment

    Description: Progression of respiratory failure defined as percentage of patients admitted to ICU

    Measure: Progression of respiratory failure

    Time: 30 days from enrollment

    Description: Progression of respiratory failure defined as percentage of patients undergoing oro-tracheal intubation

    Measure: Progression of respiratory failure

    Time: 30 days from enrollment

    Description: Major bleeding (ISTH criteria) and/or clinically relevant non-major bleeding

    Measure: Number of major bleeding episodes

    Time: up to 6 months from randomization

    Secondary Outcomes

    Description: Amelioration of the respiratory function defined as a PaO2/FiO2 increase > 300 and / or respiratory rate (RR) < 20 breaths per min

    Measure: Respiratory function improvement

    Time: at 72 hours

    Description: Amelioration of the respiratory function defined as a PaO2/FiO2 increase > 300 and / or respiratory rate (RR) < 20 breaths per min

    Measure: Respiratory function improvement

    Time: 1 week from randomization

    Description: numbers of myocardial infarction and stroke within the time frame

    Measure: Number of major cardiovascular events

    Time: 6 months from randomization

    Description: Numbers of Deep Vein Thrombosis at CUS examination within the time frame

    Measure: Deep Vein Thrombosis

    Time: 6 months from randomization

    Related HPO nodes (Using clinical trials)


    HP:0001626: Abnormality of the cardiovascular system
    Genes 4425
    MERTK SLC25A26 TRNK MTHFR ALDH18A1 SCN9A B3GLCT GNPTAB MITF GJB4 NDUFS4 MEGF8 SCYL1 TREX1 SLFN14 LMNA DOLK SDHA RANGRF SCNN1G CD247 EFTUD2 KRT16 SLC25A4 NTRK1 ATP6V1A CTNND2 ARVCF SIX3 ND1 WDR11 ANTXR1 CTSB NBEAL2 RREB1 TOPORS NOS1AP RRM2B CAV3 LETM1 GNA11 KIF3B IFT172 NPHP3 COG4 ELMO2 ANTXR1 PEX11B DNAH11 KRT2 APOB RPS6KA3 PRKAG2 GJB6 CDSN ZAP70 HRAS ZIC3 NKX2-5 BUB1B FLRT3 NXN RAF1 NKX2-6 KCTD1 TTC7A SPATA5 DNAH1 BRIP1 FGA SGO1 VPS13B TKFC CRYAB CNBP SEC24C CDK8 TULP1 MYH6 B3GALT6 TWNK PLEC SLC37A4 PIGA TSC1 ATRX FOXF1 FOXC1 WAC GNS TERC MPL THSD1 EVC2 DLST CRB2 FLNB ATP6V0A2 TPM2 AK2 ACTN4 SPAG1 RTL1 ITGA8 EFEMP2 C8ORF37 IL7 KRAS ECE1 XYLT1 VPS45 SLC25A24 POMT2 TPM2 CCR6 KCNE1 PLAGL1 AHI1 SNTA1 PALB2 FOXP1 KDSR RELN CAV1 ARL3 MYF6 IGF2 COL3A1 CBL ATP6V1E1 COL5A1 ACD PPP1R15B ACVRL1 AMMECR1 HNF4A ADA2 CDKN2B ERCC8 SBDS SOX3 FANCL NDUFB11 CPLX1 PRKAR1A LYST PRPH2 SLC18A2 RINT1 COX10 SLC2A1 VPS33A LDB3 XK TTN NKX2-5 GJA1 NGLY1 GLI2 ODAD4 MYH11 MAF FLI1 SMG9 SDHA AGPAT2 CAV1 MKS1 TAF2 LRRC6 COL11A2 HOXA13 CASK CCBE1 SMPD1 BTD KCNMB1 TDGF1 PIK3CA WDPCP LACC1 KCNJ2 ND4 RPS19 CHRNA7 IGF2 KAT6A AIRE DISP1 MYD88 DHDDS GNAI3 DOCK6 KRAS IRF8 ERMARD BAP1 APP RPE65 SLURP1 CALR FN1 SLC19A3 ALX4 TSPYL1 PEX13 SLC39A4 NDUFB11 TTN FOXC1 RBCK1 HNRNPA2B1 TRPM4 ZIC2 WDFY3 KYNU PSMB9 CD2AP APOE SMAD4 ITGB3 TRNK KCNQ1 SNX10 KCNJ2 HMBS FKBP14 FGF8 BRAF SC5D SHH ALOXE3 FAS SCARB2 HACD1 CREBBP CITED2 MMP2 HADH NEXN NODAL ABCC6 PORCN CEP57 PIK3R2 RAD21 SCYL1 VCP KCNE2 USH2A TCTN3 PTPN22 ESR1 TRNS2 CDON TIMMDC1 C1R STRA6 IL10 DLD SCNN1A DNM2 SOS1 CDKN1C TGM1 TNNC1 LPIN2 CCN2 MAP3K7 HLA-DRB1 FRG1 TSC2 PPP2R5D GLI2 SLC2A1 EYS FDFT1 IFNG ANK1 SYNE2 ARL6 IRF6 TAB2 PCSK9 TP63 CARS1 HABP2 MYSM1 ERGIC1 ALOX12B DYNC2H1 DSG1 NSUN2 FLT4 FERMT1 DNAL1 CRYAB PPARG GNB5 TRNE TSFM MEIS2 DYNC2LI1 TRNL1 NT5E EWSR1 POU6F2 CSGALNACT1 ELN PRCD FBN2 KAT6B PLCG2 THBD PEX5 SLC2A10 SPOP GBA CYP17A1 SHANK3 SGCG TRNK PNP ACTA1 AGTR1 FERMT1 SIM1 GNA11 DGCR2 NCF4 ODAD2 FMR1 CYTB HCCS GBA SNIP1 DNAI1 LMNA PSMD12 NBEAL2 MKKS LMNA WAS DMD NDUFA10 ITGA3 HESX1 PIGL SDHAF1 POMK MKS1 CYP11B2 ATAD3A IL2RB CACNA1S GLI2 RNU4ATAC NEU1 TASP1 PMS1 RNASEH2A FAH BRCA2 ODAD3 FKTN FHL1 IL17RA C2CD3 CALM2 MCTP2 PDE11A IGLL1 ODAD3 ATN1 TPM3 MYOT SMOC1 PUF60 SOX10 RYR1 NDUFAF6 TRIP4 IQSEC2 GATB ADAM17 SDHB GLMN LRRC32 TMEM216 NLRP3 CISD2 BAP1 MED12 CYBB COL1A1 STAC3 BSCL2 PTPRC VWF CHST3 FOXH1 NDUFA2 TNNI3 YWHAE SNX10 COX3 COG8 LRRK2 FBP1 TMTC3 GNPTAB CTSK TREX1 XPR1 HADHB ZFPM2 SCNN1A PCARE STRA6 NDUFAF2 IL17RD RBM20 FANCB GLI2 CLCNKB CCDC141 RPGRIP1L PHKG2 F7 RPL10 COL4A1 WDR26 HMBS EGFR ABCC8 PLAGL1 BCR NDUFAF2 CCDC22 SAMD9 DMPK ERCC5 SCN5A USP18 HYMAI C1QBP PRRX1 SLC29A3 ARMC5 PLAG1 COLGALT1 KAT6B MEFV DNAAF2 ITGA2B KDM3B GJB2 NFKB1 IL1RN EED IRAK1 FHL1 TGFBR1 REN ABCB4 COL4A2 MDH2 CALM1 UBE2A SP110 PIK3CD SRD5A3 ENG MAX ATP6 NSDHL HSPA9 PROK2 SETD2 CTLA4 SMARCD1 SOX2 ND5 PQBP1 TELO2 F10 DZIP1L JAG1 GATA6 JAM2 MYH7 KRT14 ALB PEX5 TTC8 ADA2 BPGM RIPK4 FRG1 CIB1 KCNH2 CHCHD2 TSR2 POLR1A WNT5A TET2 RGR SOX9 TGFB3 TMEM67 BMP2 CEP41 GYPC ZNF462 GPC4 FBN1 DDRGK1 COX6B1 RBM10 CFAP410 FGFR2 GDF6 TF MAP3K1 ATP2C1 BMPR1A BBS12 DPM1 MDM2 PARN RHOH NFKB2 RFWD3 VHL H19 TBX1 LIAS MOG TLL1 PPARG DCLRE1C NAXD ABL1 CFHR1 SELENOI GNAS NRL KCNE3 NHP2 CYP11B2 TGFBR3 KRAS NTNG1 OSTM1 SLC17A5 SDHB ABCG8 COL5A2 NODAL F13B SDHC TNFRSF11B IVD F9 IRX5 GDF2 PSMB4 PCNA PIGU SAMHD1 NXN DSP ANTXR1 UBR1 FGFR2 PEX6 NKX2-5 COL3A1 TRNL1 ARHGAP31 MS4A1 NODAL USB1 BBIP1 F13B CASP8 CAVIN1 CYP11B2 ASXL1 IFNG FGFR1 ARX PLAU PROC RLIM DTNBP1 ZNF408 SFTPA1 TRNS2 ITPA JAK3 BMP2 BAP1 NBAS FZD2 ATP6V1E1 BTK ATM CACNA1S HADHA MCIDAS NOS3 NODAL PTEN ZMYND10 NFIA ACTA1 PSAT1 SYNE1 BCOR ABCC9 CYLD CD81 COL3A1 GJA8 FGF8 RPGR SCN3B COX3 RPGRIP1 CPLANE1 CYBC1 FANCD2 FGFR2 RAG1 CRLF1 SMARCA2 NPHP1 MYT1L ACE CLEC7A GLI3 CYP27A1 FRAS1 NFU1 PMM2 PAFAH1B1 ZMPSTE24 CEP41 DLL1 FERMT3 CCNQ PTEN EYA4 NPHP1 KCNN4 PRDM5 HFE MPL SIK3 SLC40A1 TERC RPL27 SEC23B TRPV3 PPOX TCF3 SUMF1 SDHAF1 COL1A1 STAT5B SUFU CREBBP SOX9 STK36 BBS4 SLC7A7 GJA1 ADD1 DOCK6 CD46 DIS3L2 MFAP5 KNSTRN ARX TNNT2 SF3B1 KMT2E INPP5E BANF1 GYG1 ARHGAP31 ZFPM2 RMND1 ZIC2 G6PC3 NDUFB10 DNAJC21 PEX26 XYLT1 ERF PEX19 ENPP1 MED25 NCAPG2 FOXH1 HJV SEMA3E AIP IKBKG IQCB1 MRPL3 SP110 NAGA MED13 LIG4 NDP HPSE2 TRPM4 FZD4 FLNB FCGR2B LHX4 INPP5E KATNIP TRIP11 TTC8 PSAP TREX1 ND2 ND5 IDH2 BRCA1 RPS6KA3 FHL1 USP8 SLC25A11 MASP1 LMNA LMNA WDR37 TRPM4 PEX3 TRNF OTC FADD OTC TMEM126A MTAP PPARG TRNQ KIAA0586 ZMPSTE24 RAI1 ELN KPTN LBR KDM6B SON AGXT TRNS1 PDCD10 CYP7B1 TRDN DMXL2 SPATA7 NPHP3 TRAPPC11 ELN PTCH2 MAP1B TGFB2 ARHGEF18 JAK2 SUMF1 GUSB ADCY5 IFNGR1 DHCR7 GUSB KITLG HADHB BVES C12ORF57 SDHB GBA MPIG6B FOXP3 RAC2 STIM1 KRT83 RPL35A AKT1 MYH6 ZFPM2 GJB6 CHST3 KANSL1 PURA SATB2 PITX2 COL4A1 FN1 GLRX5 ADAMTS10 CDK4 AFF4 ZFP57 ERCC1 SCARF2 PCNT PRPF8 NPHP4 LRRC8A RPL26 RMRP ACTG1 TTN OTUD6B KDM6A ECHS1 KCNQ1 ATP5F1E CTCF TGDS CNGB3 TMEM107 GAS8 POLG DNAAF2 SCNN1A ACTA1 MTM1 FLNA POMP HABP2 MTTP TRNL1 FGFR1 TGFBR2 FKRP OTX2 PTPN22 CFI LRP2 PHF21A ZIC2 EOGT RNF6 PLIN1 INSR WRN KRT5 PIGN NDUFA10 FKBP14 WWOX PPA2 LDLR GATA4 GATA6 TBX1 ENG POLH NSMF ARID1A KCNK3 NSD1 F5 KCNN3 REEP6 NKX2-5 CREBBP KIT ZFPM2 CDH23 PDE6D ATP6V1A TMEM231 MTFMT PROS1 XYLT2 EPCAM KCNQ1 P2RY12 IL10 PDGFRB SLC4A1 LRP6 NDUFS8 GCK SDHD DCAF8 STRADA PNPLA2 NDUFB11 DDRGK1 FUCA1 RNASEH1 RNASEH2C ND4 NF1 AKAP9 NOTCH3 FLNC DNAAF5 PEX5 PDHA1 SMARCE1 ERCC4 MYH9 CCDC22 COL1A2 STAT3 CCND1 TMPO ND6 IMPG2 CALM1 CCDC8 TGIF1 NEUROD2 DNAH5 ABCA4 TRAF3IP2 ARFGEF2 TBX1 KISS1R SSR4 ALG8 DDX3X TRNS1 KDSR HAAO RIN2 TUB MKKS RSPO2 DNMT3A ETV6 GNB3 HK1 AFF4 GBA RAB3GAP2 PPCS FGB IL23R DVL1 F8 FBXW11 APOA2 CYBA RAI1 MYH11 CITED2 PEX12 TFAP2B HADH SCN9A FGF8 CASR POLE LOXL1 ICOS FADD AMMECR1 SCN5A LMNA TNNI3 CDON PDE6G SDHD MANBA PIGT TDGF1 DYSF CCDC40 ALMS1 FGA ANO5 PARS2 RPGRIP1L TERT GJB3 CDIN1 KCNE1 FOXH1 SOS1 NRAS CACNA1D WAS CASR DHODH F2 PNPLA2 EHMT1 NF2 TCIRG1 DYRK1A NDUFS1 FAS MYH7 TOP3A SAMHD1 WDR35 NSMCE3 PTEN TGIF1 G6PC1 CCDC28B KRAS GTF2I TNFRSF1A FBN2 TWNK HGSNAT GNAQ PRDM6 APOA1 DSC2 SRD5A3 IFIH1 FTO KCNJ11 GNAS AMER1 SETD5 LIPC COX2 MINPP1 NFIX RNU4ATAC OFD1 RASA1 AIP COL6A3 WDR35 FAS ACVR2B RNF135 CDH2 SFTPA2 MKS1 UPF3B ANTXR2 PRF1 KRT1 AARS2 TSHR TRNT1 SCN5A GATA1 NRAS GREB1L ERAP1 RAB27A SCN10A MC4R PACS1 PRKACA GLI3 LYST GBA GATA4 TKT TBX4 MYMK COL4A4 SCN2B CEP290 KLRC4 SCAPER MMP1 KRT9 F13A1 VIPAS39 PRPF31 PIGN HLA-DRB1 AIPL1 MPL ADAMTS2 TMEM237 CD55 MVK NKX2-1 DLK1 TPI1 APOE GNAO1 WT1 ELANE GTF2E2 PKP2 ABCC9 GPR35 CIITA TRAPPC4 MED12 CDKN1A CLCC1 CRPPA GJB3 MEIS2 RAF1 MIPEP PEX1 COX3 COX7B NEBL SH2B3 ERCC3 ERCC2 KCNAB2 TAB2 CTNS SETX ANGPTL6 CD19 TRIO STK4 POLH ERCC5 GALNS POMT2 NFKBIL1 ADAM17 TET2 NAA10 SF3B1 SLC26A3 GFI1B KMT2D ABCA12 LRP5 UBR1 PEX3 FEZF1 COL7A1 HSPG2 TRPM4 TRNK NDUFAF4 C12ORF57 MYBPC3 GTF2IRD1 CAVIN1 KRAS PIGY VWF TGFBR2 SPINK5 RASA2 APC PHGDH SLC25A24 NGLY1 LARP7 STAG1 RYR2 CCND2 FANCM UCP2 RPL10 CDKN2A DSG2 ANO10 NELFA NLRP3 KCNJ11 PIK3C2A GLI1 CTCF KCNQ1 LRP5 TCF4 CFHR3 POLG TBX5 SHPK HLA-DPA1 TMEM43 SETBP1 LMNA RIT1 SVBP CEP164 AKAP9 ATP6 FKRP CYP27A1 CACNB2 WAS SDHA NF1 LAMB2 BAG3 RARA ACTL6B TREX1 ABCC6 COL11A1 HSPG2 KCND3 CNGA3 IL36RN SLC19A2 CYP1B1 COL3A1 CD96 CYBA ERCC8 TET2 GLIS3 DLD TERT PEX2 FOXH1 SURF1 ATOH7 GFI1B HRAS CASP10 TSC1 TNPO3 NIPBL PITX2 WDR19 GAS1 MYCN TXNRD2 IL10RA ATP7A MYH9 ACTA2 TRNW GDNF CTLA4 PDE4D SPTB ADAMTS3 GLB1 SGCD ERCC3 F7 HLA-B COL5A1 CBS SNCA FGFR2 LIG4 RNU4ATAC CLN3 GNE AKR1D1 ADA2 KCNJ1 FGFR1 CFI ERCC2 DISP1 FKTN ATP6AP2 NLRP3 FGFR2 COQ2 SPECC1L ARL6IP6 FAH ND5 NR0B1 LIG4 MAP3K20 POMT1 FOXE3 PDGFB GYS1 SDHAF2 SLC26A2 FAS PRKAR1A SERPINC1 RLBP1 TCIRG1 CALR PIK3R1 LIFR KCNQ1 SDHD ZNF687 SLC35A2 FGF8 CCDC40 CTLA4 SCN5A HBA2 ARSA DCAF17 CFTR SCNN1G ESCO2 GJB4 ITGA2B KIF1B BEST1 RP2 GATA6 BBS9 ARNT2 KCNJ18 HTRA2 SPRY2 STAT1 GTPBP3 FGF8 SCNN1A SNRPN MYOC GPR101 ATP5MK HNF1A MAX LRIG2 LONP1 PLEC CXCR4 ERCC8 COQ9 PTDSS1 SLMAP STIM1 CCND1 KCNQ1OT1 AHCY ATPAF2 FANCC POLR3A SKIV2L PADI4 CYTB MAF TERT SFTPC FOXJ1 NPC1 AICDA FANCI CALM3 NDUFS2 EDA LDLRAP1 TFAP2B CALM3 PEX6 CFAP298 CSTA SELENON TRIM28 ZIC2 KLHL7 NPC2 TBX22 ALMS1 GPD1L FGF8 ELN SBDS CERKL CYP11A1 KDM6A LAMP2 B9D1 MAFB DTNA NDUFS2 PEX14 LEMD3 GJA1 FGF20 SGCB MMEL1 DNASE1L3 TGFB3 CCDC141 FANCA LIPN FLT4 MYH7 RDH5 SCNN1B FBXW11 MAN2B1 SCN5A LTBP3 PTCH1 MGME1 EPG5 NKX2-5 GAS2L2 PPP1CB F13A1 PDE6H HIC1 CBL CWC27 PDE3A FLNA CHRM3 POLG2 JPH2 IRF5 IL17RC GNAQ SMARCA4 APP PIGM HPS5 TMC8 COL4A5 LYZ NFIX RTEL1 PRKG1 PLN ATAD3A MPI BRAF IFT172 FMR1 ALG14 PAH WRN TGFB1 RBM8A NDUFB9 SFTPA2 CDH23 FGFR3 RET NR2F2 JMJD1C TNNC1 SLC30A10 GLI2 BUB1 GMPPB NRXN1 COQ7 OCLN VCL TMEM237 TFAP2B TBX1 WDR19 RRM2B COX4I2 KAT6B FLNA DNAI1 HCCS NOTCH1 IFT140 FOXA2 MPLKIP PROS1 LZTR1 SOS2 NDUFS2 CACNA1H TPI1 FECH CYP11B1 GNA14 MADD GCDH PEPD MYT1L MYO18B GTPBP3 SDHA IDH1 CDKN2A SCN4B SOX10 FBLN5 YY1AP1 CDKL5 RPS10 TANGO2 NPPA GAA AKAP9 NDUFS2 PIGO MAP3K7 LMNA MEOX1 KRAS TMEM216 RBBP8 KLF1 SCN1B BPTF SMARCB1 SOX10 BRCA2 SPTB ANK2 RNF113A BRAF MBTPS2 RAF1 COL6A1 FASLG TNNT2 CCDC39 DNAJC19 PYCR1 SMN1 EYS TNXB CFH DEAF1 LMNA PSMD12 TK2 INTU ATP6AP1 PEX6 POGZ STAT3 PLG CHRNA1 ACTN2 NEK9 ESCO2 LONP1 TGFBR1 ACAD9 CDH2 POLG TMEM127 LPIN2 KYNU PRDM16 SETBP1 SNRNP200 CFH UVSSA UBE3A MYH7 PRRX1 CPLANE1 TBX20 SFTPC SLX4 CARD9 ARL2BP RECQL4 LEMD3 TNNI3 RPL10 FGFR2 FHL2 GABRD IRF2BP2 EHMT1 NEK10 ABCG5 MYH7 RPL5 CRYAB MKS1 DOCK3 NODAL ABCC9 TFAP2A RPS24 VPS33B RPL35A FGFR2 SGCA RET COQ2 ARL13B IDH3B MGME1 ASAH1 NOTCH2 UBE2T CENPE CHRNG ATRX SNTA1 PRPF3 ERCC6 HBB MED13L KCNQ1 MRE11 JAG1 RECQL4 RPL27 DNAJC19 TDGF1 TALDO1 RNF213 RAI1 HFE NDUFS2 NR2E3 PCARE MAK PHKA2 LAT STXBP1 ZEB2 KDM5B PIGO MAP2K1 PIBF1 PAX6 ERCC4 SOX18 ERBB3 SIX3 ROR2 ND4 BMPR2 CENPF PEX16 PDX1 DUX4 PEX19 FLNA DIS3L2 DLL1 CDON SHH TPM3 CPT2 H19-ICR TBCK MTRR BMPR1A MYL2 HBA2 JAK2 FOXC1 TBL1XR1 GDAP1 RAD51C CACNA1C RRAS2 PRPF6 LIG4 AGK DNAAF6 PIGS RNF125 BIN1 NR3C2 FANCA PRKAR1A GDNF MYPN NOTCH3 IGF2 RUNX1 PRKCD BLNK KRT1 PRPF3 FCGR2C KAT6A FBLN5 ABCC9 GCLC WDPCP IRF5 WT1 LIPA RAB27A KIT TMEM43 ADA AUTS2 CYTB SALL1 SERPING1 CYP24A1 TGIF1 ASCC1 DNAH1 CSRP3 GNE CST3 IGH FAT4 JAK2 PSEN1 G6PD ACADS MYH11 TMEM43 INSR ERCC6 PQBP1 ARID1B ARL3 PDE6A SH2B3 PPOX TP63 SHH PLOD1 AKT1 TTR COPA PEPD SRY SCNN1B FBN1 SNRPB RBP3 GAA CALM2 GATA6 DYNC2I1 CASR ZNF423 RAD51C GALE SDHB HPS3 REST TGFBR2 SCNN1B TAZ PKD1 TPM1 PRKACG HIRA ACTG1 DRC1 SVBP GPC6 GDF1 HOXA1 BAP1 COX1 CSPP1 ELN MGMT ARSB PEX6 RPL11 PET100 RIPK1 CASQ2 ACTB MSX2 ND2 FOXP3 USP9X ND4 SOX4 SLC39A13 PKHD1 CHKB COLQ TTR SPEG RPL11 GLRX5 PAM16 NOTCH2NLC TET2 SCN5A AKT3 PTPN11 MEOX1 RP9 F2 ENPP1 RHO POLR1D TDGF1 TNFRSF13C GLA SELENON HSD17B10 RPL15 TULP1 NF1 ADGRE2 FGB MED13L GATA5 AGL DDC TRMU BACH2 DLX5 ZNF513 IL12RB1 SH2D1A KRAS SLC25A4 SCN5A NDUFA11 GSN CAP2 ALDH18A1 SMAD6 VPS13A EXT2 ITGA2B SLC4A1 FRAS1 NDUFA12 MFAP5 CYSLTR2 CEP55 AGXT FGF17 CLDN1 PDE8B MAGT1 FGFR1 IFNGR1 DES SMAD4 ZNF469 ND1 DOCK8 KMT2D SOS2 SLC19A2 ND5 LAMA4 CTNNA3 FOXRED1 LIPA MICOS13 CSPP1 ACAT1 RORC STING1 DCHS1 GATA3 MEGF8 HLA-DRB1 ZEB2 ARID2 CHN1 PIK3R2 RPL18 STN1 HTRA1 AP1B1 PCCA EXT1 CCND1 CYLD PDGFRA RAC1 KIF15 TBX20 FIG4 SLC20A2 BIN1 LIPA ODAD2 FLNA TRAF3IP1 SMO SLC4A1 PDHA1 DNAH9 TMEM231 GLA SCNN1G NOS3 MBTPS2 EVC NSD2 HS6ST1 DPF2 ITGA2 MAN2B1 PIK3CA LRP5 PKD1 KIF1B APP TNNT2 TNFSF15 PTCH1 LRP5 RBP4 MMP2 LMNA NLRP3 CHD4 LRRC56 FGG ABCC9 CYP11A1 RNASEH2A CIZ1 TNFSF4 ODC1 POLR3A AGPAT2 TWIST1 MMP1 NDUFA4 ND1 IDUA COG4 TP63 PAFAH1B1 PTCH1 PEX7 LCAT COX8A GP9 ABCD3 PRPH2 TP63 DISP1 TCTN2 TNXB SCN1B PPP1CB VANGL1 NR5A1 NKX2-5 TSC2 ACTA2 DGUOK GFI1 MAPK1 IFNG COL1A2 NDUFS3 PHYH MESP2 RPS28 FASTKD2 FOXE3 NLRP3 MRPS16 RAI1 NABP1 SCN9A PCGF2 FLCN DNAJC13 SFTPB ACTC1 PLVAP HBB RPS20 RPSA RAD21 INVS LYST NDUFA11 RARB CD19 BMPR2 DZIP1 APOA1 GATA1 PEX7 NEK2 ATM LMX1B GBA APOE TGFBR2 MYH11 CANT1 RECQL4 HYOU1 IGSF3 TOR1A ATP8B1 CFTR EVC FANCE PARN PRKAR1A TGFB1 MYLK WWOX MTOR RFC2 WDPCP GATA4 RRM2B CCDC103 SETD1A NEB MPLKIP POLA1 FLT1 CD19 CALM1 SIX3 SMPD1 B9D2 SERPINC1 SELENON SPARC HPS4 PTH1R SRCAP ATM MNS1 KRIT1 MYH6 SH3PXD2B GNAT2 CLCN7 TRIP13 HAND2 COL18A1 MST1 ANKS6 RPS6KA3 MEF2A ALDOA FGB FKRP NOP10 AVPR2 COG6 TRNQ BCL11B PRDM16 IVNS1ABP STOX1 ASAH1 ACTL6A NDUFS7 SMAD3 TALDO1 NUBPL CITED2 ERCC2 TAF1A COL4A1 COX15 TEK STEAP3 HADHA ALX4 ACTA1 DSP NDUFB3 EIF4G1 GATAD1 ACTA1 HBB RERE FLNA MAD2L2 CLRN1 LTBP4 PNPLA6 TMEM237 AIP DDX58 POR PGM3 DCC ABCB11 KCNJ8 EOGT VHL PIK3CA MTFMT TEK PLD1 SLC25A4 SDHC DCLRE1C SEC31A TLR4 RSPH3 APOA5 COX7B CYBC1 DCHS1 KCNH1 FANCB BBS2 HBB SRCAP GAS1 TNFRSF13B LMNA CRB1 ZMPSTE24 ANOS1 SMARCE1 KCNQ1 BCOR WARS2 KLHL3 STAT4 SMAD3 GTF2H5 TRNV RUNX1 LRP2 OPA1 PRKAG2 DNAAF4 UBAC2 MAP2K1 RIN2 THOC6 DLEC1 BIRC3 COL4A3 FGA TTC8 SCN1B GATA4 TMEM138 CD27 BMPR1A ALKBH8 CFHR3 MTHFR NSMCE2 VCL MITF QRSL1 DHCR24 CAV1 BNC2 SNAP29 ITK BICC1 RECQL4 THOC6 NAGLU TRMT1 AKT1 JAG1 RERE GDF6 DMD F2 FIP1L1 GJA5 C2CD3 ND5 ATP2C1 APC NFIX NDNF B9D1 ICOS GFM2 SARDH ND6 HLA-B PRKAR1A KCNJ18 MAGEL2 GMPPB NF1 MAP3K7 DLL1 RPS29 NODAL LRBA RDH12 PLP1 RSPH4A TERT FBN1 F5 NAGA RHO ATP6V1B2 RET HSD11B2 WASHC5 TCTN2 DMD GANAB TMEM67 C8ORF37 SLC39A13 CD46 ADAMTSL4 VPS33A DPF2 PIGQ INS SDHA MVK SMARCB1 RPS7 WT1 TRAIP NDUFB11 DNAAF1 TOP3A PRCD CUL7 TCOF1 ALG9 TRNC CALCRL F5 KAT6B POMGNT1 TTN OFD1 EPB41 TERT BRAF CLCN2 APP SLC2A10 RPS15A APP KRT14 GJC2 PTF1A MALT1 HPGD NID1 SOX3 KCNH2 ABCG5 FSHR MAFB DSE GATA6 CFC1 EFTUD2 HBB MYL3 RPL15 PPCS STK11 ALB CDC45 SNAI2 PCNT FOXH1 ESPN TPK1 IDH3A ANKRD11 COL1A2 TARS1 PKLR CEP290 WNK4 CCR6 SH2B3 ALAS2 DNAH9 HSD3B7 PLIN1 BRAF ADNP DSG2 UROS RLBP1 EXT2 TBX1 SMCHD1 PIK3CA TCAP RS1 ATP5F1A GATA6 FANCG SCN5A GP1BA NDUFV2 GMPPA NOTCH1 MAB21L1 ADAMTSL1 AKT2 MCCC2 ND6 DNMT3A SIN3A THPO NOD2 MYH6 WASHC5 CPOX FOXC2 HAMP GJA1 ANKRD26 ACTA2 CYB561 SCN1B PIGT VPS13B PRKCD HYLS1 SUFU PTCH1 DNAJB11 HOXD13 IGF2 TRRAP CFAP300 COL1A2 GDF1 MTO1 IFT27 INTS1 PHKG2 PEX19 MAP2K2 WT1 DLK1 PPP1R17 SMC3 CR2 STX11 F12 MED25 MADD COL6A2 RAB23 SHH ACADVL FAN1 TET2 TKT MYRF HRAS DLL4 F8 MVK CRELD1 GALNT3 SCN5A TPM1 KIAA0753 SCO2 SOX2 ATP8 SLC26A2 PUF60 RYR1 ELP1 AGA BEST1 NLRP3 FANCF VWF FBN1 MMP21 TCIRG1 PNKP F2 CPT1A FLI1 ZIC2 SLC29A3 KIF20A DLL4 IMPDH1 MBTPS2 POLG KRAS SIX3 PEX12 PRKCSH TCTN3 SOX10 SMARCB1 TRNN SCO1 BTK MSH6 KRAS BSCL2 RSPH1 SMAD9 CCBE1 GK DNAH11 AGTR1 ATR CSF2RA NADSYN1 UMPS CDC42 GJA1 LAMA2 SMAD4 SACS TCOF1 NTRK1 DES POMT2 SLC22A5 MCFD2 MYBPC3 XPNPEP3 NOTCH2 SKI SEC23A TTN LORICRIN MRPS14 SYT1 ODAD4 ECHS1 IDUA CACNB2 DLL1 ND1 RNF113A TBX6 RERE FLNA CASK DGCR6 TTC7A SFTPC RAG1 UROS INTU CKAP2L EDNRB NLRP1 IFT81 ABCD4 EPHX2 COG4 EED SIK1 ETHE1 RPS19 IL12A-AS1 ENG CDKN1B HLA-DRB1 HYLS1 NPM1 NDUFS4 MC1R SCN11A TACO1 RB1 CTLA4 PRG4 CEP19 KLF1 C1S CRELD1 PHYH DSE PEX1 ERBB3 RPGR TCF20 LIMS2 GUCY1A1 GALC TUBB RET JUP NLRP3 ALDH3A2 DHX38 IFT80 FGFR3 FXN FGA MKS1 SEMA3A HBA2 NPHP3 WFS1 VHL PMM2 COL4A3 BRAF ABCB6 IDUA MNX1 PRPH2 RPGRIP1L EYA4 FBN1 HBG2 SLC29A3 CNTNAP2 RAG2 CAPN5 CTSA PGM3 CHRNA7 FANCE MPL COL7A1 NDUFS6 HIBCH FKTN ZEB2 XPA NEK1 GJA1 TRDN FLNC ENG AKAP10 KIAA0586 CCNQ PLN NDP AGA LAMC2 RAG2 IL17F VAMP7 CEP104 FANCC SNCA PYGL CCN2 TPM3 TWNK GGCX COQ2 FOXE3 NCF1 CD3D ABCA4 TAF2 RIT1 MGAT2 SAA1 KIZ IL7R TBC1D24 TTC37 LTBP4 SPTA1 MLX COL1A2 IDH1 SMAD3 TGM5 FOXRED1 PEX16 NOS3 GHR DDX11 HYMAI GDF2 PRKAG2 HLA-DRB1 MRPL44 NDUFA1 DNMT3A NEU1 ATIC EDN3 FLNC CPS1 PRKAR1A APRT GPIHBP1 DNMT3B IDH2 SCN3B PTPN11 EDN1 MECP2 AGK NDUFV2 USF3 ACVRL1 TFR2 FLNA MTTP NRAS OTX2 CC2D2A DNAAF6 FGF23 CLCN7 ANK2 NOTCH1 FBN1 NUP188 NDUFAF3 STAT3 PEX2 PEX10 CARD11 TBX5 BAG3 ERCC6 STX16 SMAD4 SLC25A13 PGM1 LRP1 JAK2 HMGA2 AHI1 RPL31 ELOVL4 AQP2 PIK3CA TP53 CNGA1 BRCA2 PALB2 GAS1 PSAP PTCH1 CFI PTEN STAT3 TMEM67 SCN10A KBTBD13 TREX1 AHI1 ACTC1 JAK2 ISG15 MYH7 ACTG2 BEST1 TMEM126B MAP2K2 ACADM DLL3 RYR1 FUT8 PEX12 ASXL2 KIF11 GP1BB MSL3 HADHA TERF2IP SH3BP2 HNRNPK NFKB2 FREM2 IFT172 HIBCH PIGY ANK1 TGIF1 CAV3 IDS AVPR2 NEK9 SELENON PSTPIP1 CCM2 LEMD3 ATAD3A GATA4 NR3C1 NEUROG3 SCN2B TBX1 POU2AF1 TDGF1 PRKACA ADNP CA4 CD28 CDC73 SIX3 PML BLOC1S3 KCNJ5 CHD7 POLR1C POR TNFRSF11A FH ATRX HES7 FOXC2 NKX2-6 FOS GLB1 CC2D2A DSP MYH3 KRAS HSD3B7 ALDH18A1 ALOX5AP PEX11B SDHD DVL3 SLC12A1 SCNN1A PSEN1 WFS1 GPC3 DCTN1 ALG9 DNAAF5 JUP ZMYND10 CACNA1D IL2RG IL7R PTH1R SMPD1 HLA-A ROR2 GP1BA SMAD4 KDM6A NONO INVS TLL1 RIPPLY2 CLCN7 MYLK NODAL ND6 SERPINA6 GNE BAG3 MEN1 LRRC56 GATA1 TSC2 VPS35 DHCR7 WARS2 NDE1 SLC20A2 WNT10A SLC7A14 GSN RP1 KCNJ5 BMPR1A LBR ARID2 BBS1 SDHD ZNF513 RET CNGB1 KCNJ5 SETD5 NKX2-5 CAV1 ABCG8 DCAF17 DSG2 TF GPD1L AGT GATA1 CTBP1 BTNL2 RYR1 SNX14 CHST3 RAD21 SOX4 SAG ERCC6 TP53 IGF2 BBS10 FUZ SUFU CRTAP PSAP PEX13 GAS1 B3GLCT ABCC6 PLEKHM1 ADAMTS10 ELN RET GATA5 ALDH18A1 CALM2 GATA5 EPB42 GP1BB TCIRG1 DIS3L2 CAV3 TPM2 EMD SCO2 TXNRD2 IKBKG FUCA1 SPAG1 ARID1B GNAS AGGF1 F8 ABCA3 ND4L NLRP12 TGFBR1 NDUFAF5 NOTCH1 PMS2 SEMA5A CAV1 NDUFS8 CD28 CDON GPX4 CA2 CC2D2A PDGFRB GREM1 KIF7 STXBP2 TGM5 ADCY5 EPHB4 ESCO2 FHL1 NEDD4L BCS1L IFT88 CITED2 NDUFB11 BCL2 INPPL1 KRAS CYTB KIT MYBPC3 RPGR CALM1 GRIP1 ATP5F1D FANCD2 PTPN22 FAT4 IFIH1 IL7R LMNA JUP GPC4 FECH H19-ICR SMARCAL1 NAGA GBA CEP290 PDCD10 DISP1 HYDIN SPRY4 MAP2K2 IL2RA FGD1 CDK13 CTC1 PDSS1 PNP PRTN3 ARID1A EPB42 XYLT2 MYH6 FRA16E GP1BB RSPRY1 TRNS1 SDHD BLM CASQ2 CALM3 RRAS SALL4 FANCI LMNA DDR2 ZAP70 ALDOB MNX1 LMNA AIP ND4L C3 IFIH1 TMEM260 NRXN1 USP8 FGFRL1 DPH1 APOE C8ORF37 AP3D1 SALL4 BRCC3 ABCA1 CDK10 KDR TECRL AAAS TBXAS1 C4A MYH7 SH2B1 ERCC6 SBDS DNAI2 NKAP TBC1D24 PEX1 LIPC CHRM3 MTHFR MYL2 TRNE COA6 SERPING1 GATA6 BCL10 PRF1 RAG2 SCN4B GBA GATA4 SMARCA4 GM2A CD40LG KCNQ1 MSH2 TRMT10C MMACHC MIF HES7 GP1BB HLA-DQB1 TRIM32 NKX2-5 GMPPB SLC35A1 AMER1 EIF2AK4 SPP1 XYLT2 KIF7 LBR NCF2 MKKS PTPN22 TMC6 CEP57 FGFR2 DNAI2 SDHA SDHB TRNF TPP2 SDCCAG8 SOX5 PCNA ZNF469 RAG1 CDKN1C CDC73 IFT43 CEP120 HAVCR2 HMGCL KCNJ2 HBB MIB1 SLC4A1 ACP5 XIAP CFAP53 IL2RG ATP7A RNASEH1 FANCB CYP11B1 KAT8 BTK SDHB TTN TMEM231 OFD1 TET3 KLHL7 CDON PTPN11 TXNL4A PHGDH LRP5 FLNA PIEZO1 PIK3CA NNT ABHD5 DVL3 KCNE3 AEBP1 RYR1 CDHR1 HCN4 STRADA PSMD12 CUL3 SLC25A3 ANAPC1 LONP1 ERCC4 FBLN5 ATP6 FBN1 CLRN1 PEX16 FLT4 NIPBL SMAD4 LIPT1 SLCO2A1 NOTCH3 CD109 RPE65 CHD7 SLC37A4 COQ2 TNNT2 SRP54 CD79B SOX18 SGCD TSHR AQP5 TNNT2 CDKN2C MMP14 MED12 TGDS CCDC47 PKD1L1 ND2 ADAT3 CPOX RPS17 APC2 MYH8 TRAF7 KIF7 MYH7 SCNN1A GPD1 DHX37 VEGFC KRT5 TNFRSF1A KIAA0319L CLCN7 YARS2 TBX1 PDE11A SMC1A PIEZO2 TMEM237 NDUFS7 PDGFB TBX1 KCNA5 AKT1 TNFSF12 EFEMP2 PGAP3 ABL1 PIK3CA EHMT1 PDGFRA CTNS SDHD NCF2 NDUFAF5 TNFRSF1B WNT10A FOXP1 PSTPIP1 BCOR TMCO1 GYG1 KDM1A SDHB NDUFS1 NSD2 TECRL F13A1 B3GALT6 CLCNKB TRPS1 BBS1 CSF2RB MPL PERP FAM149B1 COL1A1 HESX1 FCGR2A EDNRA IDS TRIM28 WDPCP CACNA2D1 CD79A PIK3R1 FGFR1 PIGP HNRNPU HPS6 SCNN1G MAP2K1 PDE6A CTSA CPT2 LMAN1 GPR101 SYNE1 TFAP2A COX2 RTL1 CCDC174 COQ2 NR2F2 OFD1 ND6 KCNH2 TSC2 KCNN3 RASGRP1 SP7 GBE1 NDP GATA1 COL3A1 POGZ ENPP1 POMGNT1 SEC23B TCTN3 GLI3 SREBF1 ITGA2B SMARCE1 POU3F4 GIGYF2 SIX6 F11 SEMA3A CDAN1 KIF5A MVK ARMC5 SDHA NDP PTPN14 HAMP CNGA1 PEX26 RYR2 HEXA TP53 HPS1 TET2 COL2A1 FBN1 SCN2A DMD GATA4 FMR1 NKX2-5 ELOVL4 DMRT3 FBLN5 GUCA1B NEK8 TMEM127 CLPB LDB3 RNASEH2C TWNK TBX20 CCR1 HADHA POR WNT4 ELAC2 MEG3 GP1BA TRDN SKI NEXN RAD51 DUSP6 OTUD6B USH2A NDUFA9 MMUT HYLS1 NPHP1 HBA1 CHRND PKP2 PDE6C XRCC2 FSCN2 VHL CCDC103 ERCC6 ZDHHC9 FARSB ODAD1 CYP11B1 ANK1 JAK2 NME8 AHR VHL SLC25A22 LETM1 SLC25A3 ELANE RFWD3 XPA GPC4 ITGA8 GNAQ CDKN1B GNAS ERCC8 C4A DYRK1B TRPC6 DNASE1 CA2 PROKR2 MLXIPL LZTR1 STX3 ALG12 AK2 IDH2 SLC52A2 PDE3A HELLPAR HSD3B2 GP9 SGSH BAZ1B ALG1 WT1 TANGO2 MID1 GP1BA XPC LDB3 NR2F2 DNAL1 TGFB3 SGCB CTSH CTSB DISP1 PRKAR1A TRNL1 UBE3B LCAT MAT2A FIBP CYP11B2 TNFSF11 DSP PET100 LMNA ABCA4 KCNA1 NFE2L2 EPHB2 SGCG PROC IARS2 KCND3 D2HGDH MGP TRDN NHLRC2 SOX9 PGAP2 NAGA PUF60 FKRP CTNNB1 SDHD KCNE2 RSPH9 NOTCH2 PACS1 GNAI2 NAA10 GNB5 GGCX KRT10 CD70 ND1 PIK3CD FMO3 ASS1 EXT1 USP9X PSAP GUCY1A1 LMNA WT1 PIEZO2 GJA5 STN1 DCX KCNE5 GPC1 PROKR2 EBP GNPTAB NLRP3 CFAP221 COA5 JUP GJB2 TP63 TBX3 AP1S1 HBA1 ROBO4 CERKL RPL26 DES EDA2R OFD1 CD81 TNFRSF13B POLG2 FIG4 DDX59 MYH7 NSD1 MTHFR HLA-DPB1 AGT RYR1 CFHR1 BRF1 SLC22A4 SLC25A20 MAPRE2 AKT1 RRAS2 EPHB4 MEN1 XRCC4 COX7B HSPG2 CEP290 CCDC115 LTBP2 DLK1 PROP1 SHOC2 FLT4 ACTB DGCR8 FBP1 NEB SLC35A1 EPAS1 COL1A1 MRAP SPECC1L PSEN2 CDH23 BLM PKD2 CDON PKD2 NPHP1 CST3 RAG1 SNRPB PRKG1 USB1 MYOCD GATA4 TMEM70 NDUFAF6 FLNA STAT2 ZNF365 MEFV PYGM RASA1 NEK1 SOX6 NF1 FKTN NF1 CSRP3 RPL35 HCN4 SRY MYOT TDGF1 GATA4 GGCX TAPT1 TMEM216 COX15 SLC4A1 ROM1 PAX8 COX1 MCM4 TINF2 CD40 TOPORS ERCC2 SDHC NAA10 MPL POT1 CR2 COL1A1 FGG FOXE1 NLRC4 TFRC TRIM37 EXT2 LMNA KMT2A ITGB3 TBX3 STXBP1 DNM2 NCKAP1L ATXN7 ACADVL SERPINF2 LDB3 TPM2 PLEKHM1 PAX3 ELP1 IRF8 RMRP TGFBR2 STAG2 UQCRFS1 LMX1B SALL4 CFAP300 SIX3 BMPR1A DDB2 IGHM GJA1 HPGD MEFV KCNH2 KCNQ2 PALLD RNASEH2B NDUFAF8 MSX1 NOTCH3 BCL6 ISCU ABCC8 ATP11A FAM111A DBH ODAD1 SDHC CHRNG HBB SALL4 CTLA4 ATP7A RNF213 LOX PIGV CP POLR1A NMNAT1 ALPK3 GPC3 WNT5A CYP26C1 PTEN PPARG BBS7 DDX6 ABCC9 PQBP1 COG5 LMNA ETHE1 LDLR DVL1 RASGRP1 CHD7 TTC12 VCL GABRA3 KRT18 PROC KLLN IARS1 GPI GAS1 KIF23 ACTA2 KCNQ1OT1 WIPI2 THPO FGF8 GLI2 LBR PLCB4 ARID1B BRAF DSP IDUA ANKRD1 BCOR IL12A MMUT SF3B4 PEX7 CFB SCN1B UMPS SERPIND1 PLOD3 KIAA1109 TERT XPC SMCHD1 CD96 MYH7 ACP5 SPEG NT5E DNAJC21 MYCN IGBP1 LMNB1 ACTC1 OTX2 RHBDF2 RTL1 ESS2 FYB1 EXOC6B RPS26 SLC39A4 PIGA MID1 ARL2BP EPHB4 SFTPB ODC1 ASCL1 TTPA PIGL PEX10 ND2 GBE1 TP63 JAK1 DHPS RAI1 XPNPEP2 DNAJB13 COL2A1 AGBL5 CPT2 PROM1 PALB2 IL12B SDHC PDE6G LEPR JAK2 FGG PIGT TSPYL1 STAMBP FASLG KLF13 PIEZO1 EZH2 EPB41 RUNX1 B2M CORIN SPTA1 NR3C2 MYH6 KLHL41 PROP1 ADA2 LIMK1 DSP RPL5 HMGA2 KRAS CCM2 NDUFAF1 ERCC3 IDH3A EP300 NDUFA6 MCCC1 DCLRE1C FARSA CDC42 PLCG2 ACTC1 STAT4 C2 VAC14 PKHD1 DMD ND3 SIN3A COL7A1 CYP3A5 BRAT1 ZMIZ1 NUP107 PTCH1 LMNB1 HNRNPK ND1 IGHM TNNI3K TGIF1 TUBB GJA5 POLG FLNC HAVCR2 SMARCC2 ERCC2 TXNL4A RAB23 CD3E MLH1 BCHE SULT2B1 DISP1 PEX1 LOX DES PIK3R2 BPTF TNNC1 PPP2CA RNF168 TMEM126B FSCN2 ARCN1 PIGV IDUA NKX2-5 IGH CYBB COL5A2 BCOR JAK2 SERPING1 SLC12A3 DOLK NEU1 TGIF1 ADA STAT3 FIBP B4GALT7 ZMIZ1 HLA-B HDAC4 ECE1 CYP17A1 TSC1 ATP6V0A2 A2ML1 DPM3 RP1L1 PKDCC RPS26 MEFV ORAI1 CLIC2 ITCH SEMA4A ASXL1 TRIM8 WNT4 RPS27 SURF1 UFD1 RAF1 SERPINF2 SRP54 SCNN1B GBA DKC1 MYH7 COG7 TCIRG1 ALOXE3 BBS5 SF3B4 LAMB3 VANGL2 MYPN GLI3 LIPT1 KANSL1 PTCH1 EIF2AK3 PPA2 NDUFB10 FBN1 ARL6 ABCA3 STEAP3 GCH1 UNC13D FGFR1 FZD4 HTRA1 SALL1 CPT1A HLA-DQB1 SMC1A PCCB NDUFAF4 FAM13A NEXN KCNN4 LARS2 CTU2 CYP21A2 HSD17B10 TWIST1 SMC3 COG1 ARPC1B FBN1 CALR GATA1 WDR1 ACTC1 PRNP RHAG DOLK RBPJ INF2 HLA-DRB1 HNRNPA1 PHOX2B DPH1 MYLK TMEM94 PRPF4 ADAR SARS2 HDAC8 MLH3 COL4A1 STAG2 LRAT CITED2 EFL1 KIAA1549 TERC BUB3 CRX ITGB3 NSD1 BOLA3 KIAA1549 ATF6 TRIP13 MEG3 PRDM16 KMT2C AIRE MED13L ATP7B AMMECR1 BCR BBS2 GLB1 ABCC8 ACAD8 DSP CYP7B1 MYPN DLL1 VHL EXTL3 SH3PXD2B KCNE5 ARL6 MAN2B1 COMT MYORG ARX EMG1 AIP CSRP3 RHAG RAG2 FCGR2A GJA5 TMEM67 BTNL2 ADAMTSL2 WNT3 DSP SOX18 PIGN PAFAH1B1 HGD ITPR1 FN1 FBN1 PIEZO1 ACTN2 COL1A1 YY1AP1 NPM1 ATP6V0A2 ZBTB16 AHCY EPG5 COL7A1 DDB2 SHH CACNA1C KIT EGFR OSGEP LAMA3 TBX2 SPECC1L IKZF1 SPECC1L SAMD9 LMNA YY1 PIK3C2A LMBRD1 ELN IFT172 PDSS2 DNAAF4 SH2B3 HBG1 NDUFA2 LZTFL1 MYO5B KCNJ11 EVC2 CEP120 SEC63 UNG PTEN MYC GATA4 SLC26A2 SCNN1G NKX2-1 PLOD1 PLEC DLL1 FHL1 MUC1 KYNU ABCA1 TTC8 IGH CLIP2 H19 APOB LAMA4 PLCB3 IL6 GNAQ KCNE1 IGF1R SLC25A4 DYNC2LI1 GNAS GDF1 MYOZ2 IRF5 DST LMX1B ARMC9 NRAS KCNE1 MEN1 SIX3 HJV MYD88 THOC2 PORCN SNRNP200 SOX11 GNB5 SHOC2 CKAP2L SDCCAG8 AP3B1 POLG PDGFB CBL APOC2 POLA1 COL2A1 LPL MLYCD SON TSC1 MIR17HG DVL3 RGR HESX1 LAMP2 RANBP2 SCNN1B ALX1 IFT122 GNPTG NRAS ARL6 FGB STK11 PEX2 MRPS22 GPX4 PCCA TTC37 DACT1 WT1 SMAD4 DAXX KRT14 PACS2 RPS15A RAF1 LRRC6 TRNW DYNC2I2 TNFRSF1B SHH PDE6B WNK1 PKP1 CHST14 TRNV TANC2 KIT FLNA NFIX SLC12A3 ACAD8 PRKCH TBXA2R TRAC TJP2 CCNO FGFR2 IDUA MGP KIT NDUFS3 GBA HRAS FAM161A KCNQ1 NOD2 NOD2 ADK MYCN SLC25A20 POU1F1 TRNH GAS1 AKT3 RAG1 PTPN11 SLC26A2 GATA2 STAR HMCN1 IDH3B SLC7A7 CACNA1S RARB GATA6 DPP6 FGA CBS SUFU TKFC PCCB CASP10 SRP54 SUGCT TNFRSF13C RPS17 B3GAT3 EBP ATP6 PLN TCAP CHRNA3 KCNH1 KRT5 MED12 MRAS LMOD1 TNFSF11 MYLK2 DCDC2 CAT FGFR3 CYP11B1 P2RY11 FLAD1 ADA XRCC4 MECP2 KCTD1 ND3 ACAD9 GBA CLCF1 NUMA1 TNFRSF11A FBXL4 ASXL1 GDF3 F5 MRAS ROR2 NUP107 HCN4 TNFRSF11A TWIST1 CEP290 IRF8 HLA-DRB1 DDX6 TAZ ZIC3 SEMA4A SCN4A NDUFV1 DNAAF1 LPL HOXA11 TRAF7 ERCC4 CACNA2D1 SPTB FGFR1 RBM20 NDUFA13 BCORL1 PIGW SMOC1 KRT5 ATRX ACTG2 FOXH1 COG7 MUC5B GATAD1 PRKCD HSD11B2 BGN STAG2 NPPA NDUFAF3 MYPN PSAP ABCA1 PTEN TNNI3 KCNJ2 RBM10 GANAB TACR3 CD244 PEX14 KANSL1 TNFSF12 MAP3K7 DBH COG2 SDHB IDS DNAAF3 DNAAF3 MC2R BSCL2 TNFRSF4 NAGS MYMK B2M LDLRAP1 CPN1 CAV1 DYRK1A MYOC HLCS ALPK1 KCNJ5 SCN5A SMO NONO FLT4 MAPT LEP CYP7A1 GPC6 CASQ2 TAB2 CPOX ITCH USP45 RYR2 DPM3 ZNF423 CRYAB CEP120 KIF1B SPIB NKX2-5 SELENOI PIGL FGFR1 NDUFS8 NDUFB8 CACNA1C SPEF2 NECTIN1 PBX1 AEBP1 POMT1 RAC2 JAK2 SCN5A COQ4 TBL2 BMP2 BBS2 GINS1 CFAP298 AKR1D1 TBX19 SYNE2 ACTA2 METTL5 DNAH5 WIPF1 POMT1 TLL1 CSNK2A1 MEG3 FGG LMNA KRIT1 OFD1 GATA6 IL12A TPM3 IL6 TRNT LMNA PPP2R1A SURF1 BRCA1 PSMB8 CACNA1C STAG2 CRKL SEC23A CACNA1D CDKN2B GATC SGCD LRP5 ALX3 TAZ COL5A1 MUC5B SEMA3E MRPL12 TCTN1 CDON PROS1 SRSF2 BAP1 FXN PIK3CA FOXRED1 DPP9 ARF1 RAF1 CD79B HEXB SDHC XRCC2 FGFR2 MYPN ZIC2 CALR ITGA7 LTBP2 RPGRIP1 TRIP11 APC SOX2 ABCA1 EXT2 NF1 SPINK5 DSG4 RTEL1 TNNI3 GPC3 TGFB2 SMAD4 DYNC2I1 TPM1 DMPK POMT2 DCDC2 SKI PIK3CA EBP WT1 ANKRD11 NR3C1 HFE SAMD9L TRNW SMC1A KCNE2 ICOS RTTN RB1 HGD F5 FOXF1 CHST14 GLB1 KRAS NCF1 SMAD6 PTCH1 IL2RG B3GALT6 SF3B4 GLI2 RP1L1 OTULIN F8 TET2 SEC23B ZNF148 COX3 OBSL1 WRAP53 ACTN2 PAX3 NDUFV1 ATP7A HGSNAT GLUL CARMIL2 PDGFB ABCC6 STIM1 KDSR DGUOK PTEN TERT FAT4 ALG1 PSEN2 MYL4 COX14 ITGB3 IGFBP7 PHOX2B CHD7 RBM8A ROM1 NLRC4 F10 PTGIS TMEM70 POLD1 EMD TDP2 CACNA1S PRKCSH NUP155 ALPL PKLR TRNL1 CTC1 PEX5 SDHB GATA6 MYPN ALG10B MEN1 NDUFV2 SDHD CCDC39 HEPHL1 HSD17B10 WHCR ACSL4 GP6 MTMR14 COX1 NAA10 FGFR3 EP300 TNNI3 GMPPB NDUFS4 LZTFL1 CTNNB1 INPP5E KCNJ8 HCRT HLA-DRB1 DKC1 TERT SCN10A GGCX KRT8 ERCC4 SFTPB LMBR1 NDUFAF1 RFT1 CCDC65 HDAC8 HBA1 POMT1 SEC61A1 SLC25A11 FLII CLIC2 CPT2 ATP6 DHCR24 COA8 CAV3 LFNG RLIM SUZ12 MARS2 NEU1 XIAP HLA-B BTD SREBF1 FGFR2
    HP:0002090: Pneumonia
    Genes 280
    TLL1 CHD7 TGIF1 KMT2D ACP5 PIGN JAK3 NOS1 SFTPB SRP54 MS4A1 NODAL USB1 CD79B SGCG ACTC1 CASP8 TGFB1 OFD1 CD19 CD247 NHLRC1 SHH NTRK1 EGFR LAMA3 PLOD1 FANCF JAK3 RAG2 PGM3 CACNA1C BTK IL2RG PIK3CD CREBBP KCNJ6 FMO3 ACTA1 TNFSF12 GATA6 ZAP70 PLOD1 UNC119 FGF8 GAS1 DNAI1 WAS GNPTAB FOXH1 CYBC1 LAMC2 RAG1 PEPD PDHA1 PMM2 PAFAH1B1 CD19 CD3D SIX3 CD81 DLL1 LTBP3 EP300 TNFRSF13B SIX3 GLI2 SMARCD2 TIMM8A MYH6 DCLRE1C ABCA3 IL7R TBC1D24 STAT3 CFB FOXH1 FOXP3 FCGR2A P4HTM AP3B1 POLA1 TK2 CDON PKHD1 TAF1 CDON NIPBL GRHL3 GAS1 EFEMP2 CRLF1 SLC35A1 SLC25A24 DOCK8 ZIC2 LEP AFF4 DDR2 CD3E PTPRC BLM RNU4ATAC TNFRSF13C KNSTRN CDON SELENON FOXH1 ORC6 RAG1 RNF168 SHH DISP1 CYBA IL7R CARD11 LONP1 COL11A2 CR2 FGF8 ZIC2 CARD11 CYBB NBN ICOS DNAJC21 DNMT3B DISP1 TGIF1 HLA-DQB1 ADA SETBP1 MED25 FOXH1 SLC35C1 ACADVL TDGF1 PNP SP110 SMC1A ICOS SREBF1 TDGF1 NBN DCLRE1C ALMS1 GLI2 MCIDAS FGF8 NCF1 RAG1 PTCH1 NADK2 IL2RG ZBTB24 ZAP70 GLI2 FGFR1 GAS1 TNFRSF13B GAS1 IFNGR1 CFTR COL11A2 CR2 SAMD9 CD247 TGIF1 TREX1 CARMIL2 TCIRG1 BLNK UBB SRP54 LAMB3 DISP1 RMRP TNFRSF13C NFKB1 STAG2 IRF8 PTCH1 SIX3 KPTN TBX20 TDGF1 CSPP1 IGHM BTK NFIX RNU4ATAC CXCR4 NFKB2 RAC1 CD27 TGIF1 ADA TBX20 ZIC2 MTHFD1 RAG2 GATA4 TNFRSF11A DZIP1L FGF8 KIAA0586 SHH TDGF1 RYR1 ODAD1 WDR1 CREBBP CITED2 DLL1 NCF2 TBCD SHH NODAL RAC2 SIX3 GBA PTCH1 DNAI2 ZIC2 TNFRSF13C ALMS1 PURA STAG2 DLL1 SBDS ICOS EFL1 ACP5 SFTPC CFAP410 MASP2 IL2RG IGLL1 AFF4 BTK LIG4 NFKB2 WDR19 CD55 CDON GAS8 EPM2A NKX2-1 RNF125 DCLRE1C NODAL LRBA ELANE MAN2B1 DLL1 PTCH1 HLA-DQA1 EXTL3 SLC35C1 MAN2B1 FOXN1 PRKCD GLI2 RANBP2 MID1 IL2RG FBLN5 NKX2-5 NODAL GFI1 TNFSF12 RAG2 ADA IL21R KDM6A OSTM1 ASAH1 DISP1 PANK2 FGFR1
    SNP 0

    HPO

    Alphabetical listing of all HPO terms. Navigate: Correlations   Clinical Trials


    Related HPO nodes (Using clinical trials)


    HP:0001626: Abnormality of the cardiovascular system
    Genes 4425
    MERTK SLC25A26 TRNK MTHFR ALDH18A1 SCN9A B3GLCT GNPTAB MITF GJB4 NDUFS4 MEGF8 SCYL1 TREX1 SLFN14 LMNA DOLK SDHA RANGRF SCNN1G CD247 EFTUD2 KRT16 SLC25A4 NTRK1 ATP6V1A CTNND2 ARVCF SIX3 ND1 WDR11 ANTXR1 CTSB NBEAL2 RREB1 TOPORS NOS1AP RRM2B CAV3 LETM1 GNA11 KIF3B IFT172 NPHP3 COG4 ELMO2 ANTXR1 PEX11B DNAH11 KRT2 APOB RPS6KA3 PRKAG2 GJB6 CDSN ZAP70 HRAS ZIC3 NKX2-5 BUB1B FLRT3 NXN RAF1 NKX2-6 KCTD1 TTC7A SPATA5 DNAH1 BRIP1 FGA SGO1 VPS13B TKFC CRYAB CNBP SEC24C CDK8 TULP1 MYH6 B3GALT6 TWNK PLEC SLC37A4 PIGA TSC1 ATRX FOXF1 FOXC1 WAC GNS TERC MPL THSD1 EVC2 DLST CRB2 FLNB ATP6V0A2 TPM2 AK2 ACTN4 SPAG1 RTL1 ITGA8 EFEMP2 C8ORF37 IL7 KRAS ECE1 XYLT1 VPS45 SLC25A24 POMT2 TPM2 CCR6 KCNE1 PLAGL1 AHI1 SNTA1 PALB2 FOXP1 KDSR RELN CAV1 ARL3 MYF6 IGF2 COL3A1 CBL ATP6V1E1 COL5A1 ACD PPP1R15B ACVRL1 AMMECR1 HNF4A ADA2 CDKN2B ERCC8 SBDS SOX3 FANCL NDUFB11 CPLX1 PRKAR1A LYST PRPH2 SLC18A2 RINT1 COX10 SLC2A1 VPS33A LDB3 XK TTN NKX2-5 GJA1 NGLY1 GLI2 ODAD4 MYH11 MAF FLI1 SMG9 SDHA AGPAT2 CAV1 MKS1 TAF2 LRRC6 COL11A2 HOXA13 CASK CCBE1 SMPD1 BTD KCNMB1 TDGF1 PIK3CA WDPCP LACC1 KCNJ2 ND4 RPS19 CHRNA7 IGF2 KAT6A AIRE DISP1 MYD88 DHDDS GNAI3 DOCK6 KRAS IRF8 ERMARD BAP1 APP RPE65 SLURP1 CALR FN1 SLC19A3 ALX4 TSPYL1 PEX13 SLC39A4 NDUFB11 TTN FOXC1 RBCK1 HNRNPA2B1 TRPM4 ZIC2 WDFY3 KYNU PSMB9 CD2AP APOE SMAD4 ITGB3 TRNK KCNQ1 SNX10 KCNJ2 HMBS FKBP14 FGF8 BRAF SC5D SHH ALOXE3 FAS SCARB2 HACD1 CREBBP CITED2 MMP2 HADH NEXN NODAL ABCC6 PORCN CEP57 PIK3R2 RAD21 SCYL1 VCP KCNE2 USH2A TCTN3 PTPN22 ESR1 TRNS2 CDON TIMMDC1 C1R STRA6 IL10 DLD SCNN1A DNM2 SOS1 CDKN1C TGM1 TNNC1 LPIN2 CCN2 MAP3K7 HLA-DRB1 FRG1 TSC2 PPP2R5D GLI2 SLC2A1 EYS FDFT1 IFNG ANK1 SYNE2 ARL6 IRF6 TAB2 PCSK9 TP63 CARS1 HABP2 MYSM1 ERGIC1 ALOX12B DYNC2H1 DSG1 NSUN2 FLT4 FERMT1 DNAL1 CRYAB PPARG GNB5 TRNE TSFM MEIS2 DYNC2LI1 TRNL1 NT5E EWSR1 POU6F2 CSGALNACT1 ELN PRCD FBN2 KAT6B PLCG2 THBD PEX5 SLC2A10 SPOP GBA CYP17A1 SHANK3 SGCG TRNK PNP ACTA1 AGTR1 FERMT1 SIM1 GNA11 DGCR2 NCF4 ODAD2 FMR1 CYTB HCCS GBA SNIP1 DNAI1 LMNA PSMD12 NBEAL2 MKKS LMNA WAS DMD NDUFA10 ITGA3 HESX1 PIGL SDHAF1 POMK MKS1 CYP11B2 ATAD3A IL2RB CACNA1S GLI2 RNU4ATAC NEU1 TASP1 PMS1 RNASEH2A FAH BRCA2 ODAD3 FKTN FHL1 IL17RA C2CD3 CALM2 MCTP2 PDE11A IGLL1 ODAD3 ATN1 TPM3 MYOT SMOC1 PUF60 SOX10 RYR1 NDUFAF6 TRIP4 IQSEC2 GATB ADAM17 SDHB GLMN LRRC32 TMEM216 NLRP3 CISD2 BAP1 MED12 CYBB COL1A1 STAC3 BSCL2 PTPRC VWF CHST3 FOXH1 NDUFA2 TNNI3 YWHAE SNX10 COX3 COG8 LRRK2 FBP1 TMTC3 GNPTAB CTSK TREX1 XPR1 HADHB ZFPM2 SCNN1A PCARE STRA6 NDUFAF2 IL17RD RBM20 FANCB GLI2 CLCNKB CCDC141 RPGRIP1L PHKG2 F7 RPL10 COL4A1 WDR26 HMBS EGFR ABCC8 PLAGL1 BCR NDUFAF2 CCDC22 SAMD9 DMPK ERCC5 SCN5A USP18 HYMAI C1QBP PRRX1 SLC29A3 ARMC5 PLAG1 COLGALT1 KAT6B MEFV DNAAF2 ITGA2B KDM3B GJB2 NFKB1 IL1RN EED IRAK1 FHL1 TGFBR1 REN ABCB4 COL4A2 MDH2 CALM1 UBE2A SP110 PIK3CD SRD5A3 ENG MAX ATP6 NSDHL HSPA9 PROK2 SETD2 CTLA4 SMARCD1 SOX2 ND5 PQBP1 TELO2 F10 DZIP1L JAG1 GATA6 JAM2 MYH7 KRT14 ALB PEX5 TTC8 ADA2 BPGM RIPK4 FRG1 CIB1 KCNH2 CHCHD2 TSR2 POLR1A WNT5A TET2 RGR SOX9 TGFB3 TMEM67 BMP2 CEP41 GYPC ZNF462 GPC4 FBN1 DDRGK1 COX6B1 RBM10 CFAP410 FGFR2 GDF6 TF MAP3K1 ATP2C1 BMPR1A BBS12 DPM1 MDM2 PARN RHOH NFKB2 RFWD3 VHL H19 TBX1 LIAS MOG TLL1 PPARG DCLRE1C NAXD ABL1 CFHR1 SELENOI GNAS NRL KCNE3 NHP2 CYP11B2 TGFBR3 KRAS NTNG1 OSTM1 SLC17A5 SDHB ABCG8 COL5A2 NODAL F13B SDHC TNFRSF11B IVD F9 IRX5 GDF2 PSMB4 PCNA PIGU SAMHD1 NXN DSP ANTXR1 UBR1 FGFR2 PEX6 NKX2-5 COL3A1 TRNL1 ARHGAP31 MS4A1 NODAL USB1 BBIP1 F13B CASP8 CAVIN1 CYP11B2 ASXL1 IFNG FGFR1 ARX PLAU PROC RLIM DTNBP1 ZNF408 SFTPA1 TRNS2 ITPA JAK3 BMP2 BAP1 NBAS FZD2 ATP6V1E1 BTK ATM CACNA1S HADHA MCIDAS NOS3 NODAL PTEN ZMYND10 NFIA ACTA1 PSAT1 SYNE1 BCOR ABCC9 CYLD CD81 COL3A1 GJA8 FGF8 RPGR SCN3B COX3 RPGRIP1 CPLANE1 CYBC1 FANCD2 FGFR2 RAG1 CRLF1 SMARCA2 NPHP1 MYT1L ACE CLEC7A GLI3 CYP27A1 FRAS1 NFU1 PMM2 PAFAH1B1 ZMPSTE24 CEP41 DLL1 FERMT3 CCNQ PTEN EYA4 NPHP1 KCNN4 PRDM5 HFE MPL SIK3 SLC40A1 TERC RPL27 SEC23B TRPV3 PPOX TCF3 SUMF1 SDHAF1 COL1A1 STAT5B SUFU CREBBP SOX9 STK36 BBS4 SLC7A7 GJA1 ADD1 DOCK6 CD46 DIS3L2 MFAP5 KNSTRN ARX TNNT2 SF3B1 KMT2E INPP5E BANF1 GYG1 ARHGAP31 ZFPM2 RMND1 ZIC2 G6PC3 NDUFB10 DNAJC21 PEX26 XYLT1 ERF PEX19 ENPP1 MED25 NCAPG2 FOXH1 HJV SEMA3E AIP IKBKG IQCB1 MRPL3 SP110 NAGA MED13 LIG4 NDP HPSE2 TRPM4 FZD4 FLNB FCGR2B LHX4 INPP5E KATNIP TRIP11 TTC8 PSAP TREX1 ND2 ND5 IDH2 BRCA1 RPS6KA3 FHL1 USP8 SLC25A11 MASP1 LMNA LMNA WDR37 TRPM4 PEX3 TRNF OTC FADD OTC TMEM126A MTAP PPARG TRNQ KIAA0586 ZMPSTE24 RAI1 ELN KPTN LBR KDM6B SON AGXT TRNS1 PDCD10 CYP7B1 TRDN DMXL2 SPATA7 NPHP3 TRAPPC11 ELN PTCH2 MAP1B TGFB2 ARHGEF18 JAK2 SUMF1 GUSB ADCY5 IFNGR1 DHCR7 GUSB KITLG HADHB BVES C12ORF57 SDHB GBA MPIG6B FOXP3 RAC2 STIM1 KRT83 RPL35A AKT1 MYH6 ZFPM2 GJB6 CHST3 KANSL1 PURA SATB2 PITX2 COL4A1 FN1 GLRX5 ADAMTS10 CDK4 AFF4 ZFP57 ERCC1 SCARF2 PCNT PRPF8 NPHP4 LRRC8A RPL26 RMRP ACTG1 TTN OTUD6B KDM6A ECHS1 KCNQ1 ATP5F1E CTCF TGDS CNGB3 TMEM107 GAS8 POLG DNAAF2 SCNN1A ACTA1 MTM1 FLNA POMP HABP2 MTTP TRNL1 FGFR1 TGFBR2 FKRP OTX2 PTPN22 CFI LRP2 PHF21A ZIC2 EOGT RNF6 PLIN1 INSR WRN KRT5 PIGN NDUFA10 FKBP14 WWOX PPA2 LDLR GATA4 GATA6 TBX1 ENG POLH NSMF ARID1A KCNK3 NSD1 F5 KCNN3 REEP6 NKX2-5 CREBBP KIT ZFPM2 CDH23 PDE6D ATP6V1A TMEM231 MTFMT PROS1 XYLT2 EPCAM KCNQ1 P2RY12 IL10 PDGFRB SLC4A1 LRP6 NDUFS8 GCK SDHD DCAF8 STRADA PNPLA2 NDUFB11 DDRGK1 FUCA1 RNASEH1 RNASEH2C ND4 NF1 AKAP9 NOTCH3 FLNC DNAAF5 PEX5 PDHA1 SMARCE1 ERCC4 MYH9 CCDC22 COL1A2 STAT3 CCND1 TMPO ND6 IMPG2 CALM1 CCDC8 TGIF1 NEUROD2 DNAH5 ABCA4 TRAF3IP2 ARFGEF2 TBX1 KISS1R SSR4 ALG8 DDX3X TRNS1 KDSR HAAO RIN2 TUB MKKS RSPO2 DNMT3A ETV6 GNB3 HK1 AFF4 GBA RAB3GAP2 PPCS FGB IL23R DVL1 F8 FBXW11 APOA2 CYBA RAI1 MYH11 CITED2 PEX12 TFAP2B HADH SCN9A FGF8 CASR POLE LOXL1 ICOS FADD AMMECR1 SCN5A LMNA TNNI3 CDON PDE6G SDHD MANBA PIGT TDGF1 DYSF CCDC40 ALMS1 FGA ANO5 PARS2 RPGRIP1L TERT GJB3 CDIN1 KCNE1 FOXH1 SOS1 NRAS CACNA1D WAS CASR DHODH F2 PNPLA2 EHMT1 NF2 TCIRG1 DYRK1A NDUFS1 FAS MYH7 TOP3A SAMHD1 WDR35 NSMCE3 PTEN TGIF1 G6PC1 CCDC28B KRAS GTF2I TNFRSF1A FBN2 TWNK HGSNAT GNAQ PRDM6 APOA1 DSC2 SRD5A3 IFIH1 FTO KCNJ11 GNAS AMER1 SETD5 LIPC COX2 MINPP1 NFIX RNU4ATAC OFD1 RASA1 AIP COL6A3 WDR35 FAS ACVR2B RNF135 CDH2 SFTPA2 MKS1 UPF3B ANTXR2 PRF1 KRT1 AARS2 TSHR TRNT1 SCN5A GATA1 NRAS GREB1L ERAP1 RAB27A SCN10A MC4R PACS1 PRKACA GLI3 LYST GBA GATA4 TKT TBX4 MYMK COL4A4 SCN2B CEP290 KLRC4 SCAPER MMP1 KRT9 F13A1 VIPAS39 PRPF31 PIGN HLA-DRB1 AIPL1 MPL ADAMTS2 TMEM237 CD55 MVK NKX2-1 DLK1 TPI1 APOE GNAO1 WT1 ELANE GTF2E2 PKP2 ABCC9 GPR35 CIITA TRAPPC4 MED12 CDKN1A CLCC1 CRPPA GJB3 MEIS2 RAF1 MIPEP PEX1 COX3 COX7B NEBL SH2B3 ERCC3 ERCC2 KCNAB2 TAB2 CTNS SETX ANGPTL6 CD19 TRIO STK4 POLH ERCC5 GALNS POMT2 NFKBIL1 ADAM17 TET2 NAA10 SF3B1 SLC26A3 GFI1B KMT2D ABCA12 LRP5 UBR1 PEX3 FEZF1 COL7A1 HSPG2 TRPM4 TRNK NDUFAF4 C12ORF57 MYBPC3 GTF2IRD1 CAVIN1 KRAS PIGY VWF TGFBR2 SPINK5 RASA2 APC PHGDH SLC25A24 NGLY1 LARP7 STAG1 RYR2 CCND2 FANCM UCP2 RPL10 CDKN2A DSG2 ANO10 NELFA NLRP3 KCNJ11 PIK3C2A GLI1 CTCF KCNQ1 LRP5 TCF4 CFHR3 POLG TBX5 SHPK HLA-DPA1 TMEM43 SETBP1 LMNA RIT1 SVBP CEP164 AKAP9 ATP6 FKRP CYP27A1 CACNB2 WAS SDHA NF1 LAMB2 BAG3 RARA ACTL6B TREX1 ABCC6 COL11A1 HSPG2 KCND3 CNGA3 IL36RN SLC19A2 CYP1B1 COL3A1 CD96 CYBA ERCC8 TET2 GLIS3 DLD TERT PEX2 FOXH1 SURF1 ATOH7 GFI1B HRAS CASP10 TSC1 TNPO3 NIPBL PITX2 WDR19 GAS1 MYCN TXNRD2 IL10RA ATP7A MYH9 ACTA2 TRNW GDNF CTLA4 PDE4D SPTB ADAMTS3 GLB1 SGCD ERCC3 F7 HLA-B COL5A1 CBS SNCA FGFR2 LIG4 RNU4ATAC CLN3 GNE AKR1D1 ADA2 KCNJ1 FGFR1 CFI ERCC2 DISP1 FKTN ATP6AP2 NLRP3 FGFR2 COQ2 SPECC1L ARL6IP6 FAH ND5 NR0B1 LIG4 MAP3K20 POMT1 FOXE3 PDGFB GYS1 SDHAF2 SLC26A2 FAS PRKAR1A SERPINC1 RLBP1 TCIRG1 CALR PIK3R1 LIFR KCNQ1 SDHD ZNF687 SLC35A2 FGF8 CCDC40 CTLA4 SCN5A HBA2 ARSA DCAF17 CFTR SCNN1G ESCO2 GJB4 ITGA2B KIF1B BEST1 RP2 GATA6 BBS9 ARNT2 KCNJ18 HTRA2 SPRY2 STAT1 GTPBP3 FGF8 SCNN1A SNRPN MYOC GPR101 ATP5MK HNF1A MAX LRIG2 LONP1 PLEC CXCR4 ERCC8 COQ9 PTDSS1 SLMAP STIM1 CCND1 KCNQ1OT1 AHCY ATPAF2 FANCC POLR3A SKIV2L PADI4 CYTB MAF TERT SFTPC FOXJ1 NPC1 AICDA FANCI CALM3 NDUFS2 EDA LDLRAP1 TFAP2B CALM3 PEX6 CFAP298 CSTA SELENON TRIM28 ZIC2 KLHL7 NPC2 TBX22 ALMS1 GPD1L FGF8 ELN SBDS CERKL CYP11A1 KDM6A LAMP2 B9D1 MAFB DTNA NDUFS2 PEX14 LEMD3 GJA1 FGF20 SGCB MMEL1 DNASE1L3 TGFB3 CCDC141 FANCA LIPN FLT4 MYH7 RDH5 SCNN1B FBXW11 MAN2B1 SCN5A LTBP3 PTCH1 MGME1 EPG5 NKX2-5 GAS2L2 PPP1CB F13A1 PDE6H HIC1 CBL CWC27 PDE3A FLNA CHRM3 POLG2 JPH2 IRF5 IL17RC GNAQ SMARCA4 APP PIGM HPS5 TMC8 COL4A5 LYZ NFIX RTEL1 PRKG1 PLN ATAD3A MPI BRAF IFT172 FMR1 ALG14 PAH WRN TGFB1 RBM8A NDUFB9 SFTPA2 CDH23 FGFR3 RET NR2F2 JMJD1C TNNC1 SLC30A10 GLI2 BUB1 GMPPB NRXN1 COQ7 OCLN VCL TMEM237 TFAP2B TBX1 WDR19 RRM2B COX4I2 KAT6B FLNA DNAI1 HCCS NOTCH1 IFT140 FOXA2 MPLKIP PROS1 LZTR1 SOS2 NDUFS2 CACNA1H TPI1 FECH CYP11B1 GNA14 MADD GCDH PEPD MYT1L MYO18B GTPBP3 SDHA IDH1 CDKN2A SCN4B SOX10 FBLN5 YY1AP1 CDKL5 RPS10 TANGO2 NPPA GAA AKAP9 NDUFS2 PIGO MAP3K7 LMNA MEOX1 KRAS TMEM216 RBBP8 KLF1 SCN1B BPTF SMARCB1 SOX10 BRCA2 SPTB ANK2 RNF113A BRAF MBTPS2 RAF1 COL6A1 FASLG TNNT2 CCDC39 DNAJC19 PYCR1 SMN1 EYS TNXB CFH DEAF1 LMNA PSMD12 TK2 INTU ATP6AP1 PEX6 POGZ STAT3 PLG CHRNA1 ACTN2 NEK9 ESCO2 LONP1 TGFBR1 ACAD9 CDH2 POLG TMEM127 LPIN2 KYNU PRDM16 SETBP1 SNRNP200 CFH UVSSA UBE3A MYH7 PRRX1 CPLANE1 TBX20 SFTPC SLX4 CARD9 ARL2BP RECQL4 LEMD3 TNNI3 RPL10 FGFR2 FHL2 GABRD IRF2BP2 EHMT1 NEK10 ABCG5 MYH7 RPL5 CRYAB MKS1 DOCK3 NODAL ABCC9 TFAP2A RPS24 VPS33B RPL35A FGFR2 SGCA RET COQ2 ARL13B IDH3B MGME1 ASAH1 NOTCH2 UBE2T CENPE CHRNG ATRX SNTA1 PRPF3 ERCC6 HBB MED13L KCNQ1 MRE11 JAG1 RECQL4 RPL27 DNAJC19 TDGF1 TALDO1 RNF213 RAI1 HFE NDUFS2 NR2E3 PCARE MAK PHKA2 LAT STXBP1 ZEB2 KDM5B PIGO MAP2K1 PIBF1 PAX6 ERCC4 SOX18 ERBB3 SIX3 ROR2 ND4 BMPR2 CENPF PEX16 PDX1 DUX4 PEX19 FLNA DIS3L2 DLL1 CDON SHH TPM3 CPT2 H19-ICR TBCK MTRR BMPR1A MYL2 HBA2 JAK2 FOXC1 TBL1XR1 GDAP1 RAD51C CACNA1C RRAS2 PRPF6 LIG4 AGK DNAAF6 PIGS RNF125 BIN1 NR3C2 FANCA PRKAR1A GDNF MYPN NOTCH3 IGF2 RUNX1 PRKCD BLNK KRT1 PRPF3 FCGR2C KAT6A FBLN5 ABCC9 GCLC WDPCP IRF5 WT1 LIPA RAB27A KIT TMEM43 ADA AUTS2 CYTB SALL1 SERPING1 CYP24A1 TGIF1 ASCC1 DNAH1 CSRP3 GNE CST3 IGH FAT4 JAK2 PSEN1 G6PD ACADS MYH11 TMEM43 INSR ERCC6 PQBP1 ARID1B ARL3 PDE6A SH2B3 PPOX TP63 SHH PLOD1 AKT1 TTR COPA PEPD SRY SCNN1B FBN1 SNRPB RBP3 GAA CALM2 GATA6 DYNC2I1 CASR ZNF423 RAD51C GALE SDHB HPS3 REST TGFBR2 SCNN1B TAZ PKD1 TPM1 PRKACG HIRA ACTG1 DRC1 SVBP GPC6 GDF1 HOXA1 BAP1 COX1 CSPP1 ELN MGMT ARSB PEX6 RPL11 PET100 RIPK1 CASQ2 ACTB MSX2 ND2 FOXP3 USP9X ND4 SOX4 SLC39A13 PKHD1 CHKB COLQ TTR SPEG RPL11 GLRX5 PAM16 NOTCH2NLC TET2 SCN5A AKT3 PTPN11 MEOX1 RP9 F2 ENPP1 RHO POLR1D TDGF1 TNFRSF13C GLA SELENON HSD17B10 RPL15 TULP1 NF1 ADGRE2 FGB MED13L GATA5 AGL DDC TRMU BACH2 DLX5 ZNF513 IL12RB1 SH2D1A KRAS SLC25A4 SCN5A NDUFA11 GSN CAP2 ALDH18A1 SMAD6 VPS13A EXT2 ITGA2B SLC4A1 FRAS1 NDUFA12 MFAP5 CYSLTR2 CEP55 AGXT FGF17 CLDN1 PDE8B MAGT1 FGFR1 IFNGR1 DES SMAD4 ZNF469 ND1 DOCK8 KMT2D SOS2 SLC19A2 ND5 LAMA4 CTNNA3 FOXRED1 LIPA MICOS13 CSPP1 ACAT1 RORC STING1 DCHS1 GATA3 MEGF8 HLA-DRB1 ZEB2 ARID2 CHN1 PIK3R2 RPL18 STN1 HTRA1 AP1B1 PCCA EXT1 CCND1 CYLD PDGFRA RAC1 KIF15 TBX20 FIG4 SLC20A2 BIN1 LIPA ODAD2 FLNA TRAF3IP1 SMO SLC4A1 PDHA1 DNAH9 TMEM231 GLA SCNN1G NOS3 MBTPS2 EVC NSD2 HS6ST1 DPF2 ITGA2 MAN2B1 PIK3CA LRP5 PKD1 KIF1B APP TNNT2 TNFSF15 PTCH1 LRP5 RBP4 MMP2 LMNA NLRP3 CHD4 LRRC56 FGG ABCC9 CYP11A1 RNASEH2A CIZ1 TNFSF4 ODC1 POLR3A AGPAT2 TWIST1 MMP1 NDUFA4 ND1 IDUA COG4 TP63 PAFAH1B1 PTCH1 PEX7 LCAT COX8A GP9 ABCD3 PRPH2 TP63 DISP1 TCTN2 TNXB SCN1B PPP1CB VANGL1 NR5A1 NKX2-5 TSC2 ACTA2 DGUOK GFI1 MAPK1 IFNG COL1A2 NDUFS3 PHYH MESP2 RPS28 FASTKD2 FOXE3 NLRP3 MRPS16 RAI1 NABP1 SCN9A PCGF2 FLCN DNAJC13 SFTPB ACTC1 PLVAP HBB RPS20 RPSA RAD21 INVS LYST NDUFA11 RARB CD19 BMPR2 DZIP1 APOA1 GATA1 PEX7 NEK2 ATM LMX1B GBA APOE TGFBR2 MYH11 CANT1 RECQL4 HYOU1 IGSF3 TOR1A ATP8B1 CFTR EVC FANCE PARN PRKAR1A TGFB1 MYLK WWOX MTOR RFC2 WDPCP GATA4 RRM2B CCDC103 SETD1A NEB MPLKIP POLA1 FLT1 CD19 CALM1 SIX3 SMPD1 B9D2 SERPINC1 SELENON SPARC HPS4 PTH1R SRCAP ATM MNS1 KRIT1 MYH6 SH3PXD2B GNAT2 CLCN7 TRIP13 HAND2 COL18A1 MST1 ANKS6 RPS6KA3 MEF2A ALDOA FGB FKRP NOP10 AVPR2 COG6 TRNQ BCL11B PRDM16 IVNS1ABP STOX1 ASAH1 ACTL6A NDUFS7 SMAD3 TALDO1 NUBPL CITED2 ERCC2 TAF1A COL4A1 COX15 TEK STEAP3 HADHA ALX4 ACTA1 DSP NDUFB3 EIF4G1 GATAD1 ACTA1 HBB RERE FLNA MAD2L2 CLRN1 LTBP4 PNPLA6 TMEM237 AIP DDX58 POR PGM3 DCC ABCB11 KCNJ8 EOGT VHL PIK3CA MTFMT TEK PLD1 SLC25A4 SDHC DCLRE1C SEC31A TLR4 RSPH3 APOA5 COX7B CYBC1 DCHS1 KCNH1 FANCB BBS2 HBB SRCAP GAS1 TNFRSF13B LMNA CRB1 ZMPSTE24 ANOS1 SMARCE1 KCNQ1 BCOR WARS2 KLHL3 STAT4 SMAD3 GTF2H5 TRNV RUNX1 LRP2 OPA1 PRKAG2 DNAAF4 UBAC2 MAP2K1 RIN2 THOC6 DLEC1 BIRC3 COL4A3 FGA TTC8 SCN1B GATA4 TMEM138 CD27 BMPR1A ALKBH8 CFHR3 MTHFR NSMCE2 VCL MITF QRSL1 DHCR24 CAV1 BNC2 SNAP29 ITK BICC1 RECQL4 THOC6 NAGLU TRMT1 AKT1 JAG1 RERE GDF6 DMD F2 FIP1L1 GJA5 C2CD3 ND5 ATP2C1 APC NFIX NDNF B9D1 ICOS GFM2 SARDH ND6 HLA-B PRKAR1A KCNJ18 MAGEL2 GMPPB NF1 MAP3K7 DLL1 RPS29 NODAL LRBA RDH12 PLP1 RSPH4A TERT FBN1 F5 NAGA RHO ATP6V1B2 RET HSD11B2 WASHC5 TCTN2 DMD GANAB TMEM67 C8ORF37 SLC39A13 CD46 ADAMTSL4 VPS33A DPF2 PIGQ INS SDHA MVK SMARCB1 RPS7 WT1 TRAIP NDUFB11 DNAAF1 TOP3A PRCD CUL7 TCOF1 ALG9 TRNC CALCRL F5 KAT6B POMGNT1 TTN OFD1 EPB41 TERT BRAF CLCN2 APP SLC2A10 RPS15A APP KRT14 GJC2 PTF1A MALT1 HPGD NID1 SOX3 KCNH2 ABCG5 FSHR MAFB DSE GATA6 CFC1 EFTUD2 HBB MYL3 RPL15 PPCS STK11 ALB CDC45 SNAI2 PCNT FOXH1 ESPN TPK1 IDH3A ANKRD11 COL1A2 TARS1 PKLR CEP290 WNK4 CCR6 SH2B3 ALAS2 DNAH9 HSD3B7 PLIN1 BRAF ADNP DSG2 UROS RLBP1 EXT2 TBX1 SMCHD1 PIK3CA TCAP RS1 ATP5F1A GATA6 FANCG SCN5A GP1BA NDUFV2 GMPPA NOTCH1 MAB21L1 ADAMTSL1 AKT2 MCCC2 ND6 DNMT3A SIN3A THPO NOD2 MYH6 WASHC5 CPOX FOXC2 HAMP GJA1 ANKRD26 ACTA2 CYB561 SCN1B PIGT VPS13B PRKCD HYLS1 SUFU PTCH1 DNAJB11 HOXD13 IGF2 TRRAP CFAP300 COL1A2 GDF1 MTO1 IFT27 INTS1 PHKG2 PEX19 MAP2K2 WT1 DLK1 PPP1R17 SMC3 CR2 STX11 F12 MED25 MADD COL6A2 RAB23 SHH ACADVL FAN1 TET2 TKT MYRF HRAS DLL4 F8 MVK CRELD1 GALNT3 SCN5A TPM1 KIAA0753 SCO2 SOX2 ATP8 SLC26A2 PUF60 RYR1 ELP1 AGA BEST1 NLRP3 FANCF VWF FBN1 MMP21 TCIRG1 PNKP F2 CPT1A FLI1 ZIC2 SLC29A3 KIF20A DLL4 IMPDH1 MBTPS2 POLG KRAS SIX3 PEX12 PRKCSH TCTN3 SOX10 SMARCB1 TRNN SCO1 BTK MSH6 KRAS BSCL2 RSPH1 SMAD9 CCBE1 GK DNAH11 AGTR1 ATR CSF2RA NADSYN1 UMPS CDC42 GJA1 LAMA2 SMAD4 SACS TCOF1 NTRK1 DES POMT2 SLC22A5 MCFD2 MYBPC3 XPNPEP3 NOTCH2 SKI SEC23A TTN LORICRIN MRPS14 SYT1 ODAD4 ECHS1 IDUA CACNB2 DLL1 ND1 RNF113A TBX6 RERE FLNA CASK DGCR6 TTC7A SFTPC RAG1 UROS INTU CKAP2L EDNRB NLRP1 IFT81 ABCD4 EPHX2 COG4 EED SIK1 ETHE1 RPS19 IL12A-AS1 ENG CDKN1B HLA-DRB1 HYLS1 NPM1 NDUFS4 MC1R SCN11A TACO1 RB1 CTLA4 PRG4 CEP19 KLF1 C1S CRELD1 PHYH DSE PEX1 ERBB3 RPGR TCF20 LIMS2 GUCY1A1 GALC TUBB RET JUP NLRP3 ALDH3A2 DHX38 IFT80 FGFR3 FXN FGA MKS1 SEMA3A HBA2 NPHP3 WFS1 VHL PMM2 COL4A3 BRAF ABCB6 IDUA MNX1 PRPH2 RPGRIP1L EYA4 FBN1 HBG2 SLC29A3 CNTNAP2 RAG2 CAPN5 CTSA PGM3 CHRNA7 FANCE MPL COL7A1 NDUFS6 HIBCH FKTN ZEB2 XPA NEK1 GJA1 TRDN FLNC ENG AKAP10 KIAA0586 CCNQ PLN NDP AGA LAMC2 RAG2 IL17F VAMP7 CEP104 FANCC SNCA PYGL CCN2 TPM3 TWNK GGCX COQ2 FOXE3 NCF1 CD3D ABCA4 TAF2 RIT1 MGAT2 SAA1 KIZ IL7R TBC1D24 TTC37 LTBP4 SPTA1 MLX COL1A2 IDH1 SMAD3 TGM5 FOXRED1 PEX16 NOS3 GHR DDX11 HYMAI GDF2 PRKAG2 HLA-DRB1 MRPL44 NDUFA1 DNMT3A NEU1 ATIC EDN3 FLNC CPS1 PRKAR1A APRT GPIHBP1 DNMT3B IDH2 SCN3B PTPN11 EDN1 MECP2 AGK NDUFV2 USF3 ACVRL1 TFR2 FLNA MTTP NRAS OTX2 CC2D2A DNAAF6 FGF23 CLCN7 ANK2 NOTCH1 FBN1 NUP188 NDUFAF3 STAT3 PEX2 PEX10 CARD11 TBX5 BAG3 ERCC6 STX16 SMAD4 SLC25A13 PGM1 LRP1 JAK2 HMGA2 AHI1 RPL31 ELOVL4 AQP2 PIK3CA TP53 CNGA1 BRCA2 PALB2 GAS1 PSAP PTCH1 CFI PTEN STAT3 TMEM67 SCN10A KBTBD13 TREX1 AHI1 ACTC1 JAK2 ISG15 MYH7 ACTG2 BEST1 TMEM126B MAP2K2 ACADM DLL3 RYR1 FUT8 PEX12 ASXL2 KIF11 GP1BB MSL3 HADHA TERF2IP SH3BP2 HNRNPK NFKB2 FREM2 IFT172 HIBCH PIGY ANK1 TGIF1 CAV3 IDS AVPR2 NEK9 SELENON PSTPIP1 CCM2 LEMD3 ATAD3A GATA4 NR3C1 NEUROG3 SCN2B TBX1 POU2AF1 TDGF1 PRKACA ADNP CA4 CD28 CDC73 SIX3 PML BLOC1S3 KCNJ5 CHD7 POLR1C POR TNFRSF11A FH ATRX HES7 FOXC2 NKX2-6 FOS GLB1 CC2D2A DSP MYH3 KRAS HSD3B7 ALDH18A1 ALOX5AP PEX11B SDHD DVL3 SLC12A1 SCNN1A PSEN1 WFS1 GPC3 DCTN1 ALG9 DNAAF5 JUP ZMYND10 CACNA1D IL2RG IL7R PTH1R SMPD1 HLA-A ROR2 GP1BA SMAD4 KDM6A NONO INVS TLL1 RIPPLY2 CLCN7 MYLK NODAL ND6 SERPINA6 GNE BAG3 MEN1 LRRC56 GATA1 TSC2 VPS35 DHCR7 WARS2 NDE1 SLC20A2 WNT10A SLC7A14 GSN RP1 KCNJ5 BMPR1A LBR ARID2 BBS1 SDHD ZNF513 RET CNGB1 KCNJ5 SETD5 NKX2-5 CAV1 ABCG8 DCAF17 DSG2 TF GPD1L AGT GATA1 CTBP1 BTNL2 RYR1 SNX14 CHST3 RAD21 SOX4 SAG ERCC6 TP53 IGF2 BBS10 FUZ SUFU CRTAP PSAP PEX13 GAS1 B3GLCT ABCC6 PLEKHM1 ADAMTS10 ELN RET GATA5 ALDH18A1 CALM2 GATA5 EPB42 GP1BB TCIRG1 DIS3L2 CAV3 TPM2 EMD SCO2 TXNRD2 IKBKG FUCA1 SPAG1 ARID1B GNAS AGGF1 F8 ABCA3 ND4L NLRP12 TGFBR1 NDUFAF5 NOTCH1 PMS2 SEMA5A CAV1 NDUFS8 CD28 CDON GPX4 CA2 CC2D2A PDGFRB GREM1 KIF7 STXBP2 TGM5 ADCY5 EPHB4 ESCO2 FHL1 NEDD4L BCS1L IFT88 CITED2 NDUFB11 BCL2 INPPL1 KRAS CYTB KIT MYBPC3 RPGR CALM1 GRIP1 ATP5F1D FANCD2 PTPN22 FAT4 IFIH1 IL7R LMNA JUP GPC4 FECH H19-ICR SMARCAL1 NAGA GBA CEP290 PDCD10 DISP1 HYDIN SPRY4 MAP2K2 IL2RA FGD1 CDK13 CTC1 PDSS1 PNP PRTN3 ARID1A EPB42 XYLT2 MYH6 FRA16E GP1BB RSPRY1 TRNS1 SDHD BLM CASQ2 CALM3 RRAS SALL4 FANCI LMNA DDR2 ZAP70 ALDOB MNX1 LMNA AIP ND4L C3 IFIH1 TMEM260 NRXN1 USP8 FGFRL1 DPH1 APOE C8ORF37 AP3D1 SALL4 BRCC3 ABCA1 CDK10 KDR TECRL AAAS TBXAS1 C4A MYH7 SH2B1 ERCC6 SBDS DNAI2 NKAP TBC1D24 PEX1 LIPC CHRM3 MTHFR MYL2 TRNE COA6 SERPING1 GATA6 BCL10 PRF1 RAG2 SCN4B GBA GATA4 SMARCA4 GM2A CD40LG KCNQ1 MSH2 TRMT10C MMACHC MIF HES7 GP1BB HLA-DQB1 TRIM32 NKX2-5 GMPPB SLC35A1 AMER1 EIF2AK4 SPP1 XYLT2 KIF7 LBR NCF2 MKKS PTPN22 TMC6 CEP57 FGFR2 DNAI2 SDHA SDHB TRNF TPP2 SDCCAG8 SOX5 PCNA ZNF469 RAG1 CDKN1C CDC73 IFT43 CEP120 HAVCR2 HMGCL KCNJ2 HBB MIB1 SLC4A1 ACP5 XIAP CFAP53 IL2RG ATP7A RNASEH1 FANCB CYP11B1 KAT8 BTK SDHB TTN TMEM231 OFD1 TET3 KLHL7 CDON PTPN11 TXNL4A PHGDH LRP5 FLNA PIEZO1 PIK3CA NNT ABHD5 DVL3 KCNE3 AEBP1 RYR1 CDHR1 HCN4 STRADA PSMD12 CUL3 SLC25A3 ANAPC1 LONP1 ERCC4 FBLN5 ATP6 FBN1 CLRN1 PEX16 FLT4 NIPBL SMAD4 LIPT1 SLCO2A1 NOTCH3 CD109 RPE65 CHD7 SLC37A4 COQ2 TNNT2 SRP54 CD79B SOX18 SGCD TSHR AQP5 TNNT2 CDKN2C MMP14 MED12 TGDS CCDC47 PKD1L1 ND2 ADAT3 CPOX RPS17 APC2 MYH8 TRAF7 KIF7 MYH7 SCNN1A GPD1 DHX37 VEGFC KRT5 TNFRSF1A KIAA0319L CLCN7 YARS2 TBX1 PDE11A SMC1A PIEZO2 TMEM237 NDUFS7 PDGFB TBX1 KCNA5 AKT1 TNFSF12 EFEMP2 PGAP3 ABL1 PIK3CA EHMT1 PDGFRA CTNS SDHD NCF2 NDUFAF5 TNFRSF1B WNT10A FOXP1 PSTPIP1 BCOR TMCO1 GYG1 KDM1A SDHB NDUFS1 NSD2 TECRL F13A1 B3GALT6 CLCNKB TRPS1 BBS1 CSF2RB MPL PERP FAM149B1 COL1A1 HESX1 FCGR2A EDNRA IDS TRIM28 WDPCP CACNA2D1 CD79A PIK3R1 FGFR1 PIGP HNRNPU HPS6 SCNN1G MAP2K1 PDE6A CTSA CPT2 LMAN1 GPR101 SYNE1 TFAP2A COX2 RTL1 CCDC174 COQ2 NR2F2 OFD1 ND6 KCNH2 TSC2 KCNN3 RASGRP1 SP7 GBE1 NDP GATA1 COL3A1 POGZ ENPP1 POMGNT1 SEC23B TCTN3 GLI3 SREBF1 ITGA2B SMARCE1 POU3F4 GIGYF2 SIX6 F11 SEMA3A CDAN1 KIF5A MVK ARMC5 SDHA NDP PTPN14 HAMP CNGA1 PEX26 RYR2 HEXA TP53 HPS1 TET2 COL2A1 FBN1 SCN2A DMD GATA4 FMR1 NKX2-5 ELOVL4 DMRT3 FBLN5 GUCA1B NEK8 TMEM127 CLPB LDB3 RNASEH2C TWNK TBX20 CCR1 HADHA POR WNT4 ELAC2 MEG3 GP1BA TRDN SKI NEXN RAD51 DUSP6 OTUD6B USH2A NDUFA9 MMUT HYLS1 NPHP1 HBA1 CHRND PKP2 PDE6C XRCC2 FSCN2 VHL CCDC103 ERCC6 ZDHHC9 FARSB ODAD1 CYP11B1 ANK1 JAK2 NME8 AHR VHL SLC25A22 LETM1 SLC25A3 ELANE RFWD3 XPA GPC4 ITGA8 GNAQ CDKN1B GNAS ERCC8 C4A DYRK1B TRPC6 DNASE1 CA2 PROKR2 MLXIPL LZTR1 STX3 ALG12 AK2 IDH2 SLC52A2 PDE3A HELLPAR HSD3B2 GP9 SGSH BAZ1B ALG1 WT1 TANGO2 MID1 GP1BA XPC LDB3 NR2F2 DNAL1 TGFB3 SGCB CTSH CTSB DISP1 PRKAR1A TRNL1 UBE3B LCAT MAT2A FIBP CYP11B2 TNFSF11 DSP PET100 LMNA ABCA4 KCNA1 NFE2L2 EPHB2 SGCG PROC IARS2 KCND3 D2HGDH MGP TRDN NHLRC2 SOX9 PGAP2 NAGA PUF60 FKRP CTNNB1 SDHD KCNE2 RSPH9 NOTCH2 PACS1 GNAI2 NAA10 GNB5 GGCX KRT10 CD70 ND1 PIK3CD FMO3 ASS1 EXT1 USP9X PSAP GUCY1A1 LMNA WT1 PIEZO2 GJA5 STN1 DCX KCNE5 GPC1 PROKR2 EBP GNPTAB NLRP3 CFAP221 COA5 JUP GJB2 TP63 TBX3 AP1S1 HBA1 ROBO4 CERKL RPL26 DES EDA2R OFD1 CD81 TNFRSF13B POLG2 FIG4 DDX59 MYH7 NSD1 MTHFR HLA-DPB1 AGT RYR1 CFHR1 BRF1 SLC22A4 SLC25A20 MAPRE2 AKT1 RRAS2 EPHB4 MEN1 XRCC4 COX7B HSPG2 CEP290 CCDC115 LTBP2 DLK1 PROP1 SHOC2 FLT4 ACTB DGCR8 FBP1 NEB SLC35A1 EPAS1 COL1A1 MRAP SPECC1L PSEN2 CDH23 BLM PKD2 CDON PKD2 NPHP1 CST3 RAG1 SNRPB PRKG1 USB1 MYOCD GATA4 TMEM70 NDUFAF6 FLNA STAT2 ZNF365 MEFV PYGM RASA1 NEK1 SOX6 NF1 FKTN NF1 CSRP3 RPL35 HCN4 SRY MYOT TDGF1 GATA4 GGCX TAPT1 TMEM216 COX15 SLC4A1 ROM1 PAX8 COX1 MCM4 TINF2 CD40 TOPORS ERCC2 SDHC NAA10 MPL POT1 CR2 COL1A1 FGG FOXE1 NLRC4 TFRC TRIM37 EXT2 LMNA KMT2A ITGB3 TBX3 STXBP1 DNM2 NCKAP1L ATXN7 ACADVL SERPINF2 LDB3 TPM2 PLEKHM1 PAX3 ELP1 IRF8 RMRP TGFBR2 STAG2 UQCRFS1 LMX1B SALL4 CFAP300 SIX3 BMPR1A DDB2 IGHM GJA1 HPGD MEFV KCNH2 KCNQ2 PALLD RNASEH2B NDUFAF8 MSX1 NOTCH3 BCL6 ISCU ABCC8 ATP11A FAM111A DBH ODAD1 SDHC CHRNG HBB SALL4 CTLA4 ATP7A RNF213 LOX PIGV CP POLR1A NMNAT1 ALPK3 GPC3 WNT5A CYP26C1 PTEN PPARG BBS7 DDX6 ABCC9 PQBP1 COG5 LMNA ETHE1 LDLR DVL1 RASGRP1 CHD7 TTC12 VCL GABRA3 KRT18 PROC KLLN IARS1 GPI GAS1 KIF23 ACTA2 KCNQ1OT1 WIPI2 THPO FGF8 GLI2 LBR PLCB4 ARID1B BRAF DSP IDUA ANKRD1 BCOR IL12A MMUT SF3B4 PEX7 CFB SCN1B UMPS SERPIND1 PLOD3 KIAA1109 TERT XPC SMCHD1 CD96 MYH7 ACP5 SPEG NT5E DNAJC21 MYCN IGBP1 LMNB1 ACTC1 OTX2 RHBDF2 RTL1 ESS2 FYB1 EXOC6B RPS26 SLC39A4 PIGA MID1 ARL2BP EPHB4 SFTPB ODC1 ASCL1 TTPA PIGL PEX10 ND2 GBE1 TP63 JAK1 DHPS RAI1 XPNPEP2 DNAJB13 COL2A1 AGBL5 CPT2 PROM1 PALB2 IL12B SDHC PDE6G LEPR JAK2 FGG PIGT TSPYL1 STAMBP FASLG KLF13 PIEZO1 EZH2 EPB41 RUNX1 B2M CORIN SPTA1 NR3C2 MYH6 KLHL41 PROP1 ADA2 LIMK1 DSP RPL5 HMGA2 KRAS CCM2 NDUFAF1 ERCC3 IDH3A EP300 NDUFA6 MCCC1 DCLRE1C FARSA CDC42 PLCG2 ACTC1 STAT4 C2 VAC14 PKHD1 DMD ND3 SIN3A COL7A1 CYP3A5 BRAT1 ZMIZ1 NUP107 PTCH1 LMNB1 HNRNPK ND1 IGHM TNNI3K TGIF1 TUBB GJA5 POLG FLNC HAVCR2 SMARCC2 ERCC2 TXNL4A RAB23 CD3E MLH1 BCHE SULT2B1 DISP1 PEX1 LOX DES PIK3R2 BPTF TNNC1 PPP2CA RNF168 TMEM126B FSCN2 ARCN1 PIGV IDUA NKX2-5 IGH CYBB COL5A2 BCOR JAK2 SERPING1 SLC12A3 DOLK NEU1 TGIF1 ADA STAT3 FIBP B4GALT7 ZMIZ1 HLA-B HDAC4 ECE1 CYP17A1 TSC1 ATP6V0A2 A2ML1 DPM3 RP1L1 PKDCC RPS26 MEFV ORAI1 CLIC2 ITCH SEMA4A ASXL1 TRIM8 WNT4 RPS27 SURF1 UFD1 RAF1 SERPINF2 SRP54 SCNN1B GBA DKC1 MYH7 COG7 TCIRG1 ALOXE3 BBS5 SF3B4 LAMB3 VANGL2 MYPN GLI3 LIPT1 KANSL1 PTCH1 EIF2AK3 PPA2 NDUFB10 FBN1 ARL6 ABCA3 STEAP3 GCH1 UNC13D FGFR1 FZD4 HTRA1 SALL1 CPT1A HLA-DQB1 SMC1A PCCB NDUFAF4 FAM13A NEXN KCNN4 LARS2 CTU2 CYP21A2 HSD17B10 TWIST1 SMC3 COG1 ARPC1B FBN1 CALR GATA1 WDR1 ACTC1 PRNP RHAG DOLK RBPJ INF2 HLA-DRB1 HNRNPA1 PHOX2B DPH1 MYLK TMEM94 PRPF4 ADAR SARS2 HDAC8 MLH3 COL4A1 STAG2 LRAT CITED2 EFL1 KIAA1549 TERC BUB3 CRX ITGB3 NSD1 BOLA3 KIAA1549 ATF6 TRIP13 MEG3 PRDM16 KMT2C AIRE MED13L ATP7B AMMECR1 BCR BBS2 GLB1 ABCC8 ACAD8 DSP CYP7B1 MYPN DLL1 VHL EXTL3 SH3PXD2B KCNE5 ARL6 MAN2B1 COMT MYORG ARX EMG1 AIP CSRP3 RHAG RAG2 FCGR2A GJA5 TMEM67 BTNL2 ADAMTSL2 WNT3 DSP SOX18 PIGN PAFAH1B1 HGD ITPR1 FN1 FBN1 PIEZO1 ACTN2 COL1A1 YY1AP1 NPM1 ATP6V0A2 ZBTB16 AHCY EPG5 COL7A1 DDB2 SHH CACNA1C KIT EGFR OSGEP LAMA3 TBX2 SPECC1L IKZF1 SPECC1L SAMD9 LMNA YY1 PIK3C2A LMBRD1 ELN IFT172 PDSS2 DNAAF4 SH2B3 HBG1 NDUFA2 LZTFL1 MYO5B KCNJ11 EVC2 CEP120 SEC63 UNG PTEN MYC GATA4 SLC26A2 SCNN1G NKX2-1 PLOD1 PLEC DLL1 FHL1 MUC1 KYNU ABCA1 TTC8 IGH CLIP2 H19 APOB LAMA4 PLCB3 IL6 GNAQ KCNE1 IGF1R SLC25A4 DYNC2LI1 GNAS GDF1 MYOZ2 IRF5 DST LMX1B ARMC9 NRAS KCNE1 MEN1 SIX3 HJV MYD88 THOC2 PORCN SNRNP200 SOX11 GNB5 SHOC2 CKAP2L SDCCAG8 AP3B1 POLG PDGFB CBL APOC2 POLA1 COL2A1 LPL MLYCD SON TSC1 MIR17HG DVL3 RGR HESX1 LAMP2 RANBP2 SCNN1B ALX1 IFT122 GNPTG NRAS ARL6 FGB STK11 PEX2 MRPS22 GPX4 PCCA TTC37 DACT1 WT1 SMAD4 DAXX KRT14 PACS2 RPS15A RAF1 LRRC6 TRNW DYNC2I2 TNFRSF1B SHH PDE6B WNK1 PKP1 CHST14 TRNV TANC2 KIT FLNA NFIX SLC12A3 ACAD8 PRKCH TBXA2R TRAC TJP2 CCNO FGFR2 IDUA MGP KIT NDUFS3 GBA HRAS FAM161A KCNQ1 NOD2 NOD2 ADK MYCN SLC25A20 POU1F1 TRNH GAS1 AKT3 RAG1 PTPN11 SLC26A2 GATA2 STAR HMCN1 IDH3B SLC7A7 CACNA1S RARB GATA6 DPP6 FGA CBS SUFU TKFC PCCB CASP10 SRP54 SUGCT TNFRSF13C RPS17 B3GAT3 EBP ATP6 PLN TCAP CHRNA3 KCNH1 KRT5 MED12 MRAS LMOD1 TNFSF11 MYLK2 DCDC2 CAT FGFR3 CYP11B1 P2RY11 FLAD1 ADA XRCC4 MECP2 KCTD1 ND3 ACAD9 GBA CLCF1 NUMA1 TNFRSF11A FBXL4 ASXL1 GDF3 F5 MRAS ROR2 NUP107 HCN4 TNFRSF11A TWIST1 CEP290 IRF8 HLA-DRB1 DDX6 TAZ ZIC3 SEMA4A SCN4A NDUFV1 DNAAF1 LPL HOXA11 TRAF7 ERCC4 CACNA2D1 SPTB FGFR1 RBM20 NDUFA13 BCORL1 PIGW SMOC1 KRT5 ATRX ACTG2 FOXH1 COG7 MUC5B GATAD1 PRKCD HSD11B2 BGN STAG2 NPPA NDUFAF3 MYPN PSAP ABCA1 PTEN TNNI3 KCNJ2 RBM10 GANAB TACR3 CD244 PEX14 KANSL1 TNFSF12 MAP3K7 DBH COG2 SDHB IDS DNAAF3 DNAAF3 MC2R BSCL2 TNFRSF4 NAGS MYMK B2M LDLRAP1 CPN1 CAV1 DYRK1A MYOC HLCS ALPK1 KCNJ5 SCN5A SMO NONO FLT4 MAPT LEP CYP7A1 GPC6 CASQ2 TAB2 CPOX ITCH USP45 RYR2 DPM3 ZNF423 CRYAB CEP120 KIF1B SPIB NKX2-5 SELENOI PIGL FGFR1 NDUFS8 NDUFB8 CACNA1C SPEF2 NECTIN1 PBX1 AEBP1 POMT1 RAC2 JAK2 SCN5A COQ4 TBL2 BMP2 BBS2 GINS1 CFAP298 AKR1D1 TBX19 SYNE2 ACTA2 METTL5 DNAH5 WIPF1 POMT1 TLL1 CSNK2A1 MEG3 FGG LMNA KRIT1 OFD1 GATA6 IL12A TPM3 IL6 TRNT LMNA PPP2R1A SURF1 BRCA1 PSMB8 CACNA1C STAG2 CRKL SEC23A CACNA1D CDKN2B GATC SGCD LRP5 ALX3 TAZ COL5A1 MUC5B SEMA3E MRPL12 TCTN1 CDON PROS1 SRSF2 BAP1 FXN PIK3CA FOXRED1 DPP9 ARF1 RAF1 CD79B HEXB SDHC XRCC2 FGFR2 MYPN ZIC2 CALR ITGA7 LTBP2 RPGRIP1 TRIP11 APC SOX2 ABCA1 EXT2 NF1 SPINK5 DSG4 RTEL1 TNNI3 GPC3 TGFB2 SMAD4 DYNC2I1 TPM1 DMPK POMT2 DCDC2 SKI PIK3CA EBP WT1 ANKRD11 NR3C1 HFE SAMD9L TRNW SMC1A KCNE2 ICOS RTTN RB1 HGD F5 FOXF1 CHST14 GLB1 KRAS NCF1 SMAD6 PTCH1 IL2RG B3GALT6 SF3B4 GLI2 RP1L1 OTULIN F8 TET2 SEC23B ZNF148 COX3 OBSL1 WRAP53 ACTN2 PAX3 NDUFV1 ATP7A HGSNAT GLUL CARMIL2 PDGFB ABCC6 STIM1 KDSR DGUOK PTEN TERT FAT4 ALG1 PSEN2 MYL4 COX14 ITGB3 IGFBP7 PHOX2B CHD7 RBM8A ROM1 NLRC4 F10 PTGIS TMEM70 POLD1 EMD TDP2 CACNA1S PRKCSH NUP155 ALPL PKLR TRNL1 CTC1 PEX5 SDHB GATA6 MYPN ALG10B MEN1 NDUFV2 SDHD CCDC39 HEPHL1 HSD17B10 WHCR ACSL4 GP6 MTMR14 COX1 NAA10 FGFR3 EP300 TNNI3 GMPPB NDUFS4 LZTFL1 CTNNB1 INPP5E KCNJ8 HCRT HLA-DRB1 DKC1 TERT SCN10A GGCX KRT8 ERCC4 SFTPB LMBR1 NDUFAF1 RFT1 CCDC65 HDAC8 HBA1 POMT1 SEC61A1 SLC25A11 FLII CLIC2 CPT2 ATP6 DHCR24 COA8 CAV3 LFNG RLIM SUZ12 MARS2 NEU1 XIAP HLA-B BTD SREBF1 FGFR2
    HP:0002090: Pneumonia
    Genes 280
    TLL1 CHD7 TGIF1 KMT2D ACP5 PIGN JAK3 NOS1 SFTPB SRP54 MS4A1 NODAL USB1 CD79B SGCG ACTC1 CASP8 TGFB1 OFD1 CD19 CD247 NHLRC1 SHH NTRK1 EGFR LAMA3 PLOD1 FANCF JAK3 RAG2 PGM3 CACNA1C BTK IL2RG PIK3CD CREBBP KCNJ6 FMO3 ACTA1 TNFSF12 GATA6 ZAP70 PLOD1 UNC119 FGF8 GAS1 DNAI1 WAS GNPTAB FOXH1 CYBC1 LAMC2 RAG1 PEPD PDHA1 PMM2 PAFAH1B1 CD19 CD3D SIX3 CD81 DLL1 LTBP3 EP300 TNFRSF13B SIX3 GLI2 SMARCD2 TIMM8A MYH6 DCLRE1C ABCA3 IL7R TBC1D24 STAT3 CFB FOXH1 FOXP3 FCGR2A P4HTM AP3B1 POLA1 TK2 CDON PKHD1 TAF1 CDON NIPBL GRHL3 GAS1 EFEMP2 CRLF1 SLC35A1 SLC25A24 DOCK8 ZIC2 LEP AFF4 DDR2 CD3E PTPRC BLM RNU4ATAC TNFRSF13C KNSTRN CDON SELENON FOXH1 ORC6 RAG1 RNF168 SHH DISP1 CYBA IL7R CARD11 LONP1 COL11A2 CR2 FGF8 ZIC2 CARD11 CYBB NBN ICOS DNAJC21 DNMT3B DISP1 TGIF1 HLA-DQB1 ADA SETBP1 MED25 FOXH1 SLC35C1 ACADVL TDGF1 PNP SP110 SMC1A ICOS SREBF1 TDGF1 NBN DCLRE1C ALMS1 GLI2 MCIDAS FGF8 NCF1 RAG1 PTCH1 NADK2 IL2RG ZBTB24 ZAP70 GLI2 FGFR1 GAS1 TNFRSF13B GAS1 IFNGR1 CFTR COL11A2 CR2 SAMD9 CD247 TGIF1 TREX1 CARMIL2 TCIRG1 BLNK UBB SRP54 LAMB3 DISP1 RMRP TNFRSF13C NFKB1 STAG2 IRF8 PTCH1 SIX3 KPTN TBX20 TDGF1 CSPP1 IGHM BTK NFIX RNU4ATAC CXCR4 NFKB2 RAC1 CD27 TGIF1 ADA TBX20 ZIC2 MTHFD1 RAG2 GATA4 TNFRSF11A DZIP1L FGF8 KIAA0586 SHH TDGF1 RYR1 ODAD1 WDR1 CREBBP CITED2 DLL1 NCF2 TBCD SHH NODAL RAC2 SIX3 GBA PTCH1 DNAI2 ZIC2 TNFRSF13C ALMS1 PURA STAG2 DLL1 SBDS ICOS EFL1 ACP5 SFTPC CFAP410 MASP2 IL2RG IGLL1 AFF4 BTK LIG4 NFKB2 WDR19 CD55 CDON GAS8 EPM2A NKX2-1 RNF125 DCLRE1C NODAL LRBA ELANE MAN2B1 DLL1 PTCH1 HLA-DQA1 EXTL3 SLC35C1 MAN2B1 FOXN1 PRKCD GLI2 RANBP2 MID1 IL2RG FBLN5 NKX2-5 NODAL GFI1 TNFSF12 RAG2 ADA IL21R KDM6A OSTM1 ASAH1 DISP1 PANK2 FGFR1
    SNP 0